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Chapter 1 
Introduction 
Chronic kidney disease (CKD) is defined by either kidney damage or a 
glomerular filtration rate (GFR) less than 60 mL/min/1.73 m
2
 for at least three months; 
kidney damage may be marked by pathological abnormalities, abnormalities in 
composition of blood (e.g., elevated serum creatinine) or urine (e.g., proteinuria), or 
abnormalities in imaging tests. By convention, CKD is classified into five stages of 
severity.
1
 Stage 1 is defined by kidney damage accompanied by either normal or elevated 
GFR (i.e., ≥ 90 mL/min/1.73 m2) and stage 2 is defined by damage accompanied by 
modestly decreased GFR (i.e., 60-89 mL/min/1.73 m
2
). The large majority of patients in 
CKD Stage 1 or 2 will never progress to kidney failure. In contrast to CKD Stages 1 and 
2, latter stages are defined exclusively by level of GFR. Stages 3 and 4 are defined by 
GFR between 30 and 59 ml/min/1.73 m
2
 and between 15 and 29 mL/min/1.73 m
2
, 
respectively. Finally, Stage 5 is defined either by GFR less than 15 ml/min/1.73 m
2
 
(usually accompanied by the symptoms of uremia) or by need for initiation of renal 
replacement therapy (i.e., dialysis or kidney transplant). 
End stage renal disease (ESRD) is defined by the complete or nearly complete 
failure of the kidneys to function. ESRD typically occurs when CKD has worsened to the 
point at which kidney function is less than 10% of normal. In incident ESRD cases from 
2010 to 2012 (N = 335,334), mean estimated GFR, by the CKD-EPI equation, was 10.3 
mL/min/1.73 m
2 
at ESRD onset.
2
 Ongoing survival with ESRD requires renal 
replacement therapy, in the form of either hemodialysis (HD), peritoneal dialysis (PD), or 
kidney transplant. In HD, a machine filters wastes, salts, and fluid from the blood. 
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Hemodialysis is the most common treatment modality for ESRD in the US, although site 
(e.g., in a facility or at home) and schedule (e.g., thrice-weekly or daily) of treatment may 
vary. In PD, a patient (or a machine) uses a catheter to fill the abdominal cavity with a 
manufactured solution (i.e., dialysate), and waste products and excess fluid move via 
diffusion and osmosis, respectively, across the peritoneum from blood vessels to the 
solution. Despite considerable uncertainty regarding the comparative effectiveness of PD 
and HD, PD is currently relatively infrequently used in the US, with more than 10 HD 
patients for each PD patient in the prevalent ESRD population.
2
 In kidney transplant, an 
allograft from a deceased or living donor is implanted in the patient. Risk of death is 
generally lower for kidney transplant versus dialysis, but treatment with transplant 
requires permanent immunosuppression. In 2012, there were 17,330 kidney transplants in 
the US, with 11,710 (67.6%) from deceased donors and 5,620 (34.3%) from living 
donors.
2
 Use of this modality is constrained by availability of organs. 
Patients undergoing chronic dialysis are eligible for Medicare enrollment, 
regardless of age, as codified by the Social Security Amendments of 1972.
3
 However, the 
core elements of Medicare enrollment are the same for ESRD patients as for citizens who 
become eligible for Medicare due to elderly age. Specifically, Medicare Part A (hospital 
insurance) enrollment is premium-free, subject to satisfaction of conditions regarding 
work history or disability. For Medicare Part B (medical insurance) enrollment, patients 
must pay a monthly premium. In addition, Part B services require 20% co-insurance. This 
is a problematic expense for patients undergoing chronic dialysis, as dialysis itself is 
covered by Part B. In 2015, the base rate for outpatient dialysis covered by Medicare is 
$239.43 per session; that actual rate may be higher for medically complex patients.
4
 On a 
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schedule of three sessions per week, co-insurance for dialysis alone totals nearly $150 (at 
minimum). To cover this expense, ESRD patients typically resort to one of two options. 
Patients with some assets may purchase Medicare Supplement Insurance (i.e., Medigap), 
which covers co-insurance in exchange for a monthly premium. Patients with few or no 
assets may be concurrently enrolled in Medicare and Medicaid, the latter of which covers 
co-insurance for Part B services. Finally, as of 2006, patients may choose to enroll in 
Medicare Part D (prescription drug insurance). In fact, for patients who are concurrently 
enrolled in Medicare and Medicaid, enrollment in Medicare Part D is automatic and 
premium-free (unless a non-benchmark plan is selected). For patients who are enrolled in 
either Medicare Part A or Part B, but not in Medicaid, enrollment in Part D requires a 
monthly premium. These arcane details of Medicare eligibility suggest that many dialysis 
patients accumulate a tremendous volume of claims data regarding hospitalization, 
outpatient care (including outpatient dialysis), and prescription drug use. 
Data arising from Medicare Part D are relatively new to researchers and hold 
tremendous potential for studies of comparative effectiveness. However, these data also 
present opportunities for novel methodologic studies. In ESRD patients, observational 
studies of the efficacy and safety of pharmacologic interventions are common, partially 
because patients with severe renal impairment have typically been excluded from 
randomized clinical trials of such interventions.
5
 However, in the absence of 
randomization, the potential for unmeasured confounding exists. Particularly salient is 
confounding attributable to disease severity, as patients undergoing chronic dialysis vary 
substantially in medical complexity. ESRD patients may suffer from a wide variety of 
comorbid conditions. Identification of comorbidity in both prospective and retrospective 
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studies can be challenging and costly. Algorithms may lack either sensitivity or 
specificity. It has been proposed that prescription drug records may represent a robust 
alternative to classification of comorbidity from clinical assessment and medical record 
abstraction. In fact, with exhaustive data, one might design a comorbidity score (or more 
generally, a risk score) that grades disease severity according to use of particular 
medications. In the first study of this dissertation, I used Part D claims to construct and 
validate comorbidity scores for dialysis patients. Specifically, I constructed 4 comorbidity 
scores: 2 for incident dialysis patients and 2 for prevalent patients. For each set of 
patients, I construct scores corresponding to risks of death and hospitalization. 
Chronic kidney disease and cardiovascular disease (CVD) are tightly intertwined, 
likely partially due to the role of hypertension in the pathogeneses of both CKD and 
CVD. In patients with CKD who have not progressed to ESRD, the burden of CVD is 
severe. In adult (i.e., age ≥ 20 years) NHANES participants in 1999-2006, prevalence of 
CVD for patients with estimated GFR (from the CKD-EPI equation) ≥ 60, 45-59, 30-44, 
and < 30 mL/min/1.73 m
2
 was 6.6%, 31.0%, 49.0%, and 63.0%, respectively.
6
 A meta-
analysis of 11 prospective studies that included 2138 patients with Type 2 diabetes 
reported that the odds ratio of cardiovascular morbidity and mortality for the presence of 
micro-albuminuria (i.e., urinary albumin excretion [UAE] 30-300 mg/day) versus normal 
UAE was 2.0 (95% confidence interval, 1.4-2.7).
7
 This association does not appear to be 
substantially modified by type of diabetes. In an analysis of elderly (i.e., age ≥ 65 years) 
Medicare beneficiaries, the rate of hospitalization due to cardiovascular causes was 126.4 
versus 87.9 admissions per 1000 patient-years for CKD versus no CKD, respectively, 
with CKD status ascertained from claims.
6
 In addition, the predominant cause of death in 
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patients with CKD is CVD. In a systematic review of the association of (non-dialysis-
dependent) CKD with risk of death, cardiovascular deaths constituted 58% of all deaths; 
in contrast, during the era from 1985 to 2005, which was contemporaneous with the 
reviewed studies, the percentage of US deaths due to cardiovascular causes steadily 
declined from 44.3% to 32.5%.
8
 
The explanation for elevated risk of CVD in CKD is likely multifactorial. On one 
hand, prevalence of traditional risk factors for CVD is generally higher in CKD versus 
non-CKD patients. Prevalence of hypertension is very high. In subjects who satisfied 
initial screening criteria in the Modification of Diet in Renal Disease (MDRD) study, 
prevalence of hypertension (as indicated both from review of medical records and by use 
of antihypertensive medications) ranged from 66% in the highest decile of GFR (mean 
within-decile GFR, 83 mL/min/1.73 m
2
) to 95% in the lowest decile of GFR (12 
mL/min/1.73 m
2
).
9
 As one of the randomized interventions in the MDRD study was strict 
blood pressure control, one could speculate that volunteer bias resulted in exaggerated 
estimates of hypertensive prevalence. A later analysis of adult NHANES participants 
reported estimates of hypertension prevalence between 61% and 66% in those with 
estimated GFR < 60, regardless of estimation techniques (compared to about 25% in 
those with estimated GFR ≥ 60).6 However, prevalence of hypertension likely varies 
according to degree of renal dysfunction, as the MDRD study suggested. In five studies 
of patients with Type 2 diabetes, the prevalence of hypertension (i.e., systolic blood 
pressure [BP] > 140 or diastolic BP > 90 mm Hg) was between 40% and 83% in patients 
with micro-albuminuria and between 78% and 96% in patients with macro-albuminuria 
(i.e., UAE > 300 mg/day).
10
 Finally, dyslipidemia is common in CKD patients. In an 
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analysis of 16 studies of patients with nephrotic syndrome (i.e., urinary protein excretion 
> 3 g/day), 88% of patients had total cholesterol > 240 mg/dL.
11
 
 On the other hand, non-traditional risk factors pertaining to renal insufficiency 
may play important roles in the pathogenesis of CVD. Persistent activation of the renin-
angiotensin system (RAS), probably resulting from decreased blood flow into the 
glomeruli, may increase levels of angiotensin II, resulting in systemic vasoconstriction 
and stimulation of the sympathetic nervous system.
12
 Insufficient filtration of sodium and 
chloride encourages water retention and may result in fluid overload, thereby increasing 
blood pressure and risk of heart failure.
13
 Loss of renal function may result in 
derangements of calcium and phosphorus metabolism, as the kidneys produce too little 
calcitriol (i.e., activated vitamin D) and retain too much phosphate, resulting in secondary 
hyperparathyroidism, as well as bone resorption and probable vascular calcification.
14
 
The kidney is also responsible for production of erythropoietin, which stimulates red 
blood cell production in the bone marrow, so loss of renal function typically results in 
anemia, which may lead to increased cardiac output and left ventricular hypertrophy.
15
 
Defects in immune response arise in the presence of renal dysfunction; higher risk of 
infection may alter the risk of CVD.
16-17
 Finally, the accumulation of uremic toxins and 
subsequently increased oxidative stress may also place stress on cardiac tissue. 
In patients who have progressed to ESRD, the pathophysiology of CVD is similar, 
but the risk is even higher. While cardiovascular causes constituted only 42.1% of all 
deaths in prevalent dialysis patients in 2006-2008 (because of increased competition from 
other causes, particularly infection), the absolute rate of 87.9 cardiovascular deaths per 
1000 patient-years is far higher than in the US population (in which there were roughly 
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2.5 cardiovascular deaths per 100,000 people in 2007).
6
 The hospitalization rate for 
cardiovascular causes in prevalent dialysis patients in 2006-2008 was a staggering 525 
admissions per 1,000 years patient-years, although the rate represented a modest decline 
from the previous three-year interval (i.e., in 2003-2005), in which there were 572 
admissions per 1000 patient-years.
6
 Mix of cardiovascular morbidity is varied. In an 
analysis of hypertensive dialysis patients who were alive after one year of dialysis (after 
having begun dialysis in 2003), the prevalence of heart failure was 36.4% and 31.9% in 
those with and without diabetes, respectively.
18
 The prevalence of coronary heart disease 
and peripheral vascular disease were 12.5% and 13.7%, respectively, in patients with 
diabetes, while corresponding prevalence estimates were 9.8% and 9.6% in patients 
without diabetes.
18
 Because the most common cause of death in dialysis patients is 
sudden cardiac death, arrhythmia could be anticipated. In a study of 74 patients, 
prevalence of complex ventricular arrhythmia was 50%.
19
 
Heart failure is a clinical syndrome in which the heart is incapable of maintaining 
cardiac output adequate to meet metabolic requirements and accommodate venous 
return.
20
 Heart failure is caused by a loss of functional myocardial cells after injury to the 
heart from any number of causes. In the US, most common etiologies are ischemic heart 
disease, hypertension, and diabetes; less common causes include dilated cardiomyopathy, 
infection, toxic insults (e.g., alcohol), and valvular disease. Among dialysis patients in the 
US, ischemic events and diabetes are common causes of heart failure, but other unique 
etiologies are important.
21
 Fluid overload between dialysis sessions and anemia (resulting 
in increased preload because of reduced blood viscosity) contribute to the pathogenesis of 
heart failure. 
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In the general population, the American Heart Association currently recommends 
several pharmacological interventions for patients with current or prior symptoms of 
heart failure and reduced left ventricular ejection fraction, including diuretics, 
angiotensin-converting enzyme (ACE) inhibitors, beta blockers that have been found to 
reduce the risk of death (i.e., bisoprolol, carvedilol, and extended-release metoprolol 
succinate), angiotensin II receptor blockers (ARBs) that are indicated in the treatment of 
heart failure (i.e., candesartan, losartan, and valsartan), and aldosterone antagonists.
22
 
Prescription of diuretics to dialysis patients is mostly limited to loop diuretics in incident 
patients with residual renal function. Aldosterone antagonists, specifically spironolactone 
and eplerenone, are contraindicated in patients with renal insufficiency, because of 
increased risk of hyperkalemia, although recent data have questioned this prohibition.
23-24
 
Nevertheless, this leaves mainly ACE inhibitors, beta blockers, and ARBs in the 
armamentarium. Of course, ACE inhibitors and ARBs are closely related, as both inhibit 
the effects of the renin-angiotensin system. Whether ACE inhibitors and ARBs are 
efficacious for the treatment of heart failure in dialysis patients is unknown, although 
several small randomized clinical trials suggest therapeutic potential.
25-26
 In the second 
study of this dissertation, I used Medicare claims data to conduct a retrospective cohort 
study of dialysis patients who had been discharged from hospitalization principally for 
heart failure. I compared risks of death and hospitalization in patients who were 
dispensed a renin-angiotensin system inhibitor shortly after discharge and matched 
control patients who were not dispensed such an inhibitor. 
 ACE inhibitors and ARBs constitute large subclasses of antihypertensive 
medications. Currently in the US, there are 10 ACE inhibitors and 8 ARBs that have been 
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approved by the Food and Drug Administration for human prescription. Some of these 
agents have been rigorously assessed for efficacy in randomized clinical trials of patients 
with heart failure (and possess indications that suggest as much), while many others have 
been assessed only for blood pressure control in patients with uncomplicated 
hypertension. Aside from questions about the evidence base underlying each of these 
agents, there are known differences in the absorption, distribution, metabolism, and 
excretion of these agents. For example, all ACE inhibitors (except fosinopril) are 
removed by hemodialysis, whereas ARBs are not removed by hemodialysis. Some agents 
have relatively short half-lives and are therefore dosed twice or thrice per day, while 
other agents have longer half-lives and are dosed once per day. These and other 
differences may have important pharmacodynamic implications. However, studies of the 
comparative effectiveness of individual ACE inhibitors and ARBs are few, likely 
primarily due to the challenge of achieving sufficient statistical power to detect effects 
that can be reasonably anticipated to be small in magnitude. In the third study of my 
dissertation, I compared risks of death and hospitalization associated with dispensation of 
benazepril, enalapril, lisinopril, ramipril, losartan, and valsartan to dialysis patients that 
had been discharged from hospitalization principally for heart failure. I also investigated 
features of medication use, including dosing, adherence, and persistence. 
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Chapter 2 
Data Source 
United States Renal Data System Database 
The United States Renal Data System (USRDS) is a registry that collects, 
analyzes, and distributes information about end stage renal disease (ESRD) in the United 
States. The USRDS is operated by the National Institute of Diabetes and Digestive and 
Kidney Diseases (NIDDK), in collaboration with the Centers for Medicare & Medicaid 
Services (CMS) and the Health Resources and Services Administration (HRSA). The 
USRDS manages a relational database that is updated annually and includes information 
about demographic characteristics of ESRD patients; measures of disease severity (i.e., 
comorbid diagnoses and biochemical measurements) at the time of ESRD treatment 
initiation; longitudinal histories of treatment modalities and payors; and deaths. The 
database also include records of health care encounters, including hospitalizations, 
dialysis treatments, physician services, and prescription medications, although this 
information is limited to Medicare enrollees. The database represents a compilation of 
many sources, including CMS’s Renal Management Information System (REMIS), the 
ESRD Network Organizations’ Standard Information Management System (SIMS), 
Medicare Parts A and B claims, Medicare Part D events, the Organ Procurement and 
Transplantation Network (OPTN) database, and the Social Security Administration’s 
Death Master File (DMF). Details concerning the linking and reconciling of these sources 
have been described elsewhere.
27
 Key elements of the USRDS database are described in 
the following subsections. 
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ESRD Patient Profile 
 The ESRD patient profile enumerates all ESRD patients that have been identified 
by the USRDS since its inception in 1988. The profile includes a unique numeric 
identifier for each patient. The profile lists sex, ethnicity (Mexican Hispanic, non-
Mexican Hispanic, non-Hispanic, or unknown), and race (white, black, Native American, 
Asian or Pacific Islander, other, or unknown). The profile also lists dates of birth, ESRD 
treatment initiation, and as applicable, death, kidney transplant(s), and kidney transplant 
failure(s). The primary source of mortality information is form CMS-2746 (“ESRD Death 
Notification”), which providers (i.e., dialysis facilities and transplant centers) are required 
to submit within 2 weeks of the date of death. In addition to date of death, CMS-2746 
includes the primary cause of death (as indicated by a three-digit code that specifies a 
particular cause in one of eight general categories: cardiac, vascular, infection, liver 
disease, gastrointestinal, metabolic, endocrine, or other), between zero and four 
secondary causes of death, and information about discontinuation of renal replacement 
therapy prior to death. CMS-2746 provides greater than 99% of mortality information for 
ESRD patients; the Social Security DMF provides the remainder, although the DMF does 
not include causes of death. Since 1994, dates of kidney transplant(s) are identified 
exclusively from the OPTN database, which is necessarily comprehensive in coverage of 
organ transplant events in the US. Dates of kidney transplant failure(s) are identified 
primarily from the OPTN database, and secondarily from SIMS and Medicare claims (as 
transplant failures not resulting in death necessitate dialysis treatment). 
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Medical Evidence Report Catalog 
 The Medical Evidence Report catalog contains all copies of form CMS-2728 
(“End Stage Renal Disease Medical Evidence Report; Medicare Entitlement and/or 
Patient Registration”). CMS-2728 must be completed within 45 days of beginning renal 
replacement therapy in four cases: (1) patients who initiate dialysis as their first ESRD 
treatment modality; (2) patients who receive a kidney transplant as their first ESRD 
treatment modality; (3) patients who have been previously enrolled in Medicare and 
whose coverage was terminated at the conclusion of three years following a kidney 
transplant, but who are reapplying for Medicare coverage because of kidney transplant 
failure (thereby necessitating either the resumption of dialysis or a new kidney 
transplant); (4) patients who have been previously enrolled in Medicare and whose 
coverage was terminated at the conclusion of one year following cessation of dialysis, but 
who are reapplying for Medicare coverage because of either the resumption of dialysis or 
a new kidney transplant. Importantly, submission of CMS-2728 has been required for all 
such ESRD patients since April 1, 1995, regardless of any considerations regarding 
Medicare insurance. The form has undergone two major revisions, first in 1995 (when 
submission was mandated) and again in 2005. 
 The primary epidemiologic use of the catalog is the description of patients 
initiating treatment for ESRD (i.e., incident ESRD patients). In this respect, the catalog 
includes several important elements. First, the catalog includes primary cause of renal 
failure, as indicated by a single diagnosis code from The International Classification of 
Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). While the 1995 and 2005 
revisions of CMS-2728 specify 72 and 82 diagnosis codes as possible causes of renal 
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failure, respectively, the USRDS typically lists eight categories of primary cause 
(diabetes, hypertension, glomerulonephritis, cystic kidney disease, urological disease, 
other, or unknown) in its analysis, with an implicit acknowledgment that the pathologies 
of ESRD vary widely in patients with “other” primary causes. Second, the catalog 
includes height and dry weight, from which body mass index (BMI) can be calculated. 
Third, the catalog lists employment status, both six months prior to CMS-2728 
submission and at the time of submission. Fourth, the catalog lists specified comorbid 
conditions, present either at the time of CMS-2728 submission or during the preceding 
ten years. Fifth, the catalog includes fields about health care utilization preceding 
initiation of renal replacement therapy. Sixth, the catalog includes biochemical 
measurements within the 45 days prior to CMS-2728 submission. 
Regarding comorbid conditions, the 1995 and 2005 revisions of CMS-2728 are 
modestly different. In the former revision, specified conditions include congestive heart 
failure (CHF), ischemic heart disease, myocardial infarction, cardiac arrest, cardiac 
dysrhythmia, pericarditis, cerebrovascular disease (i.e., cerebrovascular accident or 
transient ischemic attack), peripheral vascular disease (PVD), (history of) hypertension, 
diabetes (as either the primary cause of renal failure or a contributing factor), diabetes 
with current insulin treatment, chronic obstructive pulmonary disease (COPD), tobacco 
use, malignant neoplasm or cancer, alcohol dependence, drug dependence, human 
immunodeficiency virus (HIV), acquired immunodeficiency syndrome (AIDS), inability 
to ambulate, and inability to transfer. In the latter revision, specified conditions include 
CHF, atherosclerotic heart disease, other cardiac disease, cerebrovascular disease, PVD, 
(history of) hypertension, amputation, diabetes with current insulin treatment, diabetes 
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with current oral pharmacological treatment, diabetes without current pharmacological 
treatment, diabetic retinopathy, COPD, tobacco use, malignant neoplasm or cancer, toxic 
nephropathy, alcohol dependence, drug dependence, inability to ambulate, inability to 
transfer, need for assistance with daily activities, institutional residency, and non-renal 
congenital abnormality. Definitions of only ischemic heart disease, cerebrovascular 
disease, PVD, and drug dependence are delineated in some detail in the instructions for 
completion of CMS-2728. In fact, only one study has assessed the accuracy of comorbid 
conditions specified on CMS-2728. Longenecker et al estimated sensitivity and 
specificity of the 1995 revision to measure comorbidity in a sample of 1005 incident 
dialysis patients in the CHOICE (Choices for Healthy Outcomes in Caring for ESRD) 
study, with medical record documentation as the de facto gold standard measurement.
28
 
Sensitivity estimated ranged from a minimum of 0.15 to a maximum of 0.83. Among the 
most highly prevalent conditions, sensitivity estimates were 0.77 (95% confidence 
interval [CI], 0.75-0.80) for (history of) hypertension, 0.75 (0.71-0.79) for diabetes, 0.52 
(0.47-0.56) for CHF, 0.48 (0.43-0.53) for ischemic heart disease, 0.15 (0.11-0.20) for 
cardiac dysrhythmia, and 0.40 (0.34-0.46) for PVD. The sensitivity of CMS-2728 to 
detect any cardiovascular disease was 0.61 (0.57-0.65). In contrast to sensitivity, 
specificity was generally high, with a range from 0.95 to 1.00. 
Regarding health care utilization preceding initiation of renal replacement 
therapy, the 1995 revision merely provides data about pre-ESRD use of exogenous 
erythropoietin (EPO) for the treatment of anemia. The 2005 revision also provides data 
about use of EPO prior to ESRD. In addition, the 2005 revision indicates whether the 
patient received care from a nephrologist or a renal dietitian. The 2005 revision also 
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indicates the type of vascular access (arteriovenous fistula, graft, catheter, or other) in use 
during the first outpatient dialysis treatment. 
Finally, regarding biochemical measurements, the 1995 and 2005 revisions both 
include values of serum albumin, serum creatinine, and either hematocrit or hemoglobin. 
Both revisions also include values of the lower limit of the normal range for serum 
albumin (i.e., 3.5 g/dl for the bromcresol green dye-binding technique and 3.2 g/dL for 
the bromcresol purple technique), but these values are frequently missing. The 1995 
revision also lists values of blood urea nitrogen (BUN), creatinine clearance, and urea 
clearance. The 2005 revision lists values of glycosylated hemoglobin (HbA1c) and serum 
lipids (total cholesterol, low-density lipoprotein, high-density lipoprotein, and 
triglycerides).  
Payor History 
 The payor history is a sequential profile of payors of health care services for each 
ESRD patient, beginning with the initiation of renal replacement therapy. Each record in 
the history file represents a discrete time interval with a single level of payor 
categorization. The record includes beginning and ending dates for the interval. Levels of 
payor categorizations include Medicare as primary payor, with Parts A and B insurance; 
Medicare as primary payor, without both Parts A and B insurance; Medicare as secondary 
payor, in coordination with an employer group health plan (EGHP); Medicare as 
secondary payor, in coordination with a non-EGHP entity; Medicare health maintenance 
organization payor; non-Medicare payor; and unknown payor. Payor status is unknown 
during the first three calendar months of in-center hemodialysis treatment in patients 
without existing Medicare insurance at the time of initiation of renal replacement therapy. 
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In these patients, Medicare eligibility does not begin until the first day of the fourth 
calendar month of in-center hemodialysis treatment. The primary epidemiologic purpose 
of the payor history is identification of patients with Medicare as primary payor, with 
Parts A and B insurance. In these patients, the USRDS database includes all records of 
health care utilization billed to Parts A and B, including hospitalization, dialysis 
treatments, and physician services. 
Residence History 
 The residence history is a sequential profile of the places of residence for each 
ESRD patient, beginning with the initiation of renal replacement therapy. Each record in 
the history file represents a discrete time interval with a single ZIP code as the most 
granular description of the place of residence. The record includes beginning and ending 
dates for the interval. The history file, by derivation from ZIP code, also includes 
identification of the county, state, and ESRD Network Organization of place of residence. 
Treatment Modality History 
 The treatment modality history is a sequential profile of renal replacement 
therapies for each ESRD patient, beginning with the initiation of renal replacement 
therapy. Each record in the history file represents a discrete time interval with a single 
treatment modality (with an exception that I describe later). The record includes 
beginning and ending dates for the interval. Treatment modalities include hemodialysis, 
peritoneal dialysis (of unknown type), continuous ambulatory peritoneal dialysis, 
continuous circulatory peritoneal dialysis, dialysis (of unknown type), kidney transplant, 
recovery of endogenous renal function, and unknown modality. (ESRD is typically 
accompanied by a permanent need for renal replacement therapy, but a minority of 
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patients with reversible causes of renal failure may eventually discontinue therapy. 
Examples of such causes include allergic interstitial nephritis, athero-embolic renal 
disease, hemolytic-uremic syndrome, malignant hypertension, and scleroderma.) The 
USRDS also constructs a more detailed version of the treatment modality history, in 
which each of the aforementioned records is divided into discrete intervals accompanied 
by a single renal replacement therapy provider. Providers are identified by a numeric 
code, which can be used to aggregate patients receiving treatment at a dialysis facility, in 
a dialysis organization, or at a transplant program. 
Medicare Part A Claims 
Medicare Part A is commonly known as “hospital insurance.” The USRDS 
database includes final action (i.e., paid) Medicare Part A claims from 1991 to 2012 for 
all ESRD patients; these claims are extracted from CMS’s Standard Analysis Files. The 
compendium of Part A claims is divided into four discrete subsets, according to the type 
of facility from which the claim originated. These subsets include hospice facilities, home 
health agencies, inpatient hospitals, and skilled nursing facilities; claims from inpatient 
hospital stays are most numerous. Medicare Part A claims are submitted via form CMS-
1450 (also known as form UB-04). The key elements of CMS-1450 include the beginning 
and ending dates of service (i.e., admission and discharge dates, in the case of hospital 
stays), value codes, diagnosis codes, E-codes, and procedure codes. 
Value codes are primarily used to report financial data, but may be used to report 
clinical data, insofar as such data are deemed necessary to justify claims for particular 
health care services. In the context of Medicare Part A claims, an important use of value 
coding is to report the total number of pints of whole blood or units of packed red blood 
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cells that are furnished to a patient during the service interval. CMS-1450 may include up 
to twelve value codes. Diagnosis codes are reported in ICD-9-CM format. Each claim 
includes one principal diagnosis that is chiefly responsible for the health care encounter, 
along with a maximum of eight other diagnoses that either coexisted at the beginning of 
the encounter or developed subsequently. E-codes are also reported in ICD-9-CM format. 
These codes are used for supplementary classification of external causes of injury and 
poisoning. CMS-1450 may include one E-code. Finally, procedure codes are likewise 
reported in ICD-9-CM format. Among Part A claims, these codes are used primarily to 
report services during hospitalization. CMS-1450 may include a principal procedure 
code, along with a maximum of five other procedures. Per CMS regulations, the principal 
procedure must be performed for definitive treatment, rather than for diagnostic or 
exploratory purposes. Because of the structure of CMS-1450, procedures codes are not 
explicitly linked to diagnosis codes. 
 Beginning in October of 1983, Part A claims that originated from inpatient 
hospitals were reimbursed through a prospective payment system (PPS); Congress 
initiated this reform in an attempt to slow the escalation of Medicare costs during the 
preceding 15 years. Essentially, the PPS reimburses inpatient hospital facilities at a fixed 
rate per patient discharge, where the rate is a function of the diagnosis-related group 
(DRG) that is assigned to the hospitalization ending in that discharge. The majority of 
DRG assignments are decided by an automated algorithm (i.e., with “grouper” software), 
although some are adjudicated during a formal review process. The DRG is determined 
from the principal diagnosis, secondary diagnoses specifying comorbid conditions 
present on admission or complications arising during hospitalization, any surgical 
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procedures performed during hospitalization, discharge status, age, and sex. In short, the 
DRG represents an alternative instrument for the identification of disease from Part A 
inpatient hospital claims. Beginning in July of 1998, Part A claims that originated from 
skilled nursing facilities were also reimbursed through a PPS, although the collection of 
applicable DRGs is different than the corresponding set of DRGs for inpatient hospital 
claims. In general, because the PPS serves as a substitute for itemized billing of rendered 
health care services, medication use in hospitals and skilled nursing facilities is not 
identifiable from Medicare claims. 
Medicare Part B claims 
Medicare Part B is commonly known as “supplemental medical insurance.” 
Unlike Part A, which requires no premium payment from individuals who have 
accumulated at least forty quarters of employment (or whose spouse has accumulated at 
least forty quarters), Part B does require a monthly premium payment. Consequently, 
while entitlement for Medicare Parts A and B necessarily occurs simultaneously, 
enrollment in each part may not occur simultaneously. The USRDS database includes all 
final action Part B claims from 1991 to 2012 for ESRD patients; these claims are 
extracted from CMS’s Standard Analysis Files. The compendium of Part B claims is 
divided into three discrete subsets, according to the type of health care institution or 
provider that submitted the claim. The subsets include outpatient facilities, carriers, and 
durable medical equipment (DME) suppliers. Claims from outpatient facilities are 
submitted via form CMS-1450, but claims from carriers and DME suppliers are 
submitted via form CMS-1500. CMS-1500 is considerably simpler in structure than 
CMS-1450, as CMS-1500 is designed only for itemized billing of health care procedures, 
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services, and supplies. In addition, unlike CMS-1450, the format of CMS-1500 allows 
explicit linkage of procedure codes with diagnosis codes. 
Regarding outpatient facilities, these entities include outpatient hospital 
departments, rural health clinics, outpatient rehabilitation facilities, community mental 
health centers, and notably, dialysis facilities. (Therefore, while enrollment in Medicare 
Part B is generally elective, it is essentially mandatory in dialysis patients for whom 
Medicare is the primary payor.) Claims that originate from outpatient facilities include all 
of the elements that are included on Part A claims. Additionally, Part B claims that 
originate from outpatient facilities include itemized billing for medical services and 
supplies, including injectable medications. Each item is identified by a Healthcare 
Common Procedure Coding System (HCPCS) code. Codes may be specified in either 
HCPCS Level I or II format. HCPCS Level I codes, commonly known as Current 
Procedural Terminology (CPT) codes, are five-digit numeric codes that can be used to 
identify medical procedures and services. HCPCS Level II codes are five-character 
alphanumeric codes that can be used to identify durable medical equipment, (ordinarily 
non-oral) medications, orthotic and prosthetic procedures, and surgical supplies. Each 
item includes a date of service and, as applicable, the number of rendered units (e.g., of a 
medication). 
Part B claims that originate from carriers are mostly submitted by non-
institutional health care providers, including physicians, physician assistants, nurse 
practitioners, and clinical social workers. Other examples of carriers include ambulance 
operators, (free-standing) ambulatory surgical centers, and independent clinical 
laboratories. Such claims include itemized billing for medical services and supplies. Each 
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item is identified by a HCPCS code and a corresponding ICD-9-CM diagnosis code that 
essentially justifies the item. Each item includes beginning and ending dates of service, 
and as applicable, the number of rendered units. Each item also includes the place of 
service, which is indicated by a two-digit numeric code that identifies the type of facility 
at which the item was rendered. Part B claims that originated from DME suppliers 
similarly include itemized billing for medical supplies. 
Medicare Part D Enrollment Database 
 Medicare Part D is commonly known as “prescription drug insurance.” Medicare 
Part D was instituted in 2006. Like Part B, enrollment in Part D requires a monthly 
premium, at least in the absence of documented poverty. In fact, Medicare enrollees who 
choose to forgo Part D coverage without possession of creditable (i.e., at least actuarially 
equivalent) prescription drug insurance are penalized with higher monthly premiums 
upon eventual enrollment in Part D. The USRDS database includes Part D enrollment 
information from 2006 to 2011 for all ESRD patients with at least one month of 
enrollment in Medicare Parts A, B, or C (i.e., Medicare Advantage) during a calendar 
year. (Patients not enrolled in Medicare Parts A, B, or C during a calendar year cannot 
enroll in Medicare Part D, so such patients are excluded by convention from the 
enrollment database.) For each patient, the database includes monthly data regarding Part 
D enrollment and dual eligibility (for Medicare and Medicaid) status. Additionally, the 
database includes an indication of whether the patient possessed creditable coverage from 
any of five sources for at least one month during the calendar year; these sources include 
the Federal Employees Health Benefits (FEHB) program, the TRICARE (formerly 
CHAMPUS) program, the Veterans Affairs (VA) program, any state pharmacy assistance 
 22 
 
program (SPAP), or any employer group health plan. Creditable coverage admits the 
possibility that prescription medications may be obtained outside of Part D. 
 Specifically, for each calendar month in which a patient is enrolled in Medicare 
Parts A or B, the enrollment database indicates the source of prescription drug insurance: 
Part D with assistance via the low-income subsidy (LIS), Part D without assistance via 
the LIS, an employer group health plan reimbursed by CMS via the retiree drug subsidy 
(RDS), creditable coverage not through an employer group health plan, or no (known) 
prescription drug insurance. The LIS is designed to improve access to medications by 
subsidizing monthly premiums and reducing coinsurance for those individuals with 
limited financial resources. Individuals may be either deemed eligible for receipt of the 
LIS exclusively because of dual eligibility for Medicare and Medicaid or declared 
eligible for receipt of the LIS because of application to the Social Security 
Administration with documentation of both limited income and assets. For individuals 
who are deemed eligible, there are three degrees of assistance: no monthly premiums and 
no prescription copayments, no premiums and low copayments, and no premiums and 
high copayments. On the other hand, for individuals who are declared eligible, there are 
five degrees of assistance: no monthly premiums and high copayments, no premiums and 
15% coinsurance, a 75% discount in premiums and 15% coinsurance, a 50% discount in 
premiums and 15% coinsurance, and a 25% discount in premiums and 15% coinsurance. 
Low copayments were set at maxima of $1.00, $1.00, $1.05, $1.10, $1.10, and $1.10 for 
generic medications in 2006, 2007, 2008, 2009, 2010, and 2011, respectively; for branded 
medications, corresponding copayments were set at maxima of $3.00, $3.10, $3.10, 
$3.20, $3.30, and $3.30. Alternatively, high copayments were set at maxima of $2.00, 
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$2.15, $2.25, $2.40, $2.50, and $2.50 for generic medications in 2006, 2007, 2008, 2009, 
2010, and 2011, respectively; for branded medications, corresponding copayments were 
set at maxima of $5.00, $5.35, $5.60, $6.00, $6.30, and $6.30. 
The RDS is essentially a tax-exempt rebate equal to 28% of qualifying medication 
costs incurred by retirees who possess prescription drug insurance through an employer 
group health plan; the rebate itself is payable to the employer. The RDS has progressively 
lost popularity since the advent of Part D, because its administrative simplicity actually 
betrays its relative cost inefficiency, compared to other options for providing prescription 
drug insurance to retirees. 
For calendar months in which a patient is enrolled in Medicare Part D, the 
enrollment database specifies the selected contract, plan, and segment. The contract field 
represents the private entity (e.g., CVS Caremark) that administers one or more Part D 
plans that have been approved by CMS. The first character of the field identifies the type 
of contract administrator: ‘E’ for employers; ‘H’ for managed care organizations 
(MCOs), excluding regional preferred provider organizations (PPOs); ‘R’ for regional 
PPOs; and ‘S’ for standalone administrators. Employer administration of Part D contracts 
is rare, and has been historically confined to labor unions. Both MCOs and regional PPOs 
administer Part D contracts as part of Medicare Part C (i.e., Medicare Advantage), and 
therefore offer prescription drug insurance only in tandem with hospital and supplemental 
medical insurance. Standalone administrators offer prescription drug insurance without 
other forms of health insurance. Each contract may include multiple plans, which may 
vary in benefit structure and formulary constitution. Each plan may possess multiple 
segments, which cover mutually exclusive geographical regions. 
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Medicare Part D Events 
In Part D, each prescription fill generates an event record (i.e., a claim). The 
USRDS database includes all Part D events from 2006 to 2011 for ESRD patients. Each 
event record includes the National Drug Code (NDC) of the dispensed prescription. In 
data that are distributed by CMS, the NDC is an 11-digit numeric code with three 
segments: the first through fifth digits specify the labeler (e.g., manufacturer), the sixth 
through ninth digits specify the product (i.e., a specific agent, form, and strength), and the 
tenth and eleventh digits specify the package (e.g., the tablet count). In the past, labelers 
were allowed to recycle previously assigned NDCs. Each record includes a date of 
service (i.e., the date on which the prescription was filled), the quantity of medication that 
was dispensed, and the number of days that were thereby supplied. Each record also 
includes numeric codes that uniquely identify the medication prescriber and dispensing 
pharmacy. 
Finally, each record specifies the benefit phase in which the prescription was 
filled. Each Part D plan has a unique benefit structure, but all plans must be at least 
actuarially equivalent to the standard benefit that is defined by CMS. In the standard 
benefit, there are four phases: the deductible phase, the pre-initial coverage limit (pre-
ICL) phase, the initial coverage limit (ICL) phase, and the catastrophic phase. These 
phases are defined with respect to the calendar year; in other words, on January 1 of each 
year, all Part D enrollees begin in the deductible phase. In the deductible phase, an 
enrollee is responsible for all medication costs. In the pre-ICL phase, an enrollee is 
responsible for 25% of costs. Again in the ICL phase, an enrollee is responsible for all 
costs. Finally, in the catastrophic phase, an enrollee is responsible for only 5% of costs. 
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The boundaries between these phases are a function of cumulative medication costs, and 
are annually set by CMS. In 2006, 2007, 2008, 2009, 2010, and 2011, the deductible 
phase ended at $250, $265, $275, $295, $310, and $310 of cumulative costs, respectively. 
The pre-ICL phase ended at $2,250, $2,400, $2,510, $2,700, $2,830, and $2,840 of 
cumulative costs in corresponding years, while the ICL phase ended at $3,600, $3,850, 
$4,050, $4,350, $4,550, and $4,550 of cumulative out-of-pocket (OOP) costs. Enrollees 
may select plans that eliminate the deductible phase or provide coverage during the ICL 
phase (typically in exchange for higher monthly premiums). Importantly, the standard 
benefit is applicable only to patients who are not eligible for receipt of the LIS. For 
enrollees who are dually eligible and for enrollees who are not dually eligible, but who 
pay no monthly premiums and high copayments, there is no deductible phase, no 
distinction between pre-ICL and ICL phases (i.e., copayments remain the same), and no 
out-of-pocket (OOP) cost in the catastrophic phase. For enrollees who are not dually 
eligible and pay 15% coinsurance, there is a small deductible phase, no distinction 
between the pre-ICL and ICL phases (i.e., coinsurance remains the same), and high 
copayments in the catastrophic phase. 
First DataBank™ Drug Database 
 Attached to each Part D event record in the USRDS database is drug information 
for the specified NDC, as listed in the First DataBank™ drug database. Such information 
is appended by CMS. Data includes the branded and generic names of the medication, 
both in text string format; the strength of the medication, in applicable units (e.g., 
milligrams, micrograms, or percentage concentration); and the dosage form (e.g., tablet, 
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capsule, or vial). Specifically, dosage form is listed with a two-character code that 
facilitates precise identification of route of administration. 
Medi-Span™ Drug Database 
 In the Medi-Span drug database, each NDC is linked to a generic product 
identifier (GPI) code, which is a fourteen-character numeric identifier. Multiple NDCs 
may be mapped to a single GPI code. The format of the GPI code facilitates precise 
identification of both drug class and generic ingredient. Specifically, the first pair of 
digits indicates drug group (e.g., diuretics); the second pair indicates drug class (e.g., loop 
diuretics); the third pair indicates drug sub-class; the fourth pair indicates drug name; the 
fifth pair indicates drug name extension; and the sixth and seventh pairs indicates form 
and strength (although not in a systematic manner across all drugs). 
Completeness of the USRDS Database 
The primary instrument for the identification of a new ESRD patient is form 
CMS-2728 (“End Stage Renal Disease Medical Evidence Report; Medicare Entitlement 
and/or Patient Registration”). The form is used to establish Medicare eligibility for 
individuals who are not existing Medicare enrollees; to reclassify existing Medicare 
enrollees as ESRD patients; and to collect information about the demographic 
characteristics, comorbid diagnoses, biochemical measurements, and initial treatment 
modality of ESRD patients. Since April 1, 1995, providers have been required to submit 
CMS-2728 for all ESRD patients within 45 days of the initiation of renal replacement 
therapy (i.e., dialysis or kidney transplant), regardless of considerations of either current 
or future need for Medicare insurance. Secondary instruments for the identification of a 
new ESRD patient include a Medicare Part A claim for a kidney transplant, a Medicare 
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Part B claim for dialysis treatment, or a kidney transplant recipient registration in the 
OPTN database. Given the statutory requirement for submission of form CMS-2728 and 
the breadth of secondary instruments listed here, the USRDS database is considered to be 
complete in its identification of patients who have initiated treatment for ESRD since 
April 1, 1995. 
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Chapter 3 
Risk Scores Developed from Prescription Drug Claims in Dialysis Patients 
Abstract 
 Risk scores can be useful in both clinical and epidemiologic applications. Many 
scores are functions of diagnosed diseases; fewer are functions of dispensed medications. 
In chronic dialysis patients, in whom polypharmacy is common, scores based on 
medication, rather than disease, may be superior metrics of prognosis. We used Medicare 
Part D data to construct 4 risk scores for dialysis patients. Separately in incident and 
prevalent (i.e., undergoing dialysis for ≥ 1 year) patients, we constructed scores for each 
of death and hospitalization. In incident patients, medications were ascertained from Part 
D claims during the 1 year preceding dialysis initiation, whereas in prevalent patients, 
medications were ascertained from claims during a calendar year. Scores were 
constructed with a pre-specified algorithm that used training, validation, and testing sets 
from 2008, 2009, and 2010, respectively. In the testing set, we compared the performance 
of risk scores based on medications versus scores based on diseases (Deyo, van 
Walraven, and Liu) versus both. For incident patients, risk scores for death and 
hospitalization included 19 and 15 components, respectively, whereas for prevalent 
patients, corresponding scores included 28 and 20 components. Cardiovascular agents 
were the most common constituents of each score. Each score was monotonically 
associated with crude rates of death and hospitalization in the testing set. For each pair of 
cohort and event, explained variation for the score based on medication was less than 
explained variation for one or more scores based on disease. However, the explained 
variation associated with simultaneous use of two scores, one based on medication and 
 29 
 
another based on disease, was always greater than explained variation associated with 
one score. In conclusion, risk scores as functions of prescription drug claims in dialysis 
patients are useful metrics for summarizing future risk of death and hospitalization. In 
epidemiologic applications, simultaneous use of scores based on comorbid disease and 
dispensed medication is probably preferable to use of a score based on only one domain.
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Introduction 
According to the most recent census by the United States Renal Data System 
(USRDS), there were more than 450,000 chronic dialysis patients alive in the US at the 
end of 2012.
29
 Rates of death and hospitalization among dialysis patients remain much 
higher than corresponding rates in the US population.
30
 Thus, there is an ongoing need to 
identify medical interventions that can reduce the incidence of mortality and morbidity in 
dialysis patients. Pharmacologic therapy is a key dimension of intervention for all chronic 
diseases, but its application to dialysis patients is often complicated by the lack of 
rigorous evidence demonstrating efficacy and safety in patients with advanced chronic 
kidney disease. Specifically, patients with either elevated serum creatinine or end stage 
renal disease (ESRD) are typically excluded from randomized clinical trials of new 
medications.
31
 This gap in evidence creates a pressing need for observational studies. 
Fortuitously, dialysis patients are an excellent target for observational studies, including 
retrospective cohort studies, because of the availability of several large datasets.
32
 
Roughly two in three dialysis patients receive care from one of two dialysis provider 
organizations and the electronic health records of each organization allow analysis of 
more than 150,000 contemporary patients.
29
 All patients that initiate chronic dialysis are 
eligible for Medicare Part A (i.e., hospital insurance) and Part B (i.e., medical insurance) 
upon the first day of the fourth calendar month of treatment, regardless of age or 
disability status. Moreover, many dialysis patients are poor and concurrently enrolled in 
both Medicare and Medicaid, thereby resulting in automatic enrollment in Medicare Part 
D (i.e., prescription drug coverage). Medicare Parts A and B claims allow analysis of 
more than 300,000 contemporary patients and Part D claims allow further analysis in a 
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subset of more than 200,000 patients. For example, Part D claims were recently analyzed 
to assess the comparative effectiveness of sevelamer (carbonate or hydrochloride) versus 
calcium acetate in hemodialysis patients.
33
 
An important challenge with observational studies of medical interventions is the 
threat posed by confounding, which manifests when patients that receive an intervention 
differ in baseline risk from those who do not receive the intervention.
34
 Statistical 
adjustment for factors that correlate with receipt of an intervention may address 
confounding. In the case of dialysis patients, adjustment for comorbidity burden is a 
requisite element of study design, due to the relatively high prevalence of heart failure, 
atherosclerotic heart disease, diabetes, chronic obstructive pulmonary disease, and 
mineral metabolism disorders. Comorbidity scoring is a popular technique that quantifies 
comorbidity burden. The Charlson Comorbidity Index is a frequently used score that 
includes 16 conditions; each condition is tagged with a number of points and the points of 
all diagnosed diseases are summed to characterize risk of death.
35
 Many other indices 
have been developed.
36
 However, whether comorbidity scoring can be developed in one 
population and applied in another population is generally unclear, as comorbid conditions 
may heterogeneously associate with risk in disparate settings. To that point, several 
indices have been recently developed in dialysis patients.
37-39
 However, all of the indices 
for dialysis patients have been based on diagnoses of comorbidity. None have been based 
on receipt or use of medication. Dialysis patients take 11 medications (on average).
40
 
Prescription medication likely reflects comorbidity burden and data about receipt of 
medications may be more accurate than data about comorbidity, particularly when data 
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are ascertained from Medicare claims. In principle, comorbidity scoring as a function of 
dispensed medications may be a useful tool for observational studies. 
In this study, we used USRDS data to create for dialysis patients a series of 
comorbidity scores as functions of dispensed medications; data about medication were 
ascertained from Part D claims. In cohorts of incident and prevalent dialysis patients, we 
created scores that associate with risks of death and hospitalization. We analyzed 
consecutive annual cohorts of patients to develop, test, and validate scores. Finally, we 
compared the performance of the proposed scores with three published scores based on 
diagnoses ascertained from Parts A and B claims. 
 
Methods 
 We analyzed USRDS data that were obtained through a Data Use Agreement with 
the National Institute of Diabetes and Digestive and Kidney Diseases. We identified 
cohorts of incident and prevalent patients; in each case, we identified cohorts in 2008 
(training set), 2009 (validation set), and 2010 (testing set). For the incident cohort in year 
Y, we retained patients with date of initiation of chronic hemodialysis (i.e., index date) 
between January 1 and December 31 of year Y; age greater than or equal to 66 years on 
the index date; uninterrupted enrollment in Medicare Part D during the 12-month interval 
immediately preceding the index date (i.e., entry interval); and non-missing data 
regarding race, Hispanic ethnicity, primary cause of ESRD, and ESRD Network of 
residence on the index date. For the prevalent cohort in year Y, we retained patients with 
receipt of chronic dialysis on December 31 of year Y (i.e., index date), uninterrupted 
receipt of one dialytic modality (i.e., either hemodialysis or peritoneal dialysis) during 
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year Y, and date of initiation of renal replacement therapy no later than October 31 of 
year Y – 1; age greater than or equal to 20 years on the index date; uninterrupted 
enrollment in Medicare Part D during the 12-month interval immediately preceding the 
index date (i.e., entry interval); and non-missing data regarding race, ethnicity, primary 
cause of ESRD, and ESRD Network of residence. For development of scores associated 
with risk of hospitalization, we limited cohorts to patients with uninterrupted enrollment 
in Medicare Parts A and B during the entry interval. 
 For each patient, we identified age on the index date, race (white, black, Asian, 
Native American, other race), sex, primary cause of ESRD (diabetes, hypertension, 
glomerulonephritis, polycystic kidney disease, other known cause, unknown cause), and 
ESRD Network of residence on the index date. We refer to these characteristics as 
demographic factors. 
For development of scores associated with risk of mortality, follow-up began on 
the index date and ended on the earliest of the date of death, the date of kidney transplant, 
or the date that was one year after the index date. The target event was time to death. 
Scores were developed with Cox proportional hazards regression, with simultaneous 
adjustment for demographic factors. For development of scores associated with risk of 
hospitalization, follow-up was identical, except that follow-up also ended at interruption 
of enrollment in Parts A and B. The target event was cumulative hospitalized days in the 
follow-up interval, with days ascertained from Part A claims for inpatient facility care. 
Scores were developed with Poisson regression, with an offset for follow-up time and 
simultaneous adjustment for demographic factors. In all regressions, age was 
parameterized with a cubic polynomial (for flexibility). 
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Receipt of medication was ascertained from Part D claims during the 12-month 
interval immediately preceding the index date. For dialysis patients that were enrolled in 
each of Parts A, B, and D, Part D claims comprised medications that were administered 
in the home, as those that were intravenously administered during dialysis (e.g., 
erythropoiesis-stimulating agents, iron, and vitamin D sterols) were covered by Part B. 
We examined the National Drug Code (NDC) of each dispensed medication and mapped 
the NDC to a Generic Product Identifier (GPI) in the Medi-Span Master Drug Database 
(Indianapolis, IN). The GPI taxonomy categorizes each medication according to a 
hierarchy of group, class, subclass, active moiety, and salt. Separately for incident and 
prevalent cohorts, we queried Part D claims in the training and validation sets to identify 
subclasses with prevalence of use (i.e., at least one dispensed medication) greater than or 
equal to 0.5% in both sets. Only those subclasses with such level of prevalence were 
considered for inclusion in scores. 
For each combination of cohort and event, we applied the following algorithm: 
(1) In the training set, we sequentially added subclasses to the event model on the 
basis of maximal incremental change in explained variation (EV), until the change 
in EV was less than 0.1% with the addition of any outstanding subclass; by 
convention, the EV of the model with only demographic factors was equal to 0%. 
In detail, we identified first the subclass associated with maximal EV; we 
identified second the subclass associated with maximal change in EV, conditional 
upon inclusion of the first subclass; and so on. For Cox and Poisson regressions, 
EV was estimated by R
2
 metrics based on partial likelihood statistics and deviance 
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residuals, respectively.
41-42
 From each fitted model in the sequence, we retained 
the estimates of parameters associated with subclasses. 
(2) In the validation set, we fit each model in the sequence identified in (1). The 
parameters associated with demographic factors were re-estimated from data in 
the validation set, but the parameters associated with subclasses were fixed at the 
values identified in (1). We identified models with incremental change in EV less 
than 0.05% and eliminated from further development the subclasses that 
distinguished each such model from its respective antecedent in the sequence. 
(3) In the training set, we refit the event model with subclasses that were retained in 
(2). For each instance of multiple subclasses within the same class, we also refit 
the event model with joined subclasses. From each refitted model, we retained the 
estimates of parameters associated with subclasses and joined subclasses. 
(4) In the validation set, we refit each of the models in (3). The parameters associated 
with demographic factors were re-estimated from data in the validation set, but 
the parameters associated with subclasses and joined subclasses were fixed at the 
values identified in (3). For each model with joined subclasses, we calculated the 
difference between the EV of that model and the EV of the model without joined 
subclasses. We joined subclasses in further development if the difference was 
greater than -0.05%. 
(5) We inspected the set of subclasses and joined subclasses that were identified in 
(4) and made minor revisions to the set to harmonize definitions across 
combinations of cohort and event and to improve relevance in dialysis patients. 
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All revisions are displayed in Appendix 1. We refer to the revised set of 
subclasses and joined subclasses as medication factors. 
(6) In the validation set, we refit the event model with medication factors that were 
identified in (5). We assigned to each medication factor an integer number of 
points, according to the following function of the corresponding estimated 
parameter: 
    
 m ax 0 .0 2 5, 0 .0 2 5
sg n 1
0 .0 5
f

 
   
     
    
  
For each patient, the comorbidity score was finally derived as the sum of points 
associated with medication factors with at least one dispensed medication. 
 In the testing set, we assessed the characteristics of each comorbidity score. We 
estimated the distribution of each score and associations of each score with absolute risk. 
In testing set patients with concurrent enrollment in Medicare Parts A, B, and D during 
the entry interval, we also compared the performance of each comorbidity score with the 
performance of 3 scores that are functions of diagnosed diseases: the Deyo adaptation of 
the Charlson comorbidity index;
43
 the van Walraven adaptation of the Elixhauser 
comorbidity index;
44
 and the Liu comorbidity index, which was developed in dialysis 
patients.
38
 Each comorbid condition was ascertained from Parts A and B claims during 
the entry interval. We declared a condition to be present if we identified at least one 
inpatient facility, skilled nursing facility, or home health agency claim or at least two 
outpatient facility or physician claims with qualifying International Classification of 
Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes.
45
 We 
compared EV associated with each score by nonparametric bootstrapping with 2000 
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samples; EV was estimated from a model that included demographic factors. Finally, we 
assessed whether EV associated with pairs of scores was greater than EV associated with 
individual scores. 
 All analyses were conducted in SAS, version 9.2 (Cary, North Carolina). 
 
Results 
For the incident cohort, we identified 27,075, 28,504, and 29,245 patients in the 
training, validation, and testing sets, respectively. Nearly 90% of patients in each set were 
between ages 65 and 84 years, more than 70% were white, and slightly more than 50% 
were female (Table 3-1). Diabetes and hypertension were the primary causes of ESRD 
for almost 80% of patients. More than 55% of patients were enrolled in Medicare Parts A 
and B. For the prevalent cohort, we identified 163,336, 171,381, and 181,340 patients in 
the training, validation, and testing sets, respectively. The majority of patients in each set 
were between ages 20 and 64 years, more than 40% were black, and slightly more than 
50% were male (Table 3-1). The proportion of patients with either glomerulonephritis or 
polycystic kidney disease as the primary cause of ESRD was larger than in the incident 
cohort. More than 80% were enrolled in Medicare Parts A and B. 
Initially in score development, medication subclasses were sequentially added to 
an event model, according to maximization of EV in the training set. The results of this 
step are displayed in Figure 3-1. For the incident cohort, we identified 20 subclasses 
associated with death risk and 16 associated with hospitalization risk. With adjustment 
for demographic factors, 10.9% and 5.7% of variation in death and hospitalization risks, 
respectively, were accounted by these subclasses. For the prevalent cohort, we identified 
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32 subclasses associated with death risk and 20 associated with hospitalization risk. With 
adjustment for demographic factors, 14.0% and 8.5% of variation in death and 
hospitalization risks, respectively, were accounted by these subclasses. 
For incident patients, the components of death and hospitalization scores are 
displayed in Tables 3-2 and 3-3, respectively. For death, component values ranged from 
13 to +8. Among 19 components, 15 (79%) were used by ≥ 5% of testing set patients; 
for such components, values ranged from 6 to +6. Cardiovascular agents constituted 9 
components and psychotropic agents constituted 3 components. The distribution of scores 
in the testing set is displayed in Figure 3-2A. The mean score was 3.2 (standard 
deviation, 8.9). For hospitalization, component values ranged from 20 to +8. Among 15 
components, 12 (80%) were used by ≥ 5% of testing set patients; for such components, 
values ranged from 6 to +5. Cardiovascular agents constituted 3 components and 4 
therapeutic groups each included 2 components. The distribution of scores in the testing 
set is displayed in Figure 3-2B. The mean score was 1.3 (standard deviation, 6.7). 
For prevalent patients, the components of death and hospitalization scores are 
displayed in Tables 3-4 and 3-5, respectively. For death, component values ranged from 
4 to +9. Among 28 components, 21 (75%) were used by ≥ 5% of testing set patients; for 
such components, values ranged from 4 to +8. Cardiovascular agents constituted 8 
components and digestive agents constituted 4 components. The distribution of scores in 
the testing set is displayed in Figure 3-2C. The mean score was 7.5 (standard deviation, 
8.9).  For hospitalization, component values ranged from 3 to +7. Among 20 
components, 18 (90%) were used by ≥ 5% of testing set patients; for such components, 
values ranged from 3 to +6. Cardiovascular agents constituted 5 components and 
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neurological agents constituted 4 components. The distribution of scores in the testing set 
is displayed in Figure 3-2D. The mean score was 11.1 (standard deviation, 8.3). 
 Percentiles of each score and rates of death and hospitalization in groups of 
percentiles are displayed in Table 3-6. For incident patients, percentile groups were 
monotonically associated with rates of death and hospitalization. Relative to rates in 
those with scores between percentiles 0 and 4, rates in those with scores between 
percentiles 95 and 99 were 7.6 times greater for death and 4.2 times greater for 
hospitalization. For prevalent patients, percentile groups were likewise monotonically 
associated with rates of death and hospitalization. The death rate in those with scores 
between percentiles 95 and 99 was 7.0 times greater than the rate in those with scores 
between percentiles 0 and 4; for hospitalization, the rate in those with scores between 
percentiles 95 and 99 was 6.7 times greater than the rate in those with scores between 
percentiles 0 and 9. 
 Comparisons of EV in the testing set with comorbidity scores as functions of 
diagnosed diseases, comorbidity scores as functions of dispensed medications, and 
combinations thereof are displayed in Figure 3-3; in these cases, EV included the 
contribution of demographic factors. For death in incident patients, EV associated with 
the medication score was 17.5%, slightly less than with the van Walraven (17.7%) 
disease score, but greater than with other disease scores (Figure 3-3A). EV associated 
with the combination of medication and van Walraven scores was 22.9%. For 
hospitalization, EV associated with the medication score was 10.2%, slightly less than 
with the van Walraven (10.9%) and Liu (10.7%) disease scores (Figure 3-3B). EV 
associated with the combination of medication and van Walraven scores was 14.4%. For 
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death in prevalent patients, EV associated with the medication score was 31.0%, less than 
with the van Walraven (31.9%) and Liu (33.8%) scores (Figure 3-3C). Highest was the 
combination of medication and Liu scores (37.7%). Finally, for hospitalization, EV 
associated with the medication score was 10.8%, lower than with the van Walraven 
(11.9%) and Liu (15.2%) scores (Figure 3-3D). Highest again was the combination of 
medication and Liu scores (17.0%). 
 
Discussion 
 Risk scores are useful tools for clinical and epidemiologic research. In the clinical 
setting, risk scores can be used to set inclusion criteria of prospective studies, so that 
event rates might be accurately forecasted and sample size might be appropriately set to 
achieve statistical power. In epidemiologic studies, especially regarding comparative 
effectiveness, risk scores can be used to control confounding; the dimensionality 
reduction that is inherent in risk scores is useful in small cohorts and in studies of rare 
outcomes, such as hypersensitivity reactions. Ongoing need for epidemiologic studies in 
dialysis patients is pronounced, because nephrology publishes fewer randomized clinical 
trials per year than any other internal medicine specialty. Risk scores have traditionally 
been functions of diagnosed diseases, but this paradigm can be problematic for some 
sources of comorbidity data. When diagnosis codes are ascertained from administrative 
databases, in which sensitivity of codes may be low, risk scores themselves may be 
inaccurate metrics of prognosis; this information bias can engender residual confounding 
when scores are applied to risk adjustment schema. Alternatively, scores may be 
functions of prescription drug claims, which are bona fide evidence of dispensed 
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medications. However, drug claims implicitly conflate the effects of disease and the 
treatment thereof, thus resulting in unpredictable and possibly weak associations with 
risk. 
In this study, we constructed and validated 4 risk scores as functions of drug 
claims in dialysis patients. Scores were constructed as proxies of death and 
hospitalization risks in the 1 year after dialysis initiation, as well as proxies of death and 
hospitalization risks in a calendar year, among patients with at least 1 year on dialysis. 
Risk scores included between 15 and 28 components and cardiovascular agent subclasses 
were important contributors to each score. Moreover, scores were monotonically 
associated with crude rates of death and hospitalization and rate ratios for highest versus 
lowest vigintiles of scores were between 4 and 8. However, in comparison to scores 
based on diagnosed diseases, scores based on drug claims were associated with slightly 
less explained variation in event incidence in a contemporary cohort. On the other hand, 
pairs of risk scores based on diseases and drug claims were associated with significantly 
more explained variation than single risk scores. 
For incident patients, risk scores include several notable elements. First, regarding 
the score for death risk, three components – type III anti-arrhythmics, potassium-sparing 
diuretics, and potassium (supplements) – are related to the risk of cardiac dysrhythmia. 
Sudden cardiac death is the primary cause of death in 30% of cases during 1 month after 
dialysis initiation and in 25% of cases during 1 year after initiation.
46
 Second, calcium 
channel blockers were tagged with 6 and 4 points for death and hospitalization scores, 
respectively. In the Dialysis Morbidity and Mortality Study Wave 2 cohort, which 
included 2,877 incident dialysis patients with ≥ 1 antihypertensive medication 
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prescription, both dihydropyridine and non-dihydropyridine calcium channel blockers 
were associated with significantly lower risk of death, after adjustment for pre-dialysis 
blood pressure, in contrast to all other subclasses of blood pressure-lowering 
medications.
47
 Third, megestrol acetate was tagged with +8 points for the death score. 
Megestrol can be prescribed to stimulate appetite;
48
 malnutrition is an important risk 
factor for death in new dialysis patients.
49
 Fourth, both phosphate binders and oral 
vitamin D sterols were tagged with negative points for death and hospitalization scores. 
Treatment of mineral and bone disease is often initiated after dialysis initiation, but these 
point values suggest that initiation of treatment before beginning dialysis may lower risk 
of mortality and morbidity during the first year of dialysis. Fifth, several subclasses of 
psychotropic agents were tagged with positive points. Depression is associated with 
increased risk of death in dialysis patients.
50
 
In prevalent patients, risk scores based on drug claims were associated with 
significantly less explained variation than the Liu score based on diagnosed diseases. The 
Liu index includes 11 diseases: atherosclerotic heart disease, cardiac dysrhythmia, 
congestive heart failure, other cardiac disease, cerebrovascular disease, peripheral 
vascular disease, cancer, chronic obstructive pulmonary disease, diabetes, gastrointestinal 
bleeding, and liver disease.
38
 Atherosclerotic heart disease and diabetes are tagged with 
+1 point, congestive heart failure is tagged with +3 points, and all other diseases are 
tagged with +2 points. Ironically, the point values in the Liu index were derived from a 
Cox regression of death in incident dialysis patients in 2000, although follow-up of those 
patients did not begin until the end of the ninth month on dialysis and did not end until 
the end of 2005. The relatively better performance of the Liu index may be attributed to 
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the high volume of Parts A and B claims during the first year of dialysis; with a large 
number of claims, major comorbid conditions may be accurately identified. 
This study has some limitations. First, data regarding both dispensed medications 
and hospitalization were ascertained from Medicare claims. Because Medicare Part D has 
a unique benefit structure, drugs claims are generated not only by medical need, but also 
by wherewithal to purchase medication. Application of these risk scores to dialysis 
patients with commercial insurance may be inappropriate. Second, risk scores were 
constructed with data from 2008 to 2010. Medicare Part D has evolved since 2010 and 
rates of both death and hospitalization have declined in dialysis patients.
29
 Risk scores 
should be periodically evaluated for applicability in contemporary patients. As a concrete 
example, beginning in 2011, lidocaine/prilocaine was no longer covered by Part D in 
dialysis patients, as the item is typically used to prepare the vascular access and is 
therefore covered by Part B. Third, performance of risk scores based on diseases is 
predicated on ascertaining disease from ICD-9-CM diagnosis codes. However, Medicare 
will replace ICD-9-CM with ICD-10-CM later in 2015. This conversion may affect the 
accuracy of codes in claims and thereby reposition the relative performance of scores 
based on drug claims. 
In conclusion, risk scores can be constructed from prescription drug claims in 
dialysis patients. The gradient of death and hospitalization rates across risk score 
distributions suggests that scores can be useful in both clinical and epidemiologic 
settings. Moreover, the components of the scores in this study (and their associated 
indications) may be fruitful targets for further research oriented toward improving 
clinical outcomes. As tools for risk adjustment schema, the scores in this study are 
 44 
 
probably best used in tandem with previously published scores based on diagnosed 
diseases. Further research is needed to construct “hybrid” risk scores that combine 
diseases and drug claims into a single metric, as well as to construct risk scores that apply 
to dialysis patients without Medicare coverage. 
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Table 3-1. Characteristics of patients in incident and prevalent cohorts 
 Incident cohort Prevalent cohort 
 Training Validation Testing Training Validation Testing 
Sample size 27,075 28,504 29,245 163,336 171,381 181,340 
Age (%)       
20-44 years    14.9 14.4 14.1 
45-54 years    17.7 17.6 17.4 
55-64 years    22.2 22.8 23.3 
65-74 years 44.8 45.0 45.4 24.1 24.1 23.9 
75-84 years 42.8 42.3 41.8 16.6 16.5 16.5 
≥ 85 years 12.4 12.7 12.8 4.5 4.6 4.8 
Race (%)       
White 70.7 70.3 70.8 50.3 50.8 51.1 
Black 23.6 23.6 23.0 42.9 42.4 41.9 
Native American 0.8 0.8 0.8 1.6 1.5 1.5 
Asian 4.9 5.2 5.4 4.7 4.8 5.0 
Other < 0.1 < 0.1 < 0.1 0.6 0.5 0.4 
Sex (%)       
Female 51.7 51.1 50.6 48.1 47.9 47.6 
Male 48.3 48.9 49.4 51.9 52.1 52.4 
Primary cause of ESRD (%)       
Diabetes mellitus 44.3 43.6 44.2 44.1 44.5 44.8 
Hypertension 35.4 36.0 35.4 29.3 29.4 29.5 
Glomerulonephritis 3.5 3.6 3.5 10.6 10.2 9.9 
Polycystic kidney disease 0.8 0.8 0.8 2.4 2.4 2.4 
Other known cause 12.0 12.2 12.6 10.2 10.1 10.2 
Unknown cause 4.0 3.9 3.5 3.5 3.4 3.3 
Parts A and B enrollment (%) 57.5 55.9 55.4 82.5 81.0 80.2 
 
Abbreviation: ESRD, end stage renal disease.
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Table 3-2. Components of risk score for death in incident patients 
Subclass GPI Users
 a
 (%) Points 
Antimicrobial agents    
Fluoroquinolones 050000 35.9 +3 
Cardiovascular agents    
Anti-arrhythmics (type III) 354000 6.5 +6 
Calcium channel blockers 340000 64.8 6 
Digoxin 312000 7.1 +5 
Nitrates 321000 28.0 +3 
Peripheral alpha antagonists 362020 13.6 3 
Potassium-sparing diuretics 375000 8.5 +6 
Statins 394000 62.7 2 
Vasodilators 364000 28.2 4 
Warfarin sodium 832000 16.6 +4 
Dermal agents    
Lidocaine/prilocaine 9085990290 1.8 13 
Electrolytes    
Potassium 797000 23.4 +4 
Hormonal agents    
Megestrol acetate 2140402010 4.2 +8 
Mineral and bone disease agents    
Phosphate binders 528000 19.0 5 
Vitamin D sterols (oral) 309050 30.2 6 
Psychotropic agents    
Acetylcholinesterase inhibitors 620510 4.6 +5 
Phenothiazines 592000 3.0 +5 
Selective serotonin reuptake inhibitors 581600 17.5 +3 
Respiratory agents    
Anticholinergics (inhaled) 441000, 
442099 
11.0 +4 
 
Abbreviation: GPI, Generic Product Identifier. 
a 
Among testing set patients. 
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Table 3-3. Components of risk score for hospitalization in incident patients 
Subclass GPI Users
 a
 (%) Points 
Antimicrobial agents    
Antibiotics for C. difficile 1600003500, 
1600006010 
5.6 +3 
Cardiovascular agents    
Calcium channel blockers 340000 64.0 4 
Thienopyridine derivatives 851580 21.6 +2 
Warfarin sodium 832000 17.3 +5 
Dermal agents    
Lidocaine/prilocaine 9085990290 1.9 20 
Topical enzymes 907000 1.8 +8 
Digestive agents    
Lactulose 5240002000 5.1 +5 
Proton pump inhibitors 528000 40.7 +2 
Electrolytes    
Potassium 797000 24.2 +2 
Mineral and bone disorder agents    
Phosphate binders 528000 18.9 6 
Vitamin D sterols (oral) 309050 29.1 5 
Neurological agents    
Hydantoins 722000 1.2 +6 
Psychotropic agents    
Acetylcholinesterase inhibitors 620510 5.2 +5 
Selective serotonin reuptake inhibitors 581600 19.0 +2 
Respiratory    
Anticholinergics (inhaled) 441000, 
442099 
11.4 +3 
 
Abbreviation: GPI, Generic Product Identifier. 
a 
Among testing set patients concurrently enrolled in Parts A and B. 
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Table 3-4. Components of risk score for death in prevalent patients 
Subclass GPI Users
 a
 (%) Points 
Antimicrobial agents    
Aminopenicillins 012000 13.9 2 
Antibiotics for C. difficile 1600003500, 
1600006010 
7.8 +3 
Fluoroquinolones 050000 32.2 +3 
Cardiovascular agents    
Alpha-beta blockers 333000 29.2 +3 
Anti-arrhythmics (type III) 354000 5.0 +7 
Calcium channel blockers 340000 53.3 2 
Digoxin 312000 3.5 +6 
Midodrine hydrochloride 3800008310 5.1 +6 
Nitrates 321000 17.8 +4 
Statins 394000 47.1 3 
Warfarin sodium 832000 13.5 +4 
Dermal agents    
Lidocaine/prilocaine 9085990290 16.4 4 
Silver sulfadiazine 9045003000 3.4 +5 
Topical enzymes 907000 2.8 +9 
Digestive agents    
Antiperistaltics 471000 6.9 +3 
Metoclopramide 5230002010 12.0 +4 
Polyethylene glycol 3350 4699200430, 
4699200520, 
4699200530, 
4699200630 
10.7 2 
Proton pump inhibitors 528000 43.9 +2 
Hormonal agents    
Glucocorticosteroids 221000 15.4 +3 
Megestrol acetate 2140402010 5.9 +8 
Neurological agents    
Hydantoins or valproic acid 722000, 
725000 
4.0 +5 
Hydrocodone with acetaminophen 659917 41.9 +3 
Opioid agonists (without non-opioid analgesic) 651000 20.0 +5 
Nutritional agents    
Amino acid infusion 803020 1.1 +8 
Psychotropic agents    
Acetylcholinesterase inhibitors 620510 2.7 +5 
Benzisoxazoles or butyrophenones 590700, 
591000 
2.2 +7 
Selective serotonin reuptake inhibitors or 
tetracyclic antidepressants 
580300, 
581600  
21.9 +4 
Respiratory agents    
Anticholinergics (inhaled) 441000, 
442099 
7.6 +6 
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Abbreviation: GPI, Generic Product Identifier. 
a 
Among testing set patients. 
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Table 3-5. Components of risk score for hospitalization in prevalent patients 
Subclass GPI Users
 a
 (%) Points 
Antimicrobial agents    
Antibiotics for C. difficile 1600003500, 
1600006010 
8.0 +5 
Fluoroquinolones 050000 32.7 +3 
Cardiovascular agents    
Anti-arrhythmics (type III) 354000 5.0 +4 
Central alpha agonists 362010 24.5 +3 
Nitrates 321000 17.4 +3 
Thienopyridine derivatives 851580 19.5 +3 
Warfarin sodium 832000 13.4 +6 
Dermal agents    
Lidocaine/prilocaine 9085990290 16.5 3 
Silver sulfadiazine 9045003000 3.4 +5 
Digestive agents    
Metoclopramide 5230002010 12.5 +4 
Proton pump inhibitors 528000 44.9 +3 
Hormonal agents    
Glucocorticosteroids 221000 15.7 +3 
Megestrol acetate 2140402010 6.0 +5 
Neurological agents    
Gamma-aminobutyric acid analogues 7260003000, 
7260005700 
20.9 +3 
Hydrocodone with acetaminophen 659917 43.0 +3 
Oxycodone with acetaminophen 659900 18.7 +4 
Opioid agonists (without non-opioid analgesic) 651000 20.8 +5 
Psychotropic agents    
Dibenzothiazepines 591530 2.5 +7 
Selective serotonin reuptake inhibitors 581600  20.4 +4 
Respiratory agents    
Anticholinergics (inhaled) 441000, 
442099 
7.8 +6 
 
Abbreviation: GPI, Generic Product Identifier. 
a 
Among testing set patients concurrently enrolled in Parts A and B. 
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Table 3-6. Risk score percentiles and crude event rates, by risk percentile group 
 Incident cohort Prevalent cohort 
 Death Hospitalization Death Hospitalization 
Risk score percentile 
5 17 13 4 0 
10 14 9 2 0 
25 9 4 +1 +5 
50 3 0 +6 +10 
75 +2 +3 +12 +16 
90 +8 +7 +20 +23 
95 +13 +9 +24 +27 
Crude event rate,
a
 by risk score percentile group 
0-4 14.5 11.7 7.5 4.4
 b
 
5-9 19.2 15.4 9.5 4.4
 b
 
10-24 23.1 18.1 10.3 6.5 
25-49 30.8 24.9 13.1 9.4 
50-74 43.9 29.8 19.0 12.9 
75-89 60.6 36.5 28.3 17.8 
90-94 77.9 39.7 37.3 23.4 
95-99 110.3 48.8 52.5 29.6 
 
Abbreviation: NA, not applicable. 
a 
Deaths per 100 patient-years or hospitalized days per patient-year. 
b
 The percentile groups of 0-4 and 5-9 constitute one group, which comprises patients 
with risk scores of 3 or 0. 
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Figure 3-1. Explained variation with sequential addition of medication subclasses to 
event model in training set 
 
 
 53 
 
Figure 3-2A. Risk score distribution in the testing set, for the event of death in incident 
patients 
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Figure 3-2B. Risk score distribution in the testing set, for the event of hospitalization in 
incident patients 
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Figure 3-2C. Risk score distribution in the testing set, for the event of death in prevalent 
patients 
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Figure 3-2D. Risk score distribution in the testing set, for the event of hospitalization in 
prevalent patients 
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Figure 3-3A. Comparison of explained variation associated with risk score and 
combinations thereof in the testing set, for the event of death in incident patients 
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Figure 3-3B. Comparison of explained variation associated with risk score and 
combinations thereof in the testing set, for the event of hospitalization in incident patients 
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Figure 3-3C. Comparison of explained variation associated with risk score and 
combinations thereof in the testing set, for the event of death in prevalent patients 
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Figure 3-3D. Comparison of explained variation associated with risk score and 
combinations thereof in the testing set, for the event of hospitalization in prevalent 
patients 
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Chapter 4 
Associations of Renin-Angiotensin System Inhibition with Mortality and 
Hospitalization in Dialysis Patients with Heart Failure 
Abstract 
 Heart failure (HF) is a common comorbidity in chronic dialysis patients. Clinical 
practice guidelines in the general population recommend angiotensin-converting enzyme 
(ACE) inhibitors and angiotensin-receptor blockers (ARBs) for treatment of HF with 
reduced ejection fraction, but data supporting efficacy in dialysis patients are sparse. We 
used data from the United States Renal Data System to assess the relative hazards of 
death and hospitalization associated with renin-angiotensin system (RAS) inhibitor use in 
dialysis patients who had been discharged after hospitalization principally for HF. 
Discharges were ascertained from Medicare Part A claims between January 1, 2007, and 
December 31, 2011. RAS inhibitor treatment was ascertained from Part D claims during 
the 1 month following discharge. For each treated patient, we identified 2 propensity 
score-matched controls, according to demographic factors, comorbid conditions, in-
hospital care, and discharge status. We applied both intention-to-treat (ITT) and on-
treatment (OT) follow-up rules. There were 2407 treated patients and 4814 matched 
controls. Groups were generally balanced at discharge, but more patients with RAS 
inhibitor treatment were dispensed beta blockers (52.6% versus 16.8%). In ITT analysis, 
the adjusted hazard ratio (HR) of death for RAS inhibitor treatment was 0.86 (95% 
confidence interval, 0.78-0.94) and the adjusted HR for hospitalization was 0.90 (0.86-
0.95). In OT analysis, the adjusted HR of death for RAS inhibitor treatment was 0.71 
(0.62-0.82) and the HR of hospitalization was 0.89 (0.85-0.94). There were no significant 
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differences between ACE inhibitors and ARBs in the hazard of death, relative to matched 
controls, but only ACE inhibitors were associated with lower hazard of hospitalization. 
Interruption of RAS inhibitor treatment was common. In conclusion, RAS inhibitor 
treatment was associated with lower hazards of death and hospitalization in dialysis 
patients with HF, despite high incidence of treatment interruption.
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Introduction 
Heart failure (HF) is a common comorbidity in chronic dialysis patients. In one 
prospective study, 31% of new dialysis patients in 1982-1991 were diagnosed with HF.
51
 
By retrospective analysis, prevalence of HF was similar in new end-stage renal disease 
(ESRD) patients in 2010-2012.
52
 In patients without HF at initiation of dialysis, 
subsequent loss of pump function is also likely. In the noted prospective study, 25% of 
new dialysis patients presented with de novo HF after a median of 15 months.
51
 Anemia, 
vascular calcification, myocardial infarction, and persistent activation of the renin-
angiotensin system (RAS) all complicate ESRD and may favor the development of HF. 
The combination of preexisting and de novo HF results in substantial burden on patients 
and payers; in 2011, prevalent dialysis patients were hospitalized for HF at a rate of more 
than 12 admissions per 100 patient-years.
53
 
In patients with HF and normal kidney function, the efficacy of pharmacologic 
inhibition of the RAS is strongly supported by randomized trials. Clinical practice 
guidelines indicate that angiotensin-converting enzyme (ACE) inhibitors are 
recommended for patients with HF and ejection fraction (EF) less than 40%; angiotensin-
receptor blockers (ARBs) are recommended in such patients who do not tolerate ACE 
inhibitors and are further characterized as “reasonable alternatives” to ACE inhibitors as 
first-line therapy.
54
 For patients with HF and preserved EF, guidelines are limited. 
Specifically, ARBs might be considered to reduce risk of hospitalization, as was observed 
in the CHARM-Preserved trial of candesartan.
55
 For dialysis patients with HF, evidence 
from trials is sparse. A trial of fosinopril versus placebo in hemodialysis patients with left 
ventricular hypertrophy reported non-significant reductions in cardiovascular risk,
56
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whereas a trial of dual therapy with telmisartan and an ACE inhibitor versus 
monotherapy with an ACE inhibitor in hemodialysis patients with HF and reduced 
ejection fraction reported significant reductions in cardiovascular risk.
57
 
In this study, we used United States Renal Data System (USRDS) data to assess 
efficacy and safety of treatment with an ACE inhibitor or ARB in dialysis patients that 
were discharged from the hospital with a principal diagnosis of HF. Data regarding 
medication exposure were ascertained from Medicare Part D claims. Patients that were 
dispensed an ACE inhibitor or ARB were matched with patients that were dispensed 
neither an ACE inhibitor nor ARB, according to the propensity score for dispensation. 
For efficacy, we assessed all-cause death, cardiovascular death, sudden cardiac death, all-
cause hospitalization, cardiovascular hospitalization, and HF hospitalization. For safety 
outcomes, we assessed angioedema and hyperkalemia. 
 
Methods 
Protection of Human Subjects 
We analyzed USRDS data that were obtained by a Data Use Agreement with the 
National Institute of Diabetes and Digestive and Kidney Diseases. The study was 
reviewed by the Human Subjects Research Committee at Hennepin County Medical 
Center (Minneapolis, Minnesota). 
Study Cohort 
 The source cohort included prevalent and incident dialysis patients. For the 
former, we retained patients with receipt of dialysis on December 31, 2007 (i.e., index 
date); uninterrupted receipt of one dialytic modality (i.e., either hemodialysis or 
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peritoneal dialysis) during 2007; date of initiation of renal replacement therapy no later 
than October 31, 2006; age between 20 and 100 years on the index date; and 
uninterrupted enrollment in Medicare Parts A and B during the 12-month interval 
immediately preceding the index date. For the latter, we retained patients with date of 
initiation of dialysis (i.e., index date) between January 1, 2007, and December 31, 2009; 
age between 20 and 100 years on the index date; and uninterrupted enrollment in 
Medicare Parts A and B during the 12-month interval immediately preceding the index 
date. For both groups, we required non-missing data regarding race, sex, primary cause of 
ESRD, and ESRD Network of residence on the index date. We excluded patients with a 
hospitalization for HF (International Classification of Diseases, Ninth Revision, Clinical 
Modification [ICD-9-CM] diagnosis code 402.11, 402.91, 404.01, 404.03, 404.11, 
404.13, 404.91, 404.93, or 428.x as principal diagnosis
5
) during the 12-month interval 
immediately preceding the index date. 
We followed each patient from the index date to the earliest of death, kidney 
transplant, interruption of enrollment in Medicare Parts A and B, or December 31, 2011. 
During follow-up, we identified the first hospitalization for HF. We retained hospitalized 
patients with Medicare Part D enrollment during the 12-month interval immediately 
preceding the date of admission and with discharge to home, under self-care or 
supervision of a home health agency. To design the retrospective analogue of a washout 
period, we excluded patients who were dispensed an ACE inhibitor or ARB during the 3-
month interval preceding the date of admission. 
For sensitivity analyses, we repeated the cohort construction with alternative 
criteria regarding HF. For the first alternative, we identified during follow-up the first 
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hospitalization with either a principal or secondary diagnosis of HF. For the second 
alternative, we excluded patients with a hospitalization with either a principal or 
secondary diagnosis of HF during the 12-month interval immediately preceding the index 
date and we identified during follow-up the first hospitalization for HF. 
Patient Characteristics 
 For each patient, we ascertained age, race, sex, primary cause of ESRD, ESRD 
duration, ESRD Network of residence, low-income subsidy (LIS) receipt, risk scores, 
body mass index (BMI), hematocrit, hospitalization history, kidney transplant wait-list 
status, erythropoiesis-stimulating agent (ESA) and intravenous vitamin D analogue 
(VDA) exposure, dialytic modality, dialysis provider, HF hospitalization factors (co-
incident myocardial infarction and stroke, physician specialty care, diagnostic 
procedures, and length of stay), and discharge location. Age, ESRD duration, ESRD 
Network, LIS receipt, and wait-list status were identified at discharge. The risk scores 
comprised 2 comorbidity scores and 4 medication scores. For comorbidity, we used the 
Liu score and the van Walraven score of Elixhauser comorbid conditions.
59-60
 In each 
score, we declared a condition to be present if we identified at ≥ 1 inpatient facility, 
skilled nursing facility, or home health agency claim or ≥ 2 outpatient facility or 
physician claims with qualifying ICD-9-CM diagnosis codes, as specified by Quan et al, 
during the 12 months preceding admission.
61-62
 For medication, we used scores derived 
from dispensed medications during the 12 months preceding admission.
63
 BMI and 
hematocrit were calculated from the means of measurements on outpatient dialysis and 
ESA claims, respectively, during the 6 months preceding admission. Hospitalization 
history was summarized by cumulative hospitalized days during the 6 months preceding 
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admission, whereas ESA and intravenous VDA exposure were summarized by 
cumulative doses during the 3 months preceding admission. Dialytic modality and 
dialysis provider were identified on the day before admission. During HF hospitalization, 
myocardial infarction was identified from ICD-9-CM diagnosis codes 410.x0 and 
410.x1;
64
 stroke was identified from codes 430.x, 431.x, 434.x, and 436.x.
65
 Specialty care 
was identified from physician claims during hospitalization; diagnostic procedures were 
identified from both ICD-9-CM procedure codes on inpatient facility claims and Current 
Procedural Terminology (CPT) codes on physician claims during hospitalization. 
Exposure 
 From Part D claims in the 1 month following discharge, we identified dispensed 
ACE inhibitors and ARBs, according to the National Drug Code and the associated 
Generic Product Identifier (GPI) code in the Medi-Span Master Drug Database 
(Indianapolis, IN). We included combination products containing an ACE inhibitor or 
ARB. We identified class-specific dates of first dispensation in the month and set the start 
of risk for exposed patients at the latest such date. We defined candidate controls as 
patients who were not dispensed an ACE inhibitor or ARB. 
Matching 
We used propensity score matching to select 2 matched controls per exposed 
patient.
66
 We used logistic regression to model the probability of RAS inhibitor exposure 
among exposed patients and candidate controls. Covariates comprised the 
aforementioned patient characteristics; continuous covariates were parameterized with 
quadratic polynomials. From the fitted model, we estimated the propensity score (i.e., 
probability) of exposure. 
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We ordered exposed patients according to number of days between discharge and 
start of risk and arbitrarily within each number of days. For each exposed patient with 
LIS l, propensity score p, and d days between discharge and start of risk, we selected a 
candidate control with LIS l and propensity score q, such that the absolute difference of p 
and q was minimized. We set the start of risk for the matched control at d days after 
discharge. The matched control was removed from further consideration in matching. 
After we selected one matched control for each exposed patient, we repeated the 
algorithm and identified another matched control. 
Between discharge and the start of risk, we identified incidence of re-
hospitalization and dispensation of beta blockers and digoxin. 
Outcomes 
 We followed all patients from the start of risk to the earliest of death; kidney 
transplant; interruption of enrollment Medicare in Parts A, B, and D; or December 31, 
2011. We identified the incidence of all-cause death; cardiovascular death; sudden 
cardiac death; hospitalization due to any cause, cardiovascular disease, HF, myocardial 
infarction, and stroke; angioedema; and hyperkalemia. Cardiovascular deaths were 
determined from the ESRD Death Notification and sudden cardiac deaths were 
determined from the ESRD Death Notification and inpatient facility claims.
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Cardiovascular hospitalization was defined according to principal diagnosis codes, as 
specified by the USRDS.
52
 Myocardial infarction and stroke were defined by principal 
diagnosis codes on inpatient facility claims. Angioedema and hyperkalemia were defined 
by diagnosis codes 995.1 and 276.7, respectively, on inpatient facility claims; for these 
events, we queried both principal and secondary diagnosis codes. 
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Statistical Analysis 
We calculated statistical summaries of measured factors in exposed patients and 
matched controls. We assessed the match quality with absolute standardized differences; 
differences less than 10% indicate sufficient similarity to obviate adjustment.
68
 We used 
intention-to-treat (ITT) and on-treatment (OT) rules during follow-up. For the ITT rule, 
we followed patients from the start of risk to the earliest of death; kidney transplant; 
interruption of enrollment Medicare in Parts A, B, and D; or December 31, 2011. For the 
OT rule, we added change in RAS inhibitor exposure to the list of dates on which follow-
up may end. Specifically, change in exposure was defined at the end of the first 2-month 
interval without supply of an RAS inhibitor (in exposed patients) or 2 months after first 
dispensation of an RAS inhibitor (in matched controls). 
For mortality outcomes, we estimated cumulative incidence for exposed patients 
and matched controls. To compare incidence in these groups, we used Cox proportional 
hazards regression to estimate relative hazard; the model was stratified by matched 
cluster. The model was adjusted for the incidence of re-hospitalization between discharge 
and start of risk and the concomitant dispensation of beta blockers and digoxin, because 
these factors were not included in the propensity score function. Because of modest 
differences between exposed patients and matched controls, the model was also adjusted 
for co-incident myocardial infarction, cardiology care during hospitalization, and use of 
coronary catheterization, echocardiogram, and myocardial perfusion scintigraphy during 
hospitalization. For hospitalization outcomes, we used Andersen-Gill regression to 
estimate the relative hazard of admission in exposed patients versus matched controls; the 
model was stratified by matched cluster. We used the robust sandwich estimator to model 
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covariance among recurrent hospitalizations. The model was adjusted for the same 
factors in models of mortality outcomes. However, for angioedema, the model was 
unadjusted, because of the low number of events. Finally, we estimated the cumulative 
incidence of exposure status crossover, with death as a competing risk. 
For exploratory analysis, we estimated relative hazards of mortality and 
hospitalization for ACE inhibitor users and ARB users versus respective matched 
controls. For this analysis, we excluded matched clusters with an exposed patient that 
was dispensed both an ACE inhibitor and an ARB. Models were parameterized as 
previously described, but included additional adjustment for age, transplant wait-list 
status, medication scores for incident patients, and pulmonology care during 
hospitalization. 
All analyses were conducted in SAS, version 9.2 (Cary, North Carolina), except 
for the exposure status crossover analysis, which was conducted in R, version 3.1.2 
(Vienna, Austria). 
 
Results 
 We identified 11,635 hospitalized cases of HF. There were 2407 (20.7%) patients 
who were dispensed an RAS inhibitor in the 1 month following discharge and 9228 
patients who were not. From the latter subset, we identified 4814 matched controls. The 
characteristics of exposed patients and matched controls are displayed in Table 4-1. In 
exposed patients, mean age was 65.4 (standard deviation, 13.8) years, 52.4% were white, 
42.7% were black, and mean ESRD duration was 4.8 (4.4) years. Mean hospitalized days 
during the 6 months before HF hospitalization and mean days during HF hospitalization 
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were 6.9 (12.6) and 4.7 (3.8), respectively. Most patients saw a cardiologist in the 
hospital (84.3%), but only 31.6% underwent an echocardiogram. Over 80% were 
discharged to home and nearly all (96.5%) received hemodialysis. Matching balanced all 
factors included in the propensity score (absolute standardized differences < 10%). 
However, there were differences in care between discharge and start of risk. Relative to 
matched controls, exposed patients were more likely to have been re-hospitalized (9.6% 
versus 5.9%), dispensed beta blockers (52.6% versus 16.8%), and dispensed digoxin 
(3.4% versus 1.3%). 
 Event counts and crude event rates are displayed in Table 4-2. In ITT follow-up, 
exposed patients and matched controls accumulated 3762 and 7035 patient-years, 
respectively (1.56 and 1.46 years per patient). There were 1123 deaths in exposed 
patients (proportion, 46.7%) and 2344 deaths in matched controls (48.7%); corresponding 
crude mortality rates were 30 and 33 deaths per 100 patient-years. Slightly less than 50% 
of deaths in each group were attributable to cardiovascular disease and slightly less than 
30% were attributable to sudden cardiac death. There were 10,906 and 22,545 hospital 
admissions in exposed patients and matched controls, respectively; corresponding crude 
rates were 290 and 320 admissions per 100 patient-years. Nearly 40% of admissions in 
each group were for cardiovascular disease. Crude rates of both myocardial infarction 
and hyperkalemia were lower in exposed patients, while rates of both stroke and 
angioedema were higher. In OT follow-up, exposed patients and matched controls 
accumulated 1745 and 5207 patient-years, respectively (0.73 and 1.08 years per patient). 
There were 473 and 1811 deaths in exposed patients and matched controls, respectively; 
corresponding crude mortality rates were 27 and 35 deaths per 100 patient-years. Crude 
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hospitalization rates were 291 and 309 admissions per 100-patient years for exposed 
patients and matched controls, respectively. Rates of myocardial infarction, stroke, and 
angioedema were higher in exposed patients, but the rate of hyperkalemia was lower. 
Estimates of cumulative incidence of death are displayed in Figures 4-1A and 4-
1B. In ITT analysis, cumulative incidence for exposed patients versus matched controls 
was 8.4% versus 9.9% at 3 months, 15.0% versus 17.2% at 6 months, 26.2% versus 
30.6% at 1 year, 44.7% versus 49.0% at 2 years, and 59.5% versus 61.1% at 3 years 
(Figure 4-1A). In OT analysis, incidence for exposed patients versus matched controls 
was 8.5% versus 9.9% at 3 months, 14.5% versus 17.4% at 6 months, 23.5% versus 
30.9% at 1 year, 38.1% versus 49.7% at 2 years, and 51.7% versus 61.6% at 3 years 
(Figure 4-1B). Estimates of cumulative incidence of cardiovascular death are displayed in 
Figures 4-2A and 4-2B. In ITT analysis, cumulative incidence for exposed patients versus 
matched controls was 12.8% versus 14.7% at 1 year, 21.4% versus 23.4% at 2 years, and 
29.0% versus 29.0% at 3 years (Figure 4-2A). Estimates of cumulative incidence of 
sudden cardiac death are displayed in Figures 4-3A and 4-3B. In ITT analysis, 
cumulative incidence for exposed patients versus matched controls was 7.3% versus 
8.1% at 1 year, 12.7% versus 13.5% at 2 years, and 17.9% versus 17.0% at 3 years 
(Figure 4-3A). In OT analyses of both cardiovascular and sudden cardiac death, the lower 
incidence in exposed patients persisted through 4 years. 
Adjusted hazard ratios of mortality and hospitalization are displayed in Table 4-3. 
In ITT analysis, the hazard ratio (HR) of death for exposed patients versus matched 
controls was 0.86 (95% confidence interval, 0.78-0.94). HRs of cardiovascular and 
sudden cardiac death were similar in magnitude. The HR of hospitalization for exposed 
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patients versus matched controls was 0.90 (0.86-0.95). HRs of admission for 
cardiovascular disease and HF were attenuated. HRs of both myocardial infarction and 
stroke were imprecise. The hazard of angioedema was nearly 2 times greater in exposed 
patients than matched controls, but the HR of hyperkalemia was 0.84 (0.76-0.94). In OT 
analysis, the HR of death controls was 0.71 (0.62-0.82), while the HR of hospitalization 
was 0.89 (0.85-0.94). HRs of admission for cardiovascular disease and HF were again 
attenuated. The hazard of angioedema was more than 4 times greater in exposed patients 
than matched controls, but the HR of hyperkalemia again favored exposed patients. 
Full models of mortality and hospitalization in ITT analysis are displayed in Table 
4-4. For mortality, cardiologist care during hospitalization (adjusted HR, 1.22), early re-
hospitalization (1.35), and digoxin dispensation (1.51) were each strongly associated with 
mortality risk. On the other hand, beta blocker dispensation (1.08) was weakly associated. 
For hospitalization, early re-hospitalization (1.37) and digoxin dispensation (1.20) were 
strongly associated with admission risk, but other factors, including beta blocker 
dispensation (0.97), were not strongly associated. 
The cumulative incidence of change in exposure status is displayed in Figure 4-4. 
Incidence of the interruption of RAS inhibitor exposure in exposed patients versus 
initiation of exposure in matched controls was 22.3% versus 0.8% at 1 month, 33.6% 
versus 9.2% at 3 months, 45.7% versus 16.1% at 6 months, 58.5% versus 23.7% at 1 
year, 67.3% versus 31.5% at 2 years, and 71.0% versus 35.0% at 3 years. 
Subclass Associations 
 Among 2407 exposed patients, 1881 (78.1%) were dispensed an ACE inhibitor, 
466 (19.4%) were dispensed an ARB, and 60 (2.5%) were dispensed both. The 
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characteristics of exposed patients that received monotherapy and respective matched 
controls are displayed in Table 4-5, with stratification by subclass of monotherapy. ACE 
inhibitor users and matched controls were similar with respect to factors included in the 
propensity score, but they were different with respect to other factors. Relative to 
matched controls, ACE inhibitor users were more likely to have been re-hospitalized 
(9.5% versus 5.5%), dispensed beta blockers (53.3% versus 16.0%), and dispensed 
digoxin (3.4% versus 1.5%). ARB users and matched controls were generally similar 
with respect to factors included in the propensity score, although the prevalence of blacks 
was modestly lower in users and the prevalence of myocardial infarction during HF 
hospitalization was modestly higher. Relative to controls, users were more likely to have 
been dispensed beta blockers (48.1% versus 18.7%) and digoxin (3.0% versus 1.5%). 
Subclass-specific adjusted hazard ratios of mortality and hospitalization are 
displayed in Table 4-6. In ITT analysis, the HR of death for ACE inhibitor users versus 
matched controls was 0.90 (0.80-1.00), whereas the HR for ARB users versus matched 
controls was 0.83 (0.67-1.01); the difference between HRs was compatible with random 
variation (P = 0.11). In OT analysis, the HR for ACE inhibitor users versus controls was 
0.77 (0.66-0.90), whereas the HR for ARB users versus controls was 0.73 (0.54-0.99); the 
difference was compatible with random variation (P = 0.11). Regarding hospitalization, 
in ITT analysis, the HR of admission for ACE inhibitor users versus controls was 0.89 
(0.86-0.92), whereas the HR for ARB users versus controls was 1.00 (0.94-1.07); the 
difference was statistically significant (P < 0.01). Regarding hospitalization for 
cardiovascular disease, the HR of admission for ACE inhibitor users versus controls was 
0.91 (0.86-0.96), whereas the HR for ARB users versus controls was 1.05 (0.94-1.16); the 
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difference was also statistically significant (P < 0.01). Results from OT analysis were 
qualitatively similar.  
Sensitivity Analyses 
 In the first analysis, the case definition was widened to include index hospital 
admissions with either a primary or secondary diagnosis of HF. The results of this 
analysis are displayed in Tables 4-7 and 4-8. We identified 3439 exposed patients and 
6878 controls. The groups were similar with respect to factors included in the propensity 
score. However, relative to matched controls, early re-hospitalization and dispensation of 
beta blockers and digoxin were more likely in exposed patients than controls. In ITT 
analysis, the mortality HR for exposed patients versus controls was 0.88 (0.81-0.96), 
whereas the hospitalization HR was 0.92 (0.88-0.95). In OT analysis, corresponding HRs 
were 0.79 (0.70-0.89) for death and 0.92 (0.88-0.96) for hospitalization. In the second 
analysis, the case definition was narrowed to exclude patients with a history of hospital 
admissions with either a primary or secondary diagnosis of HF. The results of this 
analysis are displayed in Tables 4-9 and 4-10. We identified 1774 exposed patients and 
3548 controls. The ITT HR of death for exposed patients versus controls was 0.79 (0.70-
0.89), whereas the HR of hospitalization was 0.87 (0.82-0.93). In OT analysis, 
corresponding HRs were 0.71 (0.60-0.84) for death and 0.85 (0.79-0.91) for 
hospitalization. 
  
Discussion 
Heart failure is a common cause of morbidity in dialysis patients.  According to 
the Peer Report, in 2010-2011, the hospitalization rate for HF was between 15.5 and 20.6 
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admissions per 100 patient-years during 1 year after dialysis initiation and between 12.4 
and 15.7 admissions per 100 patient-years in prevalent dialysis patients; moreover, the 
30-day rate of re-hospitalization after discharge from hospitalization principally for HF 
was 36.5%, roughly 1.5 times the rate observed in Medicare beneficiaries without 
ESRD.
53,69
 In the broader population, ACE inhibitors and ARBs are strongly 
recommended for treatment of HF with reduced EF.
54
 Whether these agents are similarly 
effective in dialysis patients is unclear. In this study, we used Medicare claims data to 
assess relative hazards of death and hospitalization in patients who were dispensed an 
ACE inhibitor or ARB shortly after discharge from hospitalization principally for HF and 
in matched controls. With adjustment for concomitant use of beta blockers and digoxin, 
we found that treatment with an ACE inhibitor or ARB was associated with 14% lower 
risk of death and 10% lower risk of hospitalization in intention-to-treat analysis. With 
more specific criteria for hospitalized cases, associations were stronger in magnitude. 
Although angioedema was relatively more likely to occur in treated patients, 
hyperkalemia, a problematic side effect of ACE inhibitors and ARBs, was not. Regarding 
the subclasses, we found that ACE inhibitors and ARBs were similarly associated with 
lower hazard of death, but that only ACE inhibitors were associated with lower hazard of 
hospitalization. 
The efficacy of ACE inhibitors for the treatment of HF was conclusively 
demonstrated in the Studies of Left Ventricular Dysfunction (SOLVD), where patients 
with EF ≤ 35% were randomized to receive either 20 mg/day of enalapril or placebo.70 
Patients receiving enalapril had 16% lower risk of death and 26% lower risk of death or 
hospitalization due to HF. Later trials of captopril (SAVE), ramipril (AIRE), and 
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trandolapril (TRACE) collectively established the efficacy of ACE inhibitors for the 
treatment of heart failure after myocardial infarction.
71-73
 The efficacy of ARBs was first 
demonstrated in the Valsartan Heart Failure Trial (Val-HeFT), where stable patients with 
New York Heart Association class II, III, or IV HF were randomized to receive either 
320 mg/day of valsartan or placebo.
74
 Patients receiving valsartan had 20% lower risk of 
the composite of death, hospitalization due to HF, cardiac arrest (with resuscitation), or 
intravenous administration of inotropic or vasodilator medications. Later, the CHARM-
Added trial showed that treatment with candesartan, on top of an ACE inhibitor, reduced 
the risk of cardiovascular death or hospitalization due to HF by 15% in patients with class 
II, III, or IV HF and ejection fraction ≤ 40%; the CHARM-Alternative trial indicated 
similar efficacy of valsartan (versus placebo) in patients with ACE inhibitor 
intolerance.
75-76
 All of these trials, however, were conducted in patients with reduced EF. 
Meta-analysis of trials in patients with HF and preserved EF indicates no benefit with 
inhibition of the renin-angiotensin system.
77
 This may be an important distinction for 
interpretation of our study, as we were unable to differentiate systolic from diastolic heart 
failure. Recent USRDS data suggest that systolic and diastolic heart failure may be 
equally prevalent in dialysis patients.
78
 Plausibly, our results may understate the benefit 
of treatment in patients with reduced EF and overstate the benefit in those with preserved 
EF. 
One trial of ACE inhibition has been completed in dialysis patients. In the 
Fosinopril in Dialysis (FOSIDIAL) study, 397 hemodialysis patients with left ventricular 
hypertrophy were randomized to receive either 20 mg/day of fosinopril or placebo; the 
mean achieved dose in the trial was 13.2 mg/day.
56
 The primary endpoint was a 
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composite of cardiovascular death, nonfatal myocardial infarction, unstable angina, 
stroke, revascularization, hospitalization due to HF, or cardiac arrest (with resuscitation). 
In intention-to-treat analysis, the hazard ratio of the composite for fosinopril versus 
placebo was 0.93 (0.68-1.26); in a per-protocol analysis of 380 patients, the 
corresponding hazard ratio was 0.80 (0.59-1.10). Despite the difference between left 
ventricular hypertrophy and hospitalization principally for HF, as well as differences in 
outcomes, the risk ratios in FOSIDIAL are similar in magnitude to the hazard ratios in 
our study. However, we did not find identify strong associations of treatment with risk of 
ischemic events. This suggests that the primary benefit of RAS inhibition may be in the 
reduction of arrhythmias preceding sudden cardiac death (SCD). Notably, we found that 
inhibition of the RAS was associated with 16% and 29% lower hazards of SCD in ITT 
and OT analyses, respectively. 
Whether ACE inhibitors and ARBs are equally efficacious for the treatment of HF 
has been contested. In a meta-analysis of trials comparing ARBs to ACE inhibitors in 
patients with HF and EF ≤ 40%, there were no significant differences between subclasses 
in rates of death and hospitalization.
79
 We found some quantitative differences in 
mortality hazard ratios between ACE inhibitors and ARBs, although differences were 
compatible with random variation. In ITT analyses of death and cardiovascular death (but 
not SCD), HRs associated with ACE inhibitors versus no treatment were attenuated, 
relative to corresponding HRs associated with ARBs versus no treatment. It is interesting 
to speculate whether the pharmacokinetics of ACE inhibitors and ARBs may be relevant, 
as the former (excluding fosinopril) are removed by hemodialysis and the latter are not.
80
 
Recently, Weir et al reported that initiation of high-dialyzability versus low-dialyzability 
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beta blockers was acutely associated with excess risk of death.
81
 On the other hand, we 
found that only ACE inhibitors were associated with lower risk of hospitalization. 
However, this discrepancy may be attributable to informative censoring, as the lower risk 
of death in ARB-treated patients may have progressively engendered a subset that was in 
relatively poor health, but alive. Inverse probability-of-censoring weighting is needed to 
clarify these results.
82
 
Unsurprisingly, we found that the cumulative incidence of treatment interruption 
for > 2 months was high. Notably, more than 22% of patients who were dispensed an 
ACE inhibitor or ARB discontinued treatment after 1 month, i.e., in most cases, after the 
first 30-day supply was used. By 6 and 12 months, roughly 46% and 59% of exposed 
patients discontinued treatment. Polypharmacy is common in dialysis patients and 
adherence to oral medications is generally low.
83
 These data do not necessarily indicate 
that ACE inhibitors and ARBs are poorly tolerated by dialysis patients. In fact, beta 
blockers, calcium channel blockers, ACE inhibitors, and ARBs are all widely used.
28
 
Instead, these data suggest that the therapeutic potential of RAS inhibition in HF may be 
constrained by the degree to which patients simply refill medication. Delivery of oral 
medications to dialysis facilities may be a useful first step.
84
 
 This study has important limitations. First, as with all observational studies, 
unmeasured confounding may be present, despite use of propensity score matching. In 
light of the relatively high incidence of death in exposed patient and matched controls, it 
is possible that physicians prescribed ACE inhibitors and ARBs to patients that were in 
better health and perceived to benefit from treatment. Second, we were unable to describe 
the nature and severity of HF during the index hospitalization. Medicare claims during 
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the study era rarely differentiated between systolic and diastolic heart failure and ejection 
fraction is not recorded. Third, risk was assessed after HF had necessitated 
hospitalization. Whether the benefits and risks associated with inhibition of the RAS after 
initial diagnosis of HF in the outpatient setting are the same as in our study is unclear and 
thus merits further study. Finally, concomitant use of beta blockers in patients who were 
dispensed an ACE inhibitor or ARB poses a challenge to interpretation of study findings. 
We adjusted for the baseline difference in early exposure to beta blockers; for that matter, 
because beta blockers were weakly associated with risks of death and hospitalization, 
adjustment was relatively unimportant. However, adjustment does not preclude the 
possibility that the survival advantage in exposed patients was partially due to synergistic 
effects of ACE inhibitors and ARBs with beta blockers.
85
 
 In conclusion, this study suggests that pharmacologic inhibition of the renin-
angiotensin system is associated with reduced risk of death and hospitalization in dialysis 
patients with HF. Unknown is whether this association is limited to patients with systolic 
heart failure. Studies with finer definitions of heart failure are needed. This study 
reassuringly suggests that the risk of hyperkalemia necessitating hospitalization is not 
higher with ACE inhibitor or ARB treatment. However, to the extent that ACE inhibitors 
and ARBs are efficacious in heart failure on dialysis, there is clearly room to improve 
rates of prescription and persistence. Only 1 in 5 patients were dispensed an ACE 
inhibitor or ARB within 30 days of discharge to home or home health care, and among 
patients who were dispensed medication, 1 in 5 discontinued treatment after 1 month of 
treatment. Strategies to increase use of these agents may directly improve outcomes in 
chronic dialysis patients. 
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Table 4-1. Characteristics of candidate controls, matched controls, and exposed patients, among heart failure cases ascertained from 
the principal diagnosis 
 Candidate 
controls 
Matched 
controls 
Exposed 
patients 
ASD
 a
 
Sample size 9228 4814 2407  
Age 
b
 (years) 65.9 (14.0) 65.4 (13.9) 65.4 (13.8) 0.0 
Race (%)     
White 56.2 51.4 52.4 1.9 
Black 38.8 43.7 42.7 2.1 
Native American 1.1 0.9 1.1 1.5 
Asian 3.4 3.6 3.5 0.3 
Other 0.4 0.4 0.3 0.4 
Sex (%)     
Female 50.1 49.3 49.4 0.3 
Male 49.9 50.7 50.6 0.3 
Primary cause of ESRD (%)     
Diabetes 43.6 42.7 42.7 0.1 
Hypertension 32.1 33.8 33.3 1.0 
Polycystic kidney disease 9.1 9.2 9.6 1.1 
Glomerulonephritis 2.0 1.7 1.7 0.2 
Other cause 10.1 9.6 9.5 0.4 
Unknown cause 3.3 3.0 3.2 1.2 
ESRD duration 
b
 (years) 5.1 (4.5) 4.8 (4.3) 4.8 (4.4) 1.0 
Low-income subsidy reciept 
b
 (%)     
Not subsidized 30.4 26.8 26.8 0.0 
Subsidized, without Medicaid 10.4 10.9 10.9 0.0 
Subsidized, with Medicaid 59.2 62.2 62.2 0.0 
Risk scores 
c
     
Liu score 7.1 (4.1) 6.4 (4.0) 6.3 (4.0) 2.3 
van Walraven score 17.9 (9.9) 16.5 (9.7) 16.3 (9.7) 1.8 
Medication score 1 -5.3 (8.7) -6.6 (8.7) -6.7 (8.6) 0.5 
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Medication score 2 -5.7 (8.9) -6.6 (8.5) -6.6 (8.9) 0.0 
Medication score 3 10.0 (9.3) 8.5 (8.5) 8.5 (8.5) 0.8 
Medication score 4 13.2 (8.7) 12.1 (8.2) 12.1 (8.2) 0.6 
Body mass index 
d
 (kg / m
2
) 28.2 (7.1) 27.3 (6.5) 27.4 (6.5) 0.8 
Hematocrit 
e
 (%) 33.8 (3.0) 33.7 (3.1) 33.7 (3.0) 0.3 
Hospitalization history 
d
 (days) 8.2 (13.9) 6.9 (12.2) 6.9 (12.6) 0.6 
Kidney transplant waitlist registration 
b
 (%) 11.3 11.9 11.9 0.0 
ESA exposure 
e
     
No exposure (%) 7.0 7.5 7.9 1.5 
Darbepoetin alfa dose 
f
 (mcg) 744 (709) 772 (775) 823 (819) 6.4 
Epoetin alfa dose 
f
 (1000s IU) 230 (222) 223 (213) 223 (213) 0.0 
Intravenous VDA exposure 
e
     
No exposure (%) 21.8 21.0 21.3 0.9 
Calcitriol dose 
f
 (mcg) 33 (28) 38 (29) 34 (26) 15.3 
Doxercalciferol dose 
f
 (mcg) 128 (86) 130 (85) 135 (85) 5.3 
Paricalcitol dose 
f
 (mcg) 170 (139) 172 (139) 173 (139) 0.9 
Dialytic modality 
b
 (%)     
Hemodialysis 97.3 96.7 96.5 1.5 
Peritoneal dialysis 2.7 3.3 3.5 1.5 
Dialysis provider 
b
 (%)     
Fresenius Medical Care 35.7 34.9 34.9 0.0 
DaVita 27.9 27.9 27.6 0.7 
Dialysis Clinic, Inc. (DCI) 3.3 3.0 3.0 0.1 
Small dialysis organization 10.1 10.7 10.9 0.7 
Independent dialysis provider 14.5 15.4 15.5 0.2 
Hospital-based dialysis provider 8.3 7.8 7.8 0.0 
Unknown affiliation 0.1 0.2 0.2 0.5 
Co-incident cardiovascular morbidity 
g
 (%)     
Myocardial infarction 2.2 3.4 3.9 2.4 
Stroke 0.2 0.3 0.3 0.8 
Specialty care during HF hospitalization (%)     
Cardiologist 74.7 84.5 84.3 0.6 
Nephrologist 84.1 86.3 86.5 0.8 
Pulmonologist 18.1 19.0 18.6 1.1 
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Procedures during HF hospitalization (%)     
Coronary catheterization 6.8 12.3 15.7 9.8 
Echocardiogram 23.2 31.4 31.6 0.5 
Electrocardiogram 74.3 76.3 76.9 1.3 
Exercise electrocardiography 6.2 10.4 11.6 3.9 
Myocardial perfusion scintigraphy 4.4 7.4 8.7 4.7 
Length of stay 
g
 (days) 4.3 (3.9) 4.6 (3.8) 4.7 (3.8) 2.5 
Discharge location (%)     
Home, under self-care 80.0 81.6 81.8 0.4 
Home health agency 20.0 18.4 18.2 0.4 
Early re-hospitalization 
h
 (%)  5.9 9.6 14.2 
Concomitant exposure 
h
 (%)     
Beta blocker  16.8 52.6 81.0 
Digoxin  1.3 3.4 13.6 
 
Note: For quantities not displayed as percentages, summaries are displayed as mean and standard deviation (in parentheses). 
Abbreviations: ASD, absolute standardized difference; HF, heart failure; ESA, erythropoiesis-stimulating agent; ESRD, end stage 
renal disease; IU, international units; VDA, vitamin D analogue. 
a
 Difference between exposed patients and matched controls, in percentage of 1 standard deviation. 
b
 At the start of risk. 
c
 During the 12 months before admission for heart failure. 
d
 During the 6 months  before admission for heart failure. 
e
 During the 3 months before admission for heart failure. 
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f
 Among patients with at least one administration. 
g
 During hospitalization for heart failure. 
h
 Between discharge and the start of risk. 
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Table 4-2. Event counts and crude event rates in exposed patients and matched controls, by follow-up rule 
 Intention-to-treat On-treatment 
 Matched 
controls 
Exposed 
patients 
Matched 
controls 
Exposed 
patients 
Patient-years at risk 7035 3762 5207 1745 
Deaths     
All-cause 2344 
(33) 
1123 
(30) 
1811 
(35) 
473 
(27) 
Cardiovascular 1119 
(16) 
545 
(14) 
863 
(17) 
238 
(14) 
Sudden cardiac 647 
(9.2) 
332 
(8.8) 
489 
(9.4) 
145 
(8.3) 
Hospital admissions     
All-cause 22,545 
(320) 
10,906 
(290) 
16,118 
(309) 
5073 
(291) 
Cardiovascular 8706 
(124) 
4230 
(112) 
6136 
(118) 
2178 
(125) 
Heart failure 3542 
(50) 
1728 
(46) 
2492 
(48) 
950 
(54) 
Cardiovascular events     
Myocardial infarction 577 
(8.2) 
285 
(7.6) 
415 
(8.0) 
152 
(8.7) 
Stroke 207 
(2.9) 
135 
(3.6) 
146 
(2.8) 
61 
(3.5) 
Safety events     
Angioedema 27 
(0.38) 
22 
(0.58) 
13 
(0.25) 
11 
(0.63) 
Hyperkalemia 3731 
(53) 
1616 
(43) 
2450 
(47) 
682 
(39) 
 
Note: For events, summaries are displayed as cumulative count and rate per 100 patient-years (in parentheses). 
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Table 4-3. Adjusted hazard ratios for exposed patients versus matched controls, by follow-up rule 
 Intention-to-treat On-treatment 
 HR 95% CI P HR 95% CI P 
Mortality       
All-cause 0.86 (0.78-0.94) < 0.01 0.71 (0.62-0.82) < 0.01 
Cardiovascular 0.88 (0.77-1.01) 0.08 0.75 (0.62-0.91) < 0.01 
Sudden cardiac death 0.84 (0.70-1.01) 0.07 0.81 (0.63-1.05) 0.11 
Hospitalization       
All-cause 0.90 (0.86-0.95) < 0.01 0.89 (0.85-0.94) < 0.01 
Cardiovascular 0.94 (0.88-1.00) 0.04 0.95 (0.89-1.02) 0.19 
Heart failure 0.95 (0.86-1.04) 0.24 1.00 (0.90-1.10) 0.95 
Cardiovascular morbidity       
Myocardial infarction 0.91 (0.76-1.09) 0.30 1.08 (0.86-1.35) 0.53 
Stroke 1.25 (0.95-1.62) 0.11 1.19 (0.85-1.67) 0.32 
Safety       
Angioedema 1.91 (0.95-3.84) 0.07 4.12 (1.39-12.2) 0.01 
Hyperkalemia 0.84 (0.76-0.94) < 0.01 0.84 (0.74-0.96) < 0.01 
 
Abbreviations: CI, confidence interval; HR, hazard ratio. 
 
 87 
 
Table 4-4. Hazard ratios from models of all-cause mortality and all-cause hospitalization in intention-to-treat analysis 
 HR 95% CI P 
All-cause mortality    
ACE inhibitor or ARB 0.86 (0.78-0.94) < 0.01 
Co-incident myocardial infarction 1.16 (0.88-1.53) 0.28 
Cardiologist care during hospitalization 1.22 (1.04-1.42) 0.02 
Procedures during hospitalization    
Coronary catheterization 1.13 (0.93-1.38) 0.23 
Echocardiogram 1.12 (1.00-1.25) 0.06 
Myocardial perfusion scintigraphy 1.04 (0.85-1.27) 0.70 
Early rehospitalization 1.35 (1.11-1.65) < 0.01 
Concomitant exposure    
Beta blocker 1.08 (0.96-1.22) 0.21 
Digoxin 1.51 (1.08-2.10) 0.02 
All-cause hospitalization    
ACE inhibitor or ARB 0.90 (0.86-0.95) < 0.01 
Co-incident myocardial infarction 1.05 (0.92-1.20) 0.50 
Cardiologist care during hospitalization 1.00 (0.92-1.08) 0.99 
Procedures during hospitalization    
Coronary catheterization 0.97 (0.88-1.07) 0.57 
Echocardiogram 0.97 (0.92-1.03) 0.35 
Myocardial perfusion scintigraphy 1.09 (0.98-1.21) 0.10 
Early rehospitalization 1.37 (1.22-1.54) < 0.01 
Concomitant exposure    
Beta blocker 0.97 (0.91-1.03) 0.30 
Digoxin 1.20 (1.00-1.45) 0.05 
 
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; CI, confidence interval; HR, hazard ratio. 
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Table 4-5. Characteristics of ACE inhibitor-exposed patients, ARB-exposed patients, and respective matched patients, among heart 
failure cases ascertained from the principal diagnosis 
 ACE inhibitor ARB 
 Matched 
controls 
Exposed 
patients 
ASD
 a
 Matched 
controls 
Exposed 
patients 
ASD
 a
 
Sample size 3762 1881  932 466  
Age 
b
 (years) 65.5 (13.9) 65.6 (13.6) 1.1 65.4 (14.1) 64.8 (14.5) 3.8 
Race (%)       
White 51.8 52.5 1.3 50.6 53.0 4.7 
Black 43.5 43.5 0.0 43.9 38.0 12.0 
Native American 0.9 1.1 2.4 1.4 1.1 2.9 
Asian 3.5 2.7 4.6 3.8 7.1 14.7 
Other 0.3 0.2 2.1 0.3 0.9 7.0 
Sex (%)       
Female 49.7 47.9 3.6 50.1 54.9 9.7 
Male 50.3 52.1 3.6 49.9 45.1 9.7 
Primary cause of ESRD (%)       
Diabetes 42.1 42.4 0.7 42.5 44.6 4.3 
Hypertension 34.0 34.0 0.1 32.7 30.0 5.8 
Polycystic kidney disease 9.7 9.0 2.1 8.9 11.4 8.2 
Glomerulonephritis 1.8 1.8 0.0 1.7 1.7 0.0 
Other cause 9.3 9.5 0.9 10.7 9.4 4.3 
Unknown cause 3.2 3.3 0.3 3.4 2.8 3.7 
ESRD duration 
b
 (years) 4.8 (4.4) 4.8 (4.3) 1.0 4.7 (4.0) 5.0 (4.4) 7.2 
Low-income subsidy reciept 
b
 (%)       
Not subsidized 27.6 27.6 0.0 24.3 24.3 0.0 
Subsidized, without Medicaid 10.9 10.9 0.0 10.7 10.7 0.0 
Subsidized, with Medicaid 61.6 61.6 0.0 65.0 65.0 0.0 
Risk scores 
c
       
Liu score 6.4 (4.0) 6.3 (4.0) 2.6 6.2 (3.9) 6.3 (4.0) 2.1 
van Walraven score 16.6 (9.8) 16.3 (9.7) 3.2 16.0 (9.2) 16.5 (10.0) 4.9 
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Medication score 1 -6.6 (8.7) -6.6 (8.6) 2.4 -6.9 (8.6) -6.4 (8.7) 11.1 
Medication score 2 -6.6 (8.9) -6.6 (8.9) 1.6 -6.7 (8.7) -6.5 (8.9) 6.9 
Medication score 3 8.5 (8.5) 8.5 (8.5) 0.7 8.4 (8.6) 8.6 (8.3) 5.8 
Medication score 4 12.2 (8.2) 12.1 (8.2) 1.0 12.0 (7.9) 12.1 (8.2) 0.8 
Body mass index 
d
 (kg / m
2
) 27.3 (6.5) 27.4 (6.5) 2.2 27.6 (6.6) 27.4 (6.4) 3.2 
Hematocrit 
e
 (%) 33.6 (3.1) 33.7 (3.0) 2.5 33.9 (3.0) 33.6 (3.0) 9.7 
Hospitalization history 
d
 (days) 7.1 (12.7) 6.9 (12.4) 1.3 6.6 (11.9) 6.6 (13.0) 0.7 
Kidney transplant waitlist registration 
b
 (%) 11.8 10.9 2.8 13.3 15.7 6.7 
ESA exposure 
e
       
No exposure (%) 7.4 7.9 2.1 7.9 7.9 0.0 
Darbepoetin alfa dose 
f
 (mcg) 786 (778) 832 (824) 5.8 760 (690) 772 (825) 1.6 
Epoetin alfa dose 
f
 (1000s IU) 225 (217) 219 (208) 3.0 214 (196) 231 (229) 8.0 
Intravenous VDA exposure 
e
       
No exposure (%) 22.5 21.7 1.9 20.3 20.2 0.3 
Calcitriol dose 
f
 (mcg) 36 (25) 34 (26) 10.6 41 (47) 38 (25) 8.0 
Doxercalciferol dose 
f
 (mcg) 130 (83) 133 (81) 4.2 134 (85) 142 (98) 8.3 
Paricalcitol dose 
f
 (mcg) 172 (134) 175 (142) 2.2 173 (155) 165 (128) 5.6 
Dialytic modality 
b
 (%)       
Hemodialysis 96.1 96.4 1.8 97.1 96.6 3.1 
Peritoneal dialysis 3.9 3.6 1.8 2.9 3.4 3.1 
Dialysis provider 
b
 (%)       
Fresenius Medical Care 34.8 35.4 1.3 36.6 31.8 10.2 
DaVita 27.1 27.3 0.4 29.6 29.4 0.5 
Dialysis Clinic, Inc. (DCI) 2.8 3.4 3.7 2.6 1.7 5.9 
Small dialysis organization 11.2 10.7 1.5 10.6 12.7 6.4 
Independent dialysis provider 15.6 14.7 2.4 14.5 17.8 9.1 
Hospital-based dialysis provider 8.4 8.4 0.1 6.1 6.4 1.3 
Unknown affiliation 0.3 0.2 2.3 0.0 0.2 NA 
Co-incident cardiovascular morbidity 
g
 (%)       
Myocardial infarction 3.7 3.7 0.0 2.6 4.7 11.5 
Stroke 0.4 0.3 0.5 0.1 0.4 6.2 
Specialty care during HF hospitalization (%)       
Cardiologist 84.1 84.8 1.9 85.2 83.3 5.3 
Nephrologist 86.4 86.5 0.3 86.6 87.8 3.5 
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Pulmonologist 19.0 18.2 2.2 19.5 20.4 2.2 
Procedures during HF hospitalization (%)       
Coronary catheterization 12.8 16.0 9.2 11.1 15.0 11.8 
Echocardiogram 30.4 31.9 3.2 33.4 31.3 4.4 
Electrocardiogram 76.6 76.6 0.0 75.2 78.5 7.9 
Exercise electrocardiography 10.6 11.9 4.0 9.8 10.9 3.9 
Myocardial perfusion scintigraphy 7.6 8.9 4.7 6.6 7.5 3.8 
Length of stay 
g
 (days) 4.5 (3.8) 4.6 (3.7) 1.6 4.7 (3.9) 4.9 (4.3) 4.6 
Discharge location (%)       
Home, under self-care 81.3 81.7 1.0 82.5 81.1 3.6 
Home health agency 18.7 18.3 1.0 17.5 18.9 3.6 
Early re-hospitalization 
h
 (%) 5.5 9.5 15.2 6.2 7.1 3.5 
Concomitant exposure 
h
 (%)       
Beta blocker 16.0 53.3 85.3 18.7 48.1 65.6 
Digoxin 1.5 3.4 11.7 1.5 3.0 10.1 
 
Note: For quantities not displayed as percentages, summaries are displayed as mean and standard deviation (in parentheses). 
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; ASD, absolute standardized difference; HF, 
heart failure; ESA, erythropoiesis-stimulating agent; ESRD, end stage renal disease; IU, international units; VDA, vitamin D 
analogue. 
a
 Difference between exposed patients and matched controls, in percentage of 1 standard deviation. 
b
 At the start of risk. 
c
 During the 12 months before admission for heart failure. 
d
 During the 6 months  before admission for heart failure. 
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e
 During the 3 months before admission for heart failure. 
f
 Among patients with at least one administration. 
g
 During hospitalization for heart failure. 
h
 Between discharge and the start of risk. 
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Table 4-6. Adjusted hazard ratios for ACE-inhibitor exposed patients versus respective matched controls and ARB-exposed patients 
versus respective matched controls, by follow-up rule  
 Intention-to-treat On-treatment 
 HR 95% CI P HR 95% CI P 
Mortality       
All-cause       
ACE inhibitor 0.90 (0.80.1-00)  0.77 (0.66-0.90)  
ARB 0.83 (0.67-1.01) 0.11 0.73 (0.54-0.99) 0.11 
Cardiovascular       
ACE inhibitor 0.94 (0.80-1.10)  0.81 (0.65-1.01)  
ARB 0.82 (0.61-1.10) 0.06 0.77 (0.51-1.16) 0.58 
Sudden cardiac death       
ACE inhibitor 0.84 (0.68-1.04)  0.87 (0.64-1.17)  
ARB 0.97 (0.68-1.39) 0.16 0.89 (0.54-1.48) 0.16 
Hospitalization       
All-cause       
ACE inhibitor 0.89 (0.86-0.92)  0.88 (0.84-0.92)  
ARB 1.00 (0.94-1.07) < 0.01 0.98 (0.89-1.07) < 0.01 
Cardiovascular       
ACE inhibitor 0.91 (0.86-0.96)  0.91 (0.84-0.98)  
ARB 1.05 (0.94-1.16) < 0.01 1.15 (1.00-1.32) < 0.01 
Heart failure       
ACE inhibitor 0.92 (0.84-1.01)  0.96 (0.85-1.08)  
ARB 1.01 (0.86-1.20) 0.03 1.10 (0.89-1.36) 0.12 
 
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; CI, confidence interval; HR, hazard ratio. 
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Table 4-7. Characteristics of candidate controls, matched controls, and exposed patients, among heart failure cases ascertained from 
principal and secondary diagnoses 
 Candidate 
controls 
Matched 
controls 
Exposed 
patients 
ASD
 a
 
Sample size 16,084 6878 3439  
Age 
b
 (years) 64.7 (14.3) 63.9 (14.3) 63.9 (14.2) 0.1 
Race (%)     
White 54.9 50.5 50.4 0.1 
Black 39.9 43.9 43.7 0.4 
Native American 1.4 1.7 1.6 0.7 
Asian 3.4 3.5 3.8 1.2 
Other 0.5 0.5 0.6 1.2 
Sex (%)     
Female 48.5 47.1 47.3 0.4 
Male 51.5 52.9 52.7 0.4 
Primary cause of ESRD (%)     
Diabetes 42.5 41.1 41.0 0.2 
Hypertension 31.2 33.0 32.9 0.2 
Polycystic kidney disease 9.6 10.4 10.3 0.3 
Glomerulonephritis 2.3 2.2 2.3 1.2 
Other cause 11.1 10.3 10.2 0.2 
Unknown cause 3.4 3.1 3.3 0.9 
ESRD duration 
b
 (years) 5.6 (5.0) 5.2 (4.7) 5.2 (4.8) 0.5 
Low-income subsidy reciept 
b
 (%)     
Not subsidized 29.9 25.2 25.2 0.0 
Subsidized, without Medicaid 10.5 10.6 10.6 0.0 
Subsidized, with Medicaid 59.7 64.2 64.2 0.0 
Risk scores 
c
     
Liu score 5.4 (3.6) 4.6 (3.4) 4.6 (3.5) 1.1 
van Walraven score 14.4 (9.1) 13.1 (8.7) 13.0 (8.6) 0.6 
Medication score 1 -5.5 (8.3) -7.3 (8.0) -7.3 (8.0) 0.1 
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Medication score 2 -5.7 (8.5) -6.8 (8.4) -6.9 (8.4) 1.0 
Medication score 3 8.7 (8.7) 6.7 (7.6) 6.8 (7.7) 0.9 
Medication score 4 11.8 (8.2) 10.4 (7.6) 10.5 (7.6) 0.6 
Body mass index 
d
 (kg / m
2
) 28.7 (7.3) 27.7 (6.6) 27.7 (6.6) 0.1 
Hematocrit 
e
 (%) 34.0 (3.0) 33.8 (3.1) 33.9 (3.1) 0.6 
Hospitalization history 
d
 (days) 5.6 (11.6) 4.5 (9.7) 4.5 (9.8) 0.2 
Kidney transplant waitlist registration 
b
 (%) 13.1 13.0 13.1 0.4 
ESA exposure 
e
     
No exposure (%) 9.2 10.5 10.7 0.5 
Darbepoetin alfa dose 
f
 (mcg) 699 (713) 795 (820) 777 (832) 2.2 
Epoetin alfa dose 
f
 (1000s IU) 218 (222) 216 (216) 212 (212) 2.0 
Intravenous VDA exposure 
e
     
No exposure (%) 24.3 24.3 24.1 0.3 
Calcitriol dose 
f
 (mcg) 32 (29) 35 (30) 32 (31) 8.7 
Doxercalciferol dose 
f
 (mcg) 132 (90) 136 (93) 137 (88) 0.8 
Paricalcitol dose 
f
 (mcg) 173 (136) 181 (146) 178 (138) 2.0 
Dialytic modality 
b
 (%)     
Hemodialysis 95.6 95.6 95.7 0.4 
Peritoneal dialysis 4.4 4.4 4.3 0.4 
Dialysis provider 
b
 (%)     
Fresenius Medical Care 34.2 33.8 34.0 0.5 
DaVita 27.4 28.4 28.2 0.3 
Dialysis Clinic, Inc. (DCI) 3.6 3.7 3.9 0.7 
Small dialysis organization 9.8 9.9 10.2 0.7 
Independent dialysis provider 15.3 15.6 15.5 0.3 
Hospital-based dialysis provider 9.4 8.2 7.9 1.2 
Unknown affiliation 0.2 0.4 0.4 0.2 
Co-incident cardiovascular morbidity 
g
 (%)     
Myocardial infarction 5.2 10.2 12.8 7.9 
Stroke 0.6 0.9 1.0 0.9 
Specialty care during HF hospitalization (%)     
Cardiologist 68.5 83.4 82.8 1.7 
Nephrologist 84.2 85.7 85.8 0.3 
Pulmonologist 17.0 19.6 20.1 1.1 
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Procedures during HF hospitalization (%)     
Coronary catheterization 8.9 18.6 22.1 8.8 
Echocardiogram 23.0 32.5 33.2 1.4 
Electrocardiogram 67.1 74.1 73.6 1.2 
Exercise electrocardiography 5.5 10.1 10.7 2.1 
Myocardial perfusion scintigraphy 4.0 7.4 8.2 2.8 
Length of stay 
g
 (days) 5.3 (5.4) 5.6 (5.0) 5.8 (5.1) 2.1 
Discharge location (%)     
Home, under self-care 79.0 80.4 80.6 0.6 
Home health agency 21.0 19.6 19.4 0.6 
Early re-hospitalization 
h
 (%)  5.8 10.6 17.6 
Concomitant exposure 
h
 (%)     
Beta blocker  19.5 54.4 77.6 
Digoxin  1.3 2.8 10.1 
 
Note: For quantities not displayed as percentages, summaries are displayed as mean and standard deviation (in parentheses). 
Abbreviations: ASD, absolute standardized difference; HF, heart failure; ESA, erythropoiesis-stimulating agent; ESRD, end stage 
renal disease; IU, international units; VDA, vitamin D analogue. 
a
 Difference between exposed patients and matched controls, in percentage of 1 standard deviation. 
b
 At the start of risk. 
c
 During the 12 months before admission for heart failure. 
d
 During the 6 months  before admission for heart failure. 
e
 During the 3 months before admission for heart failure. 
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f
 Among patients with at least one administration. 
g
 During hospitalization for heart failure. 
h
 Between discharge and the start of risk. 
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Table 4-8. Adjusted hazard ratios for exposed patients versus matched controls, by follow-up rule, among heart failure cases 
ascertained from principal and secondary diagnoses 
 Intention-to-treat On-treatment 
 HR 95% CI P HR 95% CI P 
Mortality       
All-cause 0.88 (0.81-0.96) < 0.01 0.79 (0.70-0.89) < 0.01 
Cardiovascular 0.91 (0.80-1.03) 0.12 0.85 (0.72-1.01) 0.06 
Sudden cardiac death 0.93 (0.80-1.09) 0.39 0.91 (0.73-1.14) 0.41 
Hospitalization       
All-cause 0.92 (0.88-0.95) < 0.01 0.92 (0.88-0.96) < 0.01 
Cardiovascular 0.98 (0.92-1.04) 0.46 1.04 (0.98-1.12) 0.19 
Heart failure 1.11 (1.01-1.21) 0.02 1.23 (1.11-1.36) < 0.01 
Cardiovascular morbidity       
Myocardial infarction 0.97 (0.83-1.14) 0.69 1.28 (1.05-1.57) 0.01 
Stroke 1.02 (0.82-1.28) 0.84 0.98 (0.73-1.31) 0.90 
Safety       
Angioedema 1.76 (0.86-3.58) 0.12 2.30 (0.83-6.34) 0.11 
Hyperkalemia 0.85 (0.78-0.94) < 0.01 0.81 (0.73-0.91) < 0.01 
 
Abbreviations: CI, confidence interval; HR, hazard ratio. 
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Table 4-9. Characteristics of candidate controls, matched controls, and exposed patients, among heart failure cases ascertained from 
principal diagnoses, but with broad exclusion criteria regarding history of heart failure 
 Candidate 
controls 
Matched 
controls 
Exposed 
patients 
ASD
 a
 
Sample size 6448 3548 1774  
Age 
b
 (years) 65.5 (14.2) 64.9 (14.2) 64.9 (14.1) 0.2 
Race (%)     
White 55.9 50.9 50.8 0.3 
Black 38.9 43.7 43.8 0.3 
Native American 1.0 1.1 1.2 0.8 
Asian 3.7 3.9 3.8 0.3 
Other 0.4 0.4 0.4 0.4 
Sex (%)     
Female 49.5 49.1 48.7 0.7 
Male 50.5 50.9 51.3 0.7 
Primary cause of ESRD (%)     
Diabetes 41.7 41.0 39.9 2.3 
Hypertension 32.2 33.3 33.8 0.9 
Polycystic kidney disease 10.0 10.1 10.7 1.9 
Glomerulonephritis 2.2 2.0 2.0 0.2 
Other cause 10.5 10.2 10.2 0.3 
Unknown cause 3.3 3.4 3.6 1.2 
ESRD duration 
b
 (years) 5.4 (4.6) 5.1 (4.5) 5.1 (4.4) 0.6 
Low-income subsidy reciept 
b
 (%)     
Not subsidized 30.5 26.6 26.6 0.0 
Subsidized, without Medicaid 10.4 11.2 11.2 0.0 
Subsidized, with Medicaid 59.1 62.3 62.3 0.0 
Risk scores 
c
     
Liu score 6.4 (4.0) 5.6 (3.8) 5.5 (3.8) 2.7 
van Walraven score 16.5 (9.8) 15.0 (9.4) 14.8 (9.4) 1.9 
Medication score 1 -5.8 (8.5) -7.3 (8.5) -7.3 (8.4) 0.8 
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Medication score 2 -6.1 (8.8) -7.1 (8.8) -7.1 (8.8) 0.1 
Medication score 3 9.1 (9.1) 7.6 (8.2) 7.6 (8.2) 0.8 
Medication score 4 12.4 (18.5) 11.3 (8.0) 11.3 (7.9) 0.8 
Body mass index 
d
 (kg / m
2
) 28.2 (7.0) 27.5 (6.7) 27.5 (6.5) 0.5 
Hematocrit 
e
 (%) 33.7 (3.0) 33.6 (3.0) 33.6 (2.9) 0.3 
Hospitalization history 
d
 (days) 7.2 (12.7) 6.3 (12.1) 6.0 (12.1) 2.4 
Kidney transplant waitlist registration 
b
 (%) 12.7 13.1 13.3 0.5 
ESA exposure 
e
     
No exposure (%) 6.9 7.2 7.8 2.3 
Darbepoetin alfa dose 
f
 (mcg) 743 (697) 778 (729) 835 (839) 7.3 
Epoetin alfa dose 
f
 (1000s IU) 234 (225) 225 (211) 222 (208) 1.3 
Intravenous VDA exposure 
e
     
No exposure (%) 21.5 20.8 21.0 0.4 
Calcitriol dose 
f
 (mcg) 31 (28) 36 (29) 33 (25) 11.7 
Doxercalciferol dose 
f
 (mcg) 130 (87) 136 (91) 139 (88) 4.1 
Paricalcitol dose 
f
 (mcg) 169 (136) 177 (144) 176 (142) 0.2 
Dialytic modality 
b
 (%)     
Hemodialysis 97.0 96.6 96.3 1.5 
Peritoneal dialysis 3.0 3.4 3.7 1.5 
Dialysis provider 
b
 (%)     
Fresenius Medical Care 35.6 34.9 34.0 1.8 
DaVita 28.3 26.7 27.3 1.5 
Dialysis Clinic, Inc. (DCI) 3.5 3.1 3.2 0.5 
Small dialysis organization 9.9 11.6 11.8 0.4 
Independent dialysis provider 14.3 16.0 15.7 1.0 
Hospital-based dialysis provider 8.2 7.5 7.8 1.2 
Unknown affiliation 0.1 0.2 0.2 0.6 
Co-incident cardiovascular morbidity 
g
 (%)     
Myocardial infarction 2.3 3.4 4.1 3.4 
Stroke 0.1 0.2 0.3 2.7 
Specialty care during HF hospitalization (%)     
Cardiologist 75.0 86.0 86.0 0.0 
Nephrologist 83.4 87.3 86.0 3.9 
Pulmonologist 18.0 18.9 18.7 0.6 
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Procedures during HF hospitalization (%)     
Coronary catheterization 7.3 12.7 16.9 11.8 
Echocardiogram 24.0 30.6 32.0 2.9 
Electrocardiogram 74.5 76.3 76.8 1.3 
Exercise electrocardiography 6.8 10.6 12.9 6.9 
Myocardial perfusion scintigraphy 4.6 7.4 9.6 8.0 
Length of stay 
g
 (days) 4.2 (3.9) 4.5 (3.7) 4.6 (3.7) 1.6 
Discharge location (%)     
Home, under self-care 81.2 83.0 83.3 0.9 
Home health agency 18.8 17.0 16.7 0.9 
Early re-hospitalization 
h
 (%)  5.9 9.4 13.2 
Concomitant exposure 
h
 (%)     
Beta blocker  16.3 52.5 82.3 
Digoxin  1.5 3.0 10.7 
 
Note: For quantities not displayed as percentages, summaries are displayed as mean and standard deviation (in parentheses). 
Abbreviations: ASD, absolute standardized difference; HF, heart failure; ESA, erythropoiesis-stimulating agent; ESRD, end stage 
renal disease; IU, international units; VDA, vitamin D analogue. 
a
 Difference between exposed patients and matched controls, in percentage of 1 standard deviation. 
b
 At the start of risk. 
c
 During the 12 months before admission for heart failure. 
d
 During the 6 months  before admission for heart failure. 
e
 During the 3 months before admission for heart failure. 
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f
 Among patients with at least one administration. 
g
 During hospitalization for heart failure. 
h
 Between discharge and the start of risk. 
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Table 4-10. Adjusted hazard ratios for exposed patients versus matched controls, by follow-up rule, among heart failure cases 
ascertained from principal diagnoses, but with broad exclusion criteria regarding history of heart failure 
 Intention-to-treat On-treatment 
 HR 95% CI P HR 95% CI P 
Mortality       
All-cause 0.79 (0.70-0.89) < 0.01 0.71 (0.60-0.84) < 0.01 
Cardiovascular 0.82 (0.69-0.98) 0.03 0.78 (0.61-1.00) 0.05 
Sudden cardiac death 0.77 (0.61-0.97) 0.03 0.80 (0.57-1.11) 0.18 
Hospitalization       
All-cause 0.87 (0.82-0.93) < 0.01 0.85 (0.79-0.91) < 0.01 
Cardiovascular 0.92 (0.85-0.99) 0.03 1.01 (0.92-1.10) 0.90 
Heart failure 0.96 (0.86-1.07) 0.43 1.05 (0.93-1.18) 0.46 
Cardiovascular morbidity       
Myocardial infarction 1.14 (0.92-1.42) 0.23 1.24 (0.93-1.65) 0.14 
Stroke 1.14 (0.82-1.59) 0.44 1.04 (0.69-1.56) 0.87 
Safety       
Angioedema 1.65 (0.71-3.84) 0.24 2.09 (0.51-8.53) 0.30 
Hyperkalemia 0.85 (0.74-0.98) 0.02 0.75 (0.65-0.87) < 0.01 
 
Abbreviations: CI, confidence interval; HR, hazard ratio. 
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Figure 4-1A. Cumulative incidence of death for exposed patients and matched controls in 
intention-to-treat follow-up 
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Figure 4-1B. Cumulative incidence of death for exposed patients and matched controls in 
on-treatment follow-up 
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Figure 4-2A. Cumulative incidence of cardiovascular death for exposed patients and 
matched controls in intention-to-treat follow-up 
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Figure 4-2B. Cumulative incidence of cardiovascular death for exposed patients and 
matched controls in on-treatment follow-up 
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Figure 4-3A. Cumulative incidence of sudden cardiac death for exposed patients and 
matched controls in intention-to-treat follow-up 
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Figure 4-3B. Cumulative incidence of sudden cardiac death for exposed patients and 
matched controls in on-treatment follow-up 
 
 109 
 
Figure 4-4. Cumulative incidence of change in exposure status for exposed patients and 
matched controls 
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Chapter 5 
Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and 
Angiotensin Receptor Blockers in Hemodialysis Patients with Heart Failure 
Abstract 
Both angiotensin-converting enzyme (ACE) inhibitors and angiotensin-receptor 
blockers (ARBs) are commonly used to treat heart failure (HF), but few studies have 
compared clinical outcomes across agents in these classes. In dialysis patients, 
differences in the properties of these agents may have significant consequences. We used 
data from the United States Renal Data System to assess the relative hazards of death and 
hospitalization associated with use of benazepril, enalapril, lisinopril, ramipril, losartan, 
and valsartan in dialysis patients that had been discharged after hospitalization principally 
for HF. Discharges were ascertained from Medicare Part A claims between January 1, 
2007, and December 31, 2011. ACE inhibitor and ARB exposure was ascertained from 
Part D claims during the 1 month following discharge. We fit adjusted Cox and 
Anderson-Gill models of death and hospitalization, respectively, and used nonparametric 
bootstrapping to compare and rank hazards associated with agents. There were 3854, 
1208, 685, 624, and 457 users of lisinopril, valsartan, enalapril, losartan, benazepril, and 
ramipril, respectively. In intention-to-treat analysis, relative to lisinopril, mortality hazard 
ratios (HRs) were 0.84 (95% confidence interval, 0.75-0.94) for valsartan, 0.89 (0.77-
1.01) for enalapril, 0.97 (0.85-1.09) for losartan, 0.96 (0.82-1.13) for benazepril, and 1.15 
(0.96-1.36) for ramipril. The bootstrapped probability that valsartan was associated with 
lowest risk was 71.3%. The hospitalization HR for valsartan versus lisinopril was 0.93 
(0.87-0.99). After 3 months of treatment, 56.4% of lisinopril users received 20 or 40 
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mg/day, whereas 80.6% of valsartan users received 160 or 320 mg/day. However, after 
12 months, more than 50% of users in each group had experienced an interruption in 
treatment for > 1 month. In summary, these data suggest that the choice of a renin-
angiotensin system inhibitor for HF in dialysis patient may be important; lisinopril may 
not be the ideal agent. Randomized trials are needed to confirm findings.
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Introduction 
Pharmacologic inhibition of the renin-angiotensin system (RAS) is recommended 
for the treatment of heart failure (HF) with reduced ejection fraction (EF); for the 
treatment of HF with preserved EF, inhibition of the RAS may be effective, but evidence 
is equivocal.
86-87
 Inhibition of the RAS may be achieved with angiotensin-converting 
enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs). Today, there are ten 
orally administered ACE inhibitors and eight ARBs available for prescription in the US. 
Meta-analysis of trials that enrolled patients with HF indicates that ARBs are superior to 
placebo in reducing risks of death and HF hospitalization, but non-inferior to ACE 
inhibitors.
88
 Whether class effects exist among ACE inhibitors and ARBs is unclear.
89
 
Not all agents were tested in randomized clinical trials of patients with HF. Moreover, 
differences in absorption, distribution, metabolism, and excretion may engender 
differences in clinical efficacy. For patients without renal function, the selection of an 
ACE inhibitor or ARB may be especially important. The ratio of renal to hepatic 
elimination varies widely across ACE inhibitors and ARBs.
90
 Potentially more 
importantly, all ACE inhibitors except fosinopril are cleared by dialysis, whereas ARBs 
are not cleared.
91
 Studies are clearly needed to guide physicians in selection of these 
agents. 
In this study, we used United States Renal Data System (USRDS) data to compare 
risks of mortality and hospitalization among four ACE inhibitors (benazepril, enalapril, 
fosinopril, lisinopril) and two ARBs (losartan, valsartan) in dialysis patients who were 
discharged from the hospital with a principal diagnosis of HF. Data regarding medication 
exposure were ascertained from Medicare Part D claims. We assessed all-cause death, 
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cardiovascular death, sudden cardiac death, all-cause hospitalization, cardiovascular 
hospitalization, and HF hospitalization. 
 
Methods 
Protection of Human Subjects 
We analyzed USRDS data that were obtained by a Data Use Agreement with the 
National Institute of Diabetes and Digestive and Kidney Diseases. The study was 
reviewed by the Human Subjects Research Committee at Hennepin County Medical 
Center (Minneapolis, Minnesota). 
Study Cohort 
 The source cohort included prevalent and incident dialysis patients. For the 
former, we retained patients with receipt of dialysis on December 31, 2007 (i.e., index 
date); uninterrupted receipt of one dialytic modality (i.e., either hemodialysis or 
peritoneal dialysis) during 2007; date of initiation of renal replacement therapy no later 
than October 31, 2006; age between 20 and 100 years on the index date; and 
uninterrupted enrollment in Medicare Parts A and B during the 12-month interval 
immediately preceding the index date. For the latter, we retained patients with date of 
initiation of dialysis (i.e., index date) between January 1, 2007, and December 31, 2009; 
age between 20 and 100 years on the index date; and uninterrupted enrollment in 
Medicare Parts A and B during the 12-month interval immediately preceding the index 
date. For both groups, we required non-missing data regarding race, sex, primary cause of 
ESRD, and ESRD Network of residence on the index date. We excluded patients with a 
hospitalization for HF (International Classification of Diseases, Ninth Revision, Clinical 
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Modification [ICD-9-CM] diagnosis code 402.11, 402.91, 404.01, 404.03, 404.11, 
404.13, 404.91, 404.93, or 428.x as principal diagnosis
92
) during the 12-month interval 
immediately preceding the index date. 
We followed each patient from the index date to the earliest of death, kidney 
transplant, interruption of enrollment in Medicare Parts A and B, or December 31, 2011. 
During follow-up, we identified the first hospitalization for HF. We retained hospitalized 
patients with Medicare Part D enrollment during the 12-month interval immediately 
preceding the date of admission, in receipt of hemodialysis after admission, and with 
discharge to home, under either self-care or the supervision of a home health agency. 
Patient Characteristics 
 For each patient, we ascertained age, race, sex, primary cause of ESRD, ESRD 
duration, ESRD Network of residence, socioeconomic status, comorbidity scores, body 
mass index (BMI), hematocrit, recent hospitalization, kidney transplant wait-list status, 
erythropoiesis-stimulating agent (ESA) and intravenous vitamin D analogue (VDA) 
exposure, dialytic modality, dialysis provider, HF hospitalization factors (co-incident 
myocardial infarction and stroke, physician specialty care, diagnostic procedures, and 
length of stay), and discharge location. The risk scores comprised 2 comorbidity scores 
and 4 medication scores. For comorbidity, we used the Liu score and the van Walraven 
score derived from Elixhauser comorbid conditions.
93-94
 In each score, we declared a 
condition to be present if we identified at ≥ 1 inpatient facility, skilled nursing facility, or 
home health agency claim or ≥ 2 outpatient facility or physician claims with qualifying 
ICD-9-CM diagnosis codes, as defined by Quan et al, during the 12 months preceding 
admission.
95-96
 For medication, we used scores derived from dispensed medications 
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during the 12 months preceding admission.
97
 BMI and hematocrit were calculated from 
the means of measurements on outpatient dialysis and ESA claims, respectively, during 
the 6 months preceding admission. Hospitalization history was summarized by 
cumulative hospitalized days during the 6 months preceding admission, whereas ESA and 
intravenous VDA exposure were summarized by cumulative doses during the 3 months 
preceding admission. Dialytic modality and dialysis provider were identified on the day 
before admission. During HF hospitalization, myocardial infarction was identified from 
ICD-9-CM diagnosis codes 410.x0 and 410.x1;
98
 stroke was identified from codes 430.x, 
431.x, 434.x, and 436.x.
99
 Specialty care was identified from physician claims concurrent 
with hospitalization; diagnostic procedures were identified from both ICD-9-CM 
procedure codes on inpatient facility claims and Current Procedural Terminology (CPT) 
codes on physician claims concurrent with hospitalization. 
Exposure 
 From Part D claims in the 1 month following discharge, we identified dispensed 
ACE inhibitors and ARBs, according to the National Drug Code and the associated 
Generic Product Identifier (GPI) code in the Medi-Span Master Drug Database 
(Indianapolis, IN). We included combination products with an ACE inhibitor or ARB. 
We retained patients who were dispensed only one ACE inhibitor or ARB in the month. 
In consideration of statistical power, we retained only patients who were dispensed 
benazepril, enalapril, lisinopril, ramipril, losartan, or valsartan. The history and properties 
of these agents are described in Appendix 2. 
 We set the start of risk at the date of first dispensation. Between discharge and the 
start of risk, we identified incidence of rehospitalization and dispensation of beta blockers 
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and digoxin. We also identified dispensation of RAS inhibitors during the 3 months 
preceding admission. 
 Regarding the RAS inhibitor at the start of risk, we calculated prescribed dose per 
day from the quotient of pill count and days supplied, given the dose per pill indicated by 
the NDC. We updated prescribed dose per day on the date of each subsequent fill. 
Outcomes 
We followed all patients from the start of risk to the earliest of death; kidney 
transplant; interruption of enrollment Medicare in Parts A, B, and D; or December 31, 
2011. We identified the incidence of death and hospitalization. We also measured 
proportion of days covered (PDC) by supply of the initial RAS inhibitor.
100
 
Statistical Analysis 
We calculated statistical summaries of measured factors in each treatment group 
and also estimated absolute standardized differences between lisinopril users and 
valsartan users.
101
 We used intention-to-treat (ITT) and on-treatment (OT) rules during 
follow-up. For the ITT rule, we followed patients from the start of risk to the earliest of 
death; kidney transplant; interruption of enrollment Medicare in Parts A, B, and D; or 
December 31, 2011. For the OT rule, we added interruption of treatment with initial RAS 
inhibitor to the list of dates on which follow-up may end. Specifically, interruption of 
treatment was defined at the end of the first 1-month interval without supply of the initial 
RAS inhibitor or 1 month after first dispensation of an alternative RAS inhibitor. 
For mortality, we used Kaplan-Meier analysis to estimate survival in treatment 
groups. To compare survival in these groups, we used Cox proportional hazards 
regression to estimate relative hazards. The model was adjusted for all patient 
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characteristics, as well as recent history of dispensation of RAS inhibitors, incidence of 
rehospitalization between discharge and start of risk, and concomitant dispensation of 
beta blockers and digoxin. Continuous covariates, except for length of stay, were 
parameterized with linear monomials; length of stay was parameterized with a quadratic 
polynomial. For hospitalization, we used Andersen-Gill regression to estimate relative 
hazards of admission. The model was adjusted for the same factors as in the model for 
mortality. For both regression models, we used nonparametric bootstrapping with 2000 
iterations to estimate model parameters and associated 95% confidence intervals. 
Furthermore, we derived empirical distributions of the ranks of relative hazards 
associated with treatment groups. 
Regarding exposure during OT follow-up, we calculated the distribution of 
prescribed dose per day at the start of risk and at 3, 6, 9, and 12 months thereafter. We 
also calculated the cumulative incidence of RAS inhibitor interruption and treatment 
group crossover (to another RAS inhibitor), with death as a competing risk. Finally, we 
used bootstrapping to estimate mean PDC during OT follow-up and 2 variations thereon, 
with interruptions of treatment defined at the end of the first k-month interval without 
supply of the initial RAS inhibitor or k months after first dispensation of an alternative 
RAS inhibitor (k = 2, 3). 
All analyses were conducted in SAS, version 9.2 (Cary, North Carolina), except 
for the exposure status crossover analysis, which was conducted in R, version 3.1.2 
(Vienna, Austria). 
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Results 
 We identified 7132 hospitalized cases of HF. In the 1 month following discharge, 
3854 (54.0%) patients were dispensed lisinopril, 1208 (16.9%) valsartan, 685 (9.6%) 
enalapril, 624 (8.7%) losartan, 457 (6.4%) benazepril, and 304 (4.3%) ramipril. The 
characteristics of patients are displayed in Table 5-1, with stratification by agent. Age 
was highest in ramipril users (mean, 66.9 years) and lowest in benazepril users (63.8 
years). Whites were relatively more likely to use ramipril, while Asians were relatively 
more likely to use losartan or valsartan. Females were also relatively more likely to use 
losartan or valsartan. Mean comorbidity scores were similar across agents, although mean 
hospitalized days, both during the 6 months before HF hospitalization and during the HF 
hospitalization itself, suggested that enalapril and ramipril users were less healthy than 
other users. During the 3 months before HF hospitalization, use of RAS inhibitors was 
highest in valsartan (82.2%), benazepril (79.7%), and losartan (79.3%) users; 
intermediate in enalapril (71.1%) users; and lowest in lisinopril (66.4%) and ramipril 
(65.5%) users. Prevalence of early re-hospitalization and dispensation of beta blockers 
was similar across agents. Between lisinopril and valsartan users specifically, several 
substantial differences (absolute standardized difference > 10%) in characteristics were 
apparent. Asian race, female sex, and diabetes as the primary cause of ESRD were more 
likely in valsartan users. Valsartan users were more likely to be subsidized and dually 
enrolled in Medicare and Medicaid than lisinopril users.  
 Histories of daily dose distributions of ACE inhibitors and ARBs are displayed in 
Table 2. At the start of risk, the most common doses were 40 mg (39.8%) of benazepril, 
40 mg (27.4%) of enalapril, 40 mg (30.4%) of lisinopril, 10 mg (36.8%) of ramipril, 100 
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mg (57.7%) of losartan, and 320 mg (49.8%) of valsartan. During OT follow-up, dose 
distributions shifted in the positive direction. However, the most common doses remained 
the same, with the exception of enalapril: at 3 months and thereafter, the most common 
daily dose of enalapril was 80 mg. 
 Event counts and crude event rates are displayed in Table 5-3. In ITT follow-up, 
patients accumulated 11,232 patient-years of follow-up. Mean follow-up per patient 
ranged from 1.51 years in ramipril users to 1.68 years in enalapril users. For mortality, 
crude rates ranged from 24 deaths per 100 patient-years for valsartan to 35 deaths per 100 
patient-years for ramipril; the crude rate for lisinopril was intermediate (29 deaths per 
100 patient-years). For hospitalization, crude rates ranged from 295 admissions per 100 
patient-years for ramipril to 321 admissions per 100 patient-years for lisinopril. In OT 
follow-up, patients accumulated 4379 patient-years of follow-up. Mean follow-up per 
patient ranged from 0.57 years in ramipril users to 0.67 years in valsartan users. Mortality 
rates ranged from 17 deaths per 100 patient-years for losartan to 31 deaths per 100 
patient-years for ramipril; the rate for lisinopril was again intermediate (24 deaths per 100 
patient-years). Hospitalization rates ranged from 280 admissions per 100 patient-years for 
valsartan to 305 admissions per 100 patient-years for lisinopril. 
 Estimates of survival are displayed are displayed in Figures 5-1A and 5-1B. In 
ITT analysis, 1-year survival estimates were 79.3% for valsartan, 77.9% for enalapril, 
77.2% for losartan, 74.6% for lisinopril, 74.5% for benazepril, and 68.7% for ramipril 
(Figure 5-1A). After 2 years, survival remained highest for valsartan and lowest for 
ramipril. In contrast, 1-year survival estimates by OT analysis were 84.9% for losartan, 
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82.2% for valsartan, 81.7% for enalapril, 80.9% for benazepril, 78.9% for lisinopril, and 
76.8% for ramipril. 
 Adjusted hazard ratios (HRs) of death for pairwise comparisons of agents are 
displayed in Table 5-4. In ITT analysis, relative to lisinopril, adjusted HRs were 0.96 for 
benazepril, 0.89 for enalapril, 1.15 for ramipril, 0.97 for losartan, and 0.84 for valsartan; 
the contrast of valsartan to lisinopril was statistically significant (P < 0.05). Adjusted 
HRs for valsartan versus all other agents were less than 1, while HRs for ramipril versus 
all other agents were greater than 1. In OT analysis, relative to lisinopril, adjusted HRs 
were 0.90 for benazepril, 0.92 for enalapril, 1.19 for ramipril, 0.76 for losartan, and 0.78 
for valsartan; the contrasts of both losartan and valsartan to lisinopril were statistically 
significant (P < 0.05). Adjusted HRs for ramipril versus all other agents were greater than 
1. Meanwhile, adjusted HRs for losartan versus all other agents were less than 1, 
although the HR of losartan versus valsartan was only 0.97 (95% confidence interval, 
0.72-1.29). Bootstrapped probabilities of the ranks of adjusted relative hazards associated 
with the agents are displayed in Figures 5-2A and 5-2B. In ITT analysis, the estimated 
probability that valsartan was associated with lowest risk was 71.3%, whereas the 
probability that enalapril was associated with lowest risk was 22.4% (Figure 5-2A). The 
probability that lisinopril was associated with lowest risk was 0%. Meanwhile, the 
probability that ramipril was associated with highest risk was 89.6%. In OT analysis, the 
probability that either losartan or valsartan was associated with lowest risk was 84.3% 
(Figure 5-2B). 
 Adjusted HRs of hospitalization for pairwise comparisons of agents are displayed 
in Table 5-5. In ITT analysis, relative to lisinopril, adjusted HRs were 1.02 for 
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benazepril, 0.97 for enalapril, 0.94 for ramipril, 1.03 for losartan, and 0.93 for valsartan; 
the contrast of valsartan to lisinopril was statistically significant (P < 0.05). Adjusted 
HRs for valsartan versus all other agents were less than 1. In OT analysis, contrasts were 
generally weak in magnitude. HRs for losartan versus all other agents were greater than 
1, but HRs for valsartan versus all other agents were less than 1. Bootstrapped 
probabilities of the ranks of adjusted relative hazards associated with the agents are 
displayed in Figures 5-2C and 5-2D. In ITT analysis, the estimated probability that 
valsartan was associated with lowest risk was 52.7% (Figure 5-2C). The probability that 
lisinopril was associated with lowest risk was 0.1%. In OT analysis, the probability that 
valsartan was associated with lowest risk was 39.9%, whereas the probability that 
lisinopril was associated with lowest risk was 0.3% (Figure 5-2D). 
 The cumulative incidence of RAS inhibitor interruption is displayed in Figure 5-3. 
After 1 month, the incidence of interruption was 23.4% for ramipril, 22.4% for enalapril, 
20.6% for lisinopril, 17.9% for each of losartan and valsartan, and 16.4% for benazepril. 
After 12 months, the incidence of interruption was 63.2% for ramipril, 63.0% for 
enalapril, 61.0% for lisinopril, 58.6% for losartan, 56.5% for valsartan, and 55.2% for 
benazepril. The cumulative incidence of treatment group crossover is displayed in Figure 
5-4.  After 12 months, the incidence of crossover was 11.2% for benazepril, 7.6% for 
enalapril, 7.2% for valsartan, 6.1% for losartan, 5.0% for lisinopril, and 4.8% for 
ramipril. Thus, after 12 months, the combined incidence of interruption or crossover was 
highest for enalapril (70.8%) and lowest for valsartan (63.8%). Finally, mean PDC is 
displayed in Table 5-6. Regardless of follow-up rule, PDC was similar across agents. 
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Discussion 
By American Heart Association guidelines, ACE inhibitors are recommended in 
patients with heart failure and reduced EF, whereas ARBs are recommended in the subset 
of patients who are ACE inhibitor-intolerant.
86
 The guidelines offer no recommendations 
regarding the selection of individual ACE inhibitors or ARBs, and few agents have ever 
been evaluated in randomized clinical trials of patients with heart failure, particularly in 
absence of myocardial infarction. However, there are several pharmacokinetic differences 
among the agents and the effects of these differences may be magnified in patients with 
little or no kidney function. In this study, we assessed comparative effectiveness of 6 
agents that were dispensed to hemodialysis patients after discharge from hospitalization 
principally for heart failure: benazepril, enalapril, lisinopril, ramipril, losartan, and 
valsartan. We found that lisinopril was the dominant agent in this setting. However, with 
respect to risks of death and hospitalization, we found little evidence to support its 
preferential use. Instead, estimated probabilities that valsartan was associated with lowest 
risks of death and hospitalization were 71% and 53%, respectively, in ITT analysis. 
The pharmacology of ACE inhibitors and ARBs is clearly different. ACE 
inhibitors block the catalytic activity of angiotensin-converting enzyme, thus inhibiting 
conversion of angiotensin I to angiotensin II and breakdown of bradykinin.
102
 On the 
other hand, ARBs antagonize the type I angiotensin II receptor in blood vessels and 
cardiac tissue, but do not increase the concentration of bradykinin.
91
 Because of different 
effects on bradykinin, ARBs are less likely to induce cough than ACE inhibitors and thus 
may be better tolerated.
103
 In this study, we found that the combined incidence of 
interruption and change in treatment was lowest for valsartan. Within subclasses, there 
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are subtle differences among agents. Among ACE inhibitors in this study, lisinopril is the 
only agent that is not a prodrug that requires metabolism in the liver; this may be an 
important feature in hemodialysis patients with not only heart failure, but also fluid 
overload (e.g., between dialysis sessions) and resultant hepatic congestion.
104
 However, 
we found little evidence that risks of death and hospitalization were substantially lower 
for lisinopril versus each of benazepril and enalapril. Typical dosing schedules may 
differ, as a function of half-lives. Both lisinopril and ramipril are typically taken once per 
day, whereas enalapril is taken twice per day. For dialysis patients, in whom 
polypharmacy is common, adherence to once-daily doses may be superior.
105
 All of the 
ACE inhibitors in this study are cleared by hemodialysis. (Technically, benazepril is 
cleared by hemodialysis, but its active metabolite, benazeprilat, is not.) In contrast, 
neither of the ARBs are cleared. This may be important; Weir et al reported that high-
dialyzability versus low-dialyzability beta blockers were associated with excess risk of 
death.
106
 Among ARBs, there are also differences. Losartan has significantly less affinity 
to the type I angiotensin II receptor than valsartan, although the active metabolite of 
losartan (EXP3174) is a noncompetitive antagonist of the receptor.
107
 Regarding 
hemodialysis patients specifically, Gamboa et al compared effects of valsartan and 
ramipril in a small crossover trial (n = 15).
108
 The study found that ramipril, but not 
valsartan, conferred pro-inflammatory effects that might mediate increased 
cardiovascular risk. 
An important aspect of efficacy is dose achievement. In the Assessment of 
Treatment with Lisinopril and Survival (ATLAS) trial, high-risk heart failure patients 
were randomized to receive either 32.5-35.0 mg/day or 2.5-5.0 mg/day of lisinopril.
109
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Patients who received the high dose experienced 12% lower risk of death or 
hospitalization and 24% fewer admissions for heart failure. In the HEALL trial of high-
dose (150 mg/day) versus low-dose (50 mg/day) losartan, those who received the high 
dose experienced 13% fewer admissions for heart failure.
110
 We found that roughly 50% 
to 60% of patients that received valsartan were dispensed the target dose of 320 mg/day. 
On the other hand, more than half of lisinopril users were dispensed doses of 20 mg/day 
or less. Although we could not identify the reasons for relatively low doses of lisinopril in 
the study cohort, of concern is the possibility that patients could not tolerate upward 
titration.  
This study has several limitations. First, unmeasured confounding may exist. We 
adjusted for baseline differences in demographic and comorbid factors, but cannot 
exclude the possibility that groups of  patients were channeled to some agents. For 
example, descriptive data suggest that ramipril users were older, more likely to be white, 
and less likely to be subsidized than users of all other agents. Second, risk contrasts were 
functions of available formulations of the 6 agents in 2007-2011. Ramipril became 
available in generic form in 2008, losartan in 2010, and valsartan in 2012 (i.e., after the 
end of the study era). It is uncertain whether relative risks associated with branded and 
generic forms of valsartan are equivalent. Third, available sample size constrained the 
precision of relative risk estimates. In order to improve precision, we included patients 
with and without exposure to ACE inhibitors or ARBs during the 3-month interval 
preceding index hospitalization. Future studies should confirm study findings in cohorts 
comprising new users. 
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In conclusion, we found heterogeneous hazards of death and hospitalization 
associated with exposure to 4 ACE inhibitors and 2 ARBs in hemodialysis patients with 
heart failure. These data suggest that clinical outcomes may be improved by substituting 
valsartan for lisinopril at the time of discharge from hospitalization principally for heart 
failure. The reasons for lower risk of death and hospitalization in valsartan users are 
unclear, but lower risk may reflect the relatively high proportion of valsartan users who 
were dispensed target doses of 320 mg/day. More studies are needed to clarify the 
generalizability of results, including whether valsartan is superior to all ACE inhibitors 
and whether valsartan is associated with lowest risk among ACE inhibitors and ARBs in 
dialysis patients without heart failure.
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Table 5-1. Characteristics of exposed patients, by agent, among HF cases ascertained from the principal diagnosis 
 ACE inhibitors ARBs ASD
 a
 
 Benazepril Enalapril Lisinopril Ramipril Losartan Valsartan  
Sample size 457 685 3854 304 624 1208  
Age 
b
 (years) 63.8 (12.5) 64.4 (13.4) 64.4 (13.7) 66.9 (13.3) 65.5 (13.2) 64.8 (13.7) 3.3 
Race (%)        
White 48.4 47.7 49.5 55.9 50.0 49.4 0.2 
Black 45.5 49.9 47.1 40.5 42.5 42.7 8.8 
Asian 6.1 2.3 3.4 3.6 7.5 7.9 19.6 
Sex (%)        
Female 53.4 48.6 50.6 51.0 58.7 58.6 16.1 
Male 46.6 51.4 49.4 49.0 41.4 41.4 16.1 
Primary cause of ESRD (%)        
Diabetes 50.1 45.7 45.6 51.3 47.6 50.6 10.1 
Hypertension 36.5 32.0 32.9 28.0 31.4 30.3 5.5 
Polycystic kidney disease 6.1 8.3 8.7 7.2 8.5 8.0 2.4 
Glomerulonephritis 0.9 2.9 1.7 2.6 1.3 1.2 3.9 
Other cause 5.0 7.9 8.2 9.2 8.0 7.5 2.3 
Unknown cause 1.3 3.2 3.0 1.6 3.2 2.4 9.8 
ESRD duration 
b
 (years) 4.4 (3.5) 5.1 (4.3) 4.9 (4.1) 4.9 (4.2) 5.1 (4.1) 5.0 (4.3) 2.3 
Low-income subsidy reciept 
b
 (%)        
Not subsidized 14.2 21.0 22.1 29.3 22.4 17.5 11.5 
Subsidized, without Medicaid 10.7 10.2 11.2 8.2 9.6 9.1 7.0 
Subsidized, with Medicaid 75.1 68.8 66.7 62.5 68.0 73.4 14.7 
Risk scores 
c
        
Liu score 6.1 (4.0) 6.8 (4.0) 6.6 (4.0) 7.0 (3.9) 6.7 (4.1) 6.5 (3.8) 2.8 
van Walraven score 15.6 (9.4) 17.2 (10.0) 16.6 (9.6) 17.6 (10.0) 16.6 (9.6) 16.4 (9.3) 2.1 
Medication score 1 -5.9 (7.7) -7.4 (8.4) -7.6 (8.4) -5.5 (8.3) -8.3 (8.8) -8.2 (8.5) 7.4 
Medication score 2 -5.1 (7.4) -6.7 (8.4) -7.1 (9.0) -5.7 (8.5) -7.9 (9.2) -7.3 (8.6) 2.4 
Medication score 3 9.0 (8.5) 8.8 (8.8) 8.9 (8.6) 9.7 (8.8) 8.5 (8.4) 8.8 (8.6) 0.5 
Medication score 4 13.3 (8.4) 12.8 (7.9) 13.0 (8.4) 13.2 (8.2) 12.9 (8.0) 13.4 (8.1) 4.2 
Body mass index 
d
 (kg / m
2
) 27.8 (6.5) 27.0 (6.3) 27.3 (6.7) 27.9 (6.9) 27.8 (6.5) 27.7 (6.7) 6.8 
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Hematocrit 
e
 (%) 33.8 (2.9) 33.7 (3.0) 33.6 (3.0) 33.7 (2.9) 33.6 (3.0) 33.7 (2.8) 1.1 
Hospitalization history 
d
 (days) 6.3 (10.3) 8.3 (13.7) 7.3 (12.0) 8.2 (16.5) 6.5 (10.6) 7.1 (11.8) 1.7 
Kidney transplant waitlist registration 
b
 (%) 11.8 14.0 11.5 9.5 14.7 14.5 8.8 
ESA exposure 
e
        
No exposure (%) 4.4 5.4 3.9 4.0 3.7 2.9 5.6 
Darbepoetin alfa dose 
f
 (mcg) 811 (520) 1056 (815) 770 (769) 763 (654) 888 (946) 895 (744) 16.6 
Epoetin alfa dose 
f
 (1000s IU) 245 (226) 229 (204) 240 (215) 229 (199) 235 (216) 246 (218) 2.8 
Intravenous VDA exposure        
No exposure (%) 16.2 17.7 15.7 16.8 17.0 14.9 2.2 
Calcitriol dose 
f
 (mcg) 31 (20) 39 (34) 47 (37) 17 (14) 39 (56) 31 (32) 46.8 
Doxercalciferol dose 
f
 (mcg) 138 (83) 130 (84) 134 (90) 128 (73) 147 (97) 126 (84) 10.0 
Paricalcitol dose 
f
 (mcg) 174 (123) 174 (135) 175 (138) 202 (158) 180 (134) 170 (135) 3.7 
RAS inhibitor exposure 
e
 (%) 79.7 71.1 66.4 65.5 79.3 82.2 36.8 
Dialysis provider 
b
 (%)        
Fresenius Medical Care 36.1 34.0 34.5 34.5 31.3 30.9 7.7 
DaVita 30.9 27.0 31.3 21.7 30.9 33.2 4.1 
Dialysis Clinic, Inc. (DCI) 4.2 2.0 4.4 4.0 3.9 2.6 9.8 
Small dialysis organization 10.9 10.7 10.2 10.5 10.7 10.5 1.0 
Independent dialysis provider 15.1 19.6 11.6 16.5 15.9 16.8 15.0 
Hospital-based dialysis provider 2.8 6.7 8.1 12.8 7.4 6.0 8.0 
Co-incident myocardial infarction 
g
 (%) 2.8 2.3 2.9 2.6 4.0 2.6 2.2 
Specialty care during HF hospitalization (%)        
Cardiologist 72.4 80.6 80.1 79.9 79.0 77.4 6.6 
Nephrologist 82.7 82.0 86.4 85.5 85.6 84.8 4.5 
Pulmonologist 17.3 18.1 16.3 16.5 20.5 19.4 8.0 
Procedures during HF hospitalization (%)        
Coronary catheterization 10.3 13.3 10.5 13.2 10.7 11.5 3.1 
Echocardiogram 27.1 29.3 25.7 31.3 27.9 25.6 0.2 
Electrocardiogram 71.3 76.6 76.8 76.6 78.2 76.2 1.2 
Exercise electrocardiography 9.0 8.0 9.0 7.9 7.1 8.8 0.9 
Myocardial perfusion scintigraphy 7.2 6.9 6.6 7.6 6.3 5.8 3.2 
Length of stay 
g
 (days) 4.0 (3.0) 4.5 (3.5) 4.1 (3.5) 4.3 (3.9) 4.2 (3.8) 4.2 (3.2) 1.2 
Discharge location (%)        
Home, under self-care 85.8 82.9 82.2 79.3 79.8 82.9 1.9 
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Home health agency 14.2 17.1 17.9 20.7 20.2 17.1 1.9 
Early rehospitalization 
h
 (%) 9.9 9.8 11.1 11.5 9.5 10.8 1.1 
Concomitant exposure 
h
 (%)        
Beta blocker 49.0 53.3 53.9 54.3 48.9 50.6 6.6 
Digoxin 0.7 4.1 2.5 4.3 2.4 2.0 3.4 
 
Note: For quantities not displayed as percentages, summaries are displayed as mean and standard deviation (in parentheses). 
Abbreviations: ASD, absolute standardized difference; HF, heart failure; ESA, erythropoiesis-stimulating agent; ESRD, end stage 
renal disease; IU, international units; VDA, vitamin D analogue. 
a
 Difference between valsartan users and lisinopril users, in percentage of 1 standard deviation. 
b
 At the start of risk. 
c
 During the 12 months before admission for heart failure. 
d
 During the 6 months  before admission for heart failure. 
e
 During the 3 months before admission for heart failure. 
f
 Among patients with at least one administration. 
g
 During hospitalization for heart failure. 
h
 Between discharge and the start of risk. 
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Table 5-2. Daily dose distributions during the first 12 months of on-treatment follow-up 
 Time since date of first fill 
 0 Months 3 Months 6 Months 9 Months 12 Months 
Sample size 7132 3769 2100 1347 919 
ACE inhibitors      
Benazepril (%)      
5 mg 5.5 3.3 2.1 2.4 1.2 
10 mg 14.0 11.8 12.3 12.0 9.6 
20 mg 33.0 30.2 32.6 34.4 36.1 
40 mg 39.8 44.9 44.9 44.8 47.0 
80 mg 7.7 9.8 8.0 6.4 6.0 
Enalapril (%)      
2.5 mg 10.4 8.4 7.5 7.6 7.7 
5 mg 15.0 12.8 9.1 5.3 4.3 
10 mg 20.1 18.1 17.4 16.5 13.7 
20 mg 27.0 27.0 27.0 28.2 30.8 
40 mg 27.4 33.7 39.0 42.4 43.6 
Lisinopril (%)      
2.5 mg 9.2 6.9 5.7 5.3 4.2 
5 mg 12.9 10.5 9.3 8.6 8.1 
10 mg 19.0 16.4 15.1 14.4 12.9 
20 mg 20.9 22.4 21.6 21.9 23.2 
40 mg 30.4 34.0 38.2 37.8 39.2 
80 mg 7.5 9.9 10.1 12.0 12.3 
Ramipril (%)      
2.5 mg 25.7 22.5 19.2 17.6 20.0 
5 mg 22.7 20.9 22.1 30.9 26.7 
10 mg 36.8 36.8 39.4 35.3 42.2 
20 mg 13.2 17.0 18.3 14.7 8.9 
40 mg 1.6 2.7 1.0 1.5 2.2 
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ARBs      
Losartan (%)      
25 mg 12.3 10.1 7.0 5.6 5.6 
50 mg 28.2 24.2 22.9 21.3 18.3 
100 mg 57.7 63.5 67.4 69.1 72.2 
200 mg 1.8 2.2 2.7 3.9 4.0 
Valsartan (%)      
40 mg 1.6 4.4 3.7 4.7 4.7 
80 mg 17.1 15.0 12.7 12.4 12.0 
160 mg 28.6 27.9 24.7 25.0 24.5 
320 mg 49.8 52.7 58.9 58.0 58.8 
 
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blocker. 
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Table 5-3. Event counts and crude event rates, by agent 
 ACE inhibitors ARBs 
 Benazepril Enalapril Lisinopril Ramipril Losartan Valsartan 
Patient-years at risk       
Intention-to-treat 764 1151 5858 458 983 2018 
On-treatment 277 393 2308 173 414 814 
All-cause mortality       
Intention-to-treat 201 
(26) 
302 
(26) 
1688 
(29) 
162 
(35) 
261 
(27) 
483 
(24) 
On-treatment 60 
(22) 
85 
(22) 
559 
(24) 
54 
(31) 
72 
(17) 
149 
(18) 
All-cause hospitalization       
Intention-to-treat 2217 
(305) 
3410 
(313) 
17,844 
(321) 
1286 
(295) 
2924 
(313) 
5712 
(297) 
On-treatment 757 
(285) 
1118 
(297) 
6775 
(305) 
479 
(288) 
1189 
(299) 
2197 
(280) 
 
Note: For events, summaries are displayed as cumulative count and rate per 100 patient-years (in parentheses). 
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blocker. 
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Table 5-4. Adjusted hazard ratios of death for pairwise comparisons of ACE inhibitors and ARBs, by follow-up rule 
 ACE inhibitors ARBs 
 Benazepril Enalapril Lisinopril Ramipril Losartan Valsartan 
Intention-to-treat       
ACE inhibitors       
Benazepril  1.09 
(0.90-1.31) 
0.96 
(0.82-1.13) 
0.84 
(0.67-1.05) 
1.00 
(0.82-1.20) 
1.15 
(0.96-1.37) 
Enalapril 0.92 
(0.76-1.12) 
 0.89 
(0.77-1.01) 
0.77 
(0.62-0.95) 
0.92 
(0.77-1.08) 
1.06 
(0.91-1.22) 
Lisinopril 1.04 
(0.88-1.22) 
1.13 
(0.99-1.30) 
 0.87 
(0.73-1.04) 
1.04 
(0.92-1.18) 
1.19 
(1.07-1.33) 
Ramipril 1.20 
(0.95-1.50) 
1.30 
(1.06-1.60) 
1.15 
(0.96-1.36) 
 1.19 
(0.96-1.45) 
1.37 
(1.13-1.66) 
ARBs       
Losartan 1.00 
(0.83-1.22) 
1.09 
(0.92-1.29) 
0.97 
(0.85-1.09) 
0.84 
(0.69-1.04) 
 1.15 
(0.99-1.34) 
Valsartan 0.87 
(0.73-1.04) 
0.95 
(0.82-1.10) 
0.84 
(0.75-0.94) 
0.73 
(0.60-0.89) 
0.87 
(0.75-1.01) 
 
On-treatment       
ACE inhibitors       
Benazepril  0.98 
(0.67-1.43) 
0.90 
(0.67-1.21) 
0.76 
(0.52-1.11) 
1.19 
(0.82-1.72) 
1.16 
(0.83-1.59) 
Enalapril 1.02 
(0.70-1.49) 
 0.92 
(0.71-1.17) 
0.78 
(0.54-1.13) 
1.21 
(0.85-1.70) 
1.18 
(0.88-1.57) 
Lisinopril 1.11 
(0.83-1.49) 
1.08 
(0.85-1.41) 
 0.84 
(0.63-1.15) 
1.31 
(1.02-1.71) 
1.28 
(1.05-1.57) 
Ramipril 1.32 
(0.90-1.94) 
1.29 
(0.89-1.96) 
1.19 
(0.87-1.58) 
 1.56 
(1.07-2.25) 
1.52 
(1.09-2.14) 
ARBs       
Losartan 0.84 
(0.58-1.22) 
0.83 
(0.59-1.17) 
0.76 
(0.59-0.98) 
0.64 
(0.44-0.93) 
 0.97 
(0.72-1.29) 
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Valsartan 0.87 
(0.63-1.20) 
0.85 
(0.64-1.13) 
0.78 
(0.64-0.96) 
0.66 
(0.47-0.91) 
1.03 
(0.77-1.39) 
 
 
Note: Hazard ratios are interpreted as hazard associated with agent in row, relative to agent in column; for example, the intention-to-
treat hazard ratio of death for valsartan versus benazepril was 0.87. Statistically significant contrasts (P < 0.05) are displayed in 
boldface type. 
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blocker. 
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Table 5-5. Adjusted hazard ratios of hospitalization for pairwise comparisons of ACE inhibitors and ARBs, by follow-up rule 
 ACE inhibitors ARBs 
 Benazepril Enalapril Lisinopril Ramipril Losartan Valsartan 
Intention-to-treat       
ACE inhibitors       
Benazepril  1.06 
(0.93-1.19) 
1.02 
(0.92-1.14) 
1.08 
(0.93-1.26) 
1.00 
(0.88-1.12) 
1.10 
(0.98-1.24) 
Enalapril 0.95 
(0.84-1.08) 
 0.97 
(0.89-1.04) 
1.02 
(0.90-1.18) 
0.94 
(0.86-1.04) 
1.05 
(0.95-1.15) 
Lisinopril 0.98 
(0.88-1.08) 
1.03 
(0.96-1.12) 
 1.06 
(0.94-1.19) 
0.98 
(0.91-1.05) 
1.08 
(1.01-1.16) 
Ramipril 0.92 
(0.79-1.08) 
0.98 
(0.85-1.11) 
0.94 
(0.84-1.06) 
 0.92 
(0.80-1.05) 
1.02 
(0.90-1.06) 
ARBs       
Losartan 1.00 
(0.89-1.13) 
1.06 
(0.96-1.17) 
1.03 
(0.95-1.10) 
1.09 
(0.95-1.24) 
 1.11 
(1.02-1.21) 
Valsartan 0.91 
(0.81-1.02) 
0.96 
(0.87-1.06) 
0.93 
(0.87-0.99) 
0.98 
(0.86-1.11) 
0.90 
(0.83-0.98) 
 
On-treatment       
ACE inhibitors       
Benazepril  1.04 
(0.88-1.20) 
0.98 
(0.86-1.11) 
1.05 
(0.87-1.25) 
0.95 
(0.81-1.11) 
1.06 
(0.90-1.24) 
Enalapril 0.97 
(0.83-1.14) 
 0.95 
(0.85-1.05) 
1.01 
(0.86-1.19) 
0.92 
(0.80-1.15) 
1.03 
(0.89-1.17) 
Lisinopril 1.02 
(0.90-1.16) 
1.06 
(0.95-1.17) 
 1.07 
(0.93-1.22) 
0.97 
(0.88-1.07) 
1.09 
(0.97-1.20) 
Ramipril 0.96 
(0.80-1.16) 
0.99 
(0.84-1.16) 
0.94 
(0.82-1.07) 
 0.91 
(0.78-1.07) 
1.02 
(0.85-1.19) 
ARBs       
Losartan 1.05 
(0.90-1.23) 
1.09 
(0.95-1.25) 
1.03 
(0.93-1.14) 
1.10 
(0.93-1.28) 
 1.12 
(0.98-1.26) 
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Valsartan 0.94 
(0.80-1.11) 
0.97 
(0.85-1.12) 
0.92 
(0.84-1.03) 
0.98 
(0.84-1.17) 
0.89 
(0.79-1.02) 
 
 
Note: Hazard ratios are interpreted as hazard associated with agent in row, relative to agent in column; for example, the intention-to-
treat hazard ratio of death for valsartan versus benazepril was 0.91. Statistically significant contrasts (P < 0.05) are displayed in 
boldface type. 
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blocker. 
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Table 5-6. Proportions of days covered with supplied medication, by on-treatment follow-up rule 
 Maximum gap between supplies 
 1 month 2 months 3 months 
ACE inhibitors    
Benazepril 75.7 
(74.2-77.3) 
69.4 
(67.5-71.4) 
66.6 
(64.5-68.8) 
Enalapril 72.9 
(71.6-74.2) 
66.0 
(64.4-67.6) 
62.6 
(60.8-64.3) 
Lisinopril 74.2 
(73.6-74.8) 
68.4 
(67.7-69.1) 
65.7 
(64.9-66.5) 
Ramipril 73.1 
(71.2-74.9) 
66.4 
(63.9-68.8) 
62.5 
(59.7-65.2) 
ARBs    
Losartan 75.4 
(74.1-76.7) 
69.6 
(67.8-71.2) 
66.6 
(64.7-68.5) 
Valsartan 75.6 
(74.6-76.6) 
70.0 
(68.8-71.3) 
67.1 
(65.7-68.5) 
 
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blocker. 
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Figure 5-1A. Unadjusted survival by initial RAS inhibitor agent in intention-to-treat 
follow-up 
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Figure 5-1B. Unadjusted survival by initial RAS inhibitor agent in on-treatment follow-
up 
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Figure 5-2A. Bootstrapped probabilities of ranks of relative hazards associated with initial RAS inhibitor agents, for death in 
intention-to-treat follow-up 
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Figure 5-2B. Bootstrapped probabilities of ranks of relative hazards associated with initial RAS inhibitor agents, for death in on-
treatment follow-up 
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Figure 5-2C. Bootstrapped probabilities of ranks of relative hazards associated with initial RAS inhibitor agents, for hospitalization in 
intention-to-treat follow-up 
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Figure 5-2D. Bootstrapped probabilities of ranks of relative hazards associated with initial RAS inhibitor agents, for hospitalization in 
on-treatment follow-up 
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Figure 5-3. Cumulative incidence of RAS inhibitor interruption, by initial RAS inhibitor 
agent. 
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Figure 5-4. Cumulative incidence of treatment group crossover (to another RAS 
inhibitor), by initial RAS inhibitor agent. 
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Chapter 6 
Conclusion 
 The studies in this dissertation collectively demonstrate the potential of Medicare 
Part D claims to improve epidemiologic methodology, as well as to create clinical 
evidence in disease states characterized by a paucity of high-quality studies (i.e., 
randomized clinical trials). In the first study, I constructed risk scores based on 
prescription drug claims in dialysis patients. In the second study, I assessed the efficacy 
and safety of ACE inhibitors and ARBs in heart failure on dialysis. In the third study, I 
assessed the relative hazards of death and hospitalization for 4 ACE inhibitors and 2 
ARBs and applied nonparametric bootstrapping to neatly summarize rankings of the 6 
agents. Although each study has important limitations, each study also opens new 
avenues for further exploration, both in dialysis patients and in patients without ESRD. 
 Risk scores can be useful tools in clinical and epidemiologic settings. The 
ubiquity of the Charlson Comorbidity Index in epidemiologic studies across diverse 
disease states is proof of concept. However, risk scores should in principle be designed to 
reflect important comorbid conditions, biochemical concentrations, or medication 
exposures in the disease state of interest. I constructed multiple risk scores that can be 
used in dialysis patients. Of course, it is cumbersome to use unique scores for different 
outcomes at different points in the natural history of a disease. In light of the results of 
the first study of this dissertation, the outstanding challenge is to create a unifying risk 
score that can be used in studies of mortality and morbidity alike, possibly with scaling 
factors for point values to reflect the modifying influence of time since dialysis initiation. 
More generally, the algorithm that I have proposed can be applied to patients without 
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ESRD. For example, scores based on prescription drug claims might be developed for 
patients with CKD Stage 3 or Stage 4 or for patients with other pathologies, such as 
cardiovascular disease. In the grandest scheme, risk scores could be constructed (and 
updated) for dozens of disease states and then mapped to a common scale, such that the 
calculation and interpretation of scores could be automated by electronic health record 
systems and results could be packaged for patients. 
 The efficacy of ACE inhibitors and ARBs for the treatment of heart failure with 
reduced ejection fraction is well-established in patients with normal renal function. Very 
little data, however, exist to support their use in patients with kidney failure. Because all 
ACE inhibitors and an increasing number of ARBs are available in generic formulations, 
there is very little likelihood of a large randomized clinical trial of a RAS inhibitor versus 
placebo in dialysis patients with heart failure. In the absence of trial evidence, physicians 
must rely on observational studies to inform clinical practice. I used Medicare Parts A, B, 
and D claims to identify patients who were discharged from hospitalization principally 
for heart failure and then dispensed an ACE inhibitor or ARB. I also applied propensity 
score matching to identify controls that were similar (on average) to exposed patients 
with respect to dozens of patient characteristics. The study suggested that treatment with 
an ACE inhibitor or ARB was associated with significant reductions in the risk of death 
and hospitalization after discharge. 
For frame of reference, the present study included more than 18 times the number 
of patients that were enrolled in the FOSIDIAL trial of fosinopril versus placebo in 
hemodialysis patients with left ventricular hypertrophy. Of course, observational studies 
can never eliminate the possibility of unmeasured confounding. However, the inherent 
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flexibility of the retrospective cohort study design admits easy application of alternative 
case definitions, exposure definitions, outcomes, and follow-up rules. Therefore, the 
robustness of findings can be assessed, even if the absence of unmeasured confounding 
cannot be assured. Ultimately, the present study raises a number of important questions. 
First, it is unknown whether initiation of treatment with an ACE inhibitor or ARB after 
first diagnosis of heart failure in the outpatient setting is more or less efficacious than 
treatment after first hospitalization principally for heart failure. Second, it is unknown 
whether the results of the study apply similarly to heart failure with reduced EF and heart 
failure with preserved EF. Third, it remains uncertain whether ACE inhibitors and ARBs 
are associated with similar reductions in risk, primarily because of the limited number of 
ARB users in the present study. Fourth, the influence of the concurrent use of beta 
blockers is unclear. The identification of matching treatment groups defined by use of 
RAS inhibitors, beta blockers, or both is needed in future research. 
Within subclasses of ACE inhibitors and ARBs, the selection of a specific agent 
may be capricious or merely dictated by formulary design. Resources are likely 
unavailable to compare agents in large randomized clinical trials. However, in an era with 
large administrative databases and in the context of Medicare Part D, which has a core 
benefit structure but includes dozens of unique formularies, there are growing 
opportunities to compare outcomes across multiple agents in a single subclass. I 
compared the risks of death and hospitalization associated with exposure to benazepril, 
enalapril, lisinopril, ramipril, losartan, and valsartan in dialysis patients that had been 
discharged from hospitalization principally for heart failure. The study suggested that the 
choice of an RAS inhibitor agent may be consequential. In particular, valsartan, which 
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became available in generic form very recently, was associated with relatively low risk of 
mortality and morbidity, thereby questioning the dominance of lisinopril in dialysis 
patients. Interestingly, daily doses of supplied valsartan were more likely than any other 
agent to be maximized. The preeminent challenge with this line of inquiry is sample size 
and the associated precision of relative risk estimates. More cases, primarily from 
additional years of data, are needed to confirm findings. Of course, the ongoing evolution 
of marketed medications presents a challenge of its own. For example, it cannot be 
assumed that generic forms of valsartan are as effective as the branded form (“Diovan”), 
particularly in light of problems with major generic drug manufacturers. The continued 
investigation of heterogeneity in outcomes associated with agents that have similar or 
identical mechanisms of action is likely needed to achieve incremental gains in quality of 
care. 
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Appendix 1 
Revisions to harmonize definitions across combinations of cohort and event and 
to improve relevance in dialysis patients comprised the following: 
a. The subclass of miscellaneous anti-infective agents (GPI, 160000) was limited to 
agents indicated for Clostridium difficile colitis, because metronidazole was the 
most frequently dispensed item in the subclass. In addition, the associations of the 
subclass with risks of mortality and hospitalization were closely approximated by 
corresponding associations with metronidazole and (oral) vancomycin. 
b. The subclass of progestins indicated for cancer (GPI, 214040) was limited to 
megestrol acetate, because megestrol was the only item dispensed to patients and 
was more likely prescribed to treat anorexia or cachexia than to treat cancer. 
c. The subclass of vasopressors (GPI, 380000) was limited to midodrine 
hydrochloride, because midodrine was the only item dispensed to patients. 
d. The subclass of adrenergic bronchodilator combination agents (GPI, 442099) was 
limited to ipratropium/albuterol, because that combination was the most 
frequently dispensed item in the subclass. In addition, ipratropium/albuterol was 
pooled with the subclass of anticholinergic bronchodilators (GPI, 441000). 
e. The subclass of bowel evacuant combination agents (GPI, 469920) was limited to 
agents containing polyethylene glycol 3350, because those combinations were the 
only items dispensed to patients. 
f. The subclass of gastrointestinal stimulants (GPI, 523000) was limited to 
metoclopramide hydrochloride, because metoclopramide was the only item 
dispensed to patients. 
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g. The subclass of miscellaneous anticonvulsants (GPI, 726000) was limited to 
gamma-aminobutyric acid analogues, because the associations of the subclass 
with risks of mortality and hospitalization were closely approximated by 
corresponding associations with gabapentin and pregabalin. 
h. The subclass of topical anesthetic combination agents (GPI, 908599) was limited 
to lidocaine/prilocaine, because that combination was the only item dispensed to 
patients was likely prescribed for use during vascular access cannulation. 
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Appendix 2 
The 4 ACE inhibitors and 2 ARBs in this study are briefly described in the 
following: 
Benazepril 
Benazepril hydrochloride was approved by the FDA on June 25, 1991. Benazepril 
is currently available in either branded (“Lotensin”) or generic form. The drug is also 
available in combination with a calcium channel blocker, amlodipine, in either branded 
(“Lotrel”) or generic form; or a diuretic, hydrochlorothiazide, in either branded or generic 
(“Lotensin HCT”) form. Benazepril is indicated only in treatment of hypertension.111 
Randomized clinical trial data about monotherapy with benazepril in heart failure are 
very limited.  
Benazepril is available in potencies of 5, 10, 20, and 40 mg. Benazepril is 
metabolized to benazeprilat, which has a half-life of roughly 10 to 11 hours. At 24 hours 
after administration, between 80% and 90% of plasma ACE activity is inhibited. 
Benazepril is typically administered once per day, although twice-daily regimens may be 
necessary in patients with inadequate trough responses even after upward titration. 
Common daily doses range from 20 to 40 mg; cumulative daily doses greater than 80 mg 
have not been evaluated. Benazeprilat is predominantly excreted by the kidneys; biliary 
excretion accounts for only 11% to 12% of total clearance. Therefore, in patients with 
renal impairment, required dosage may be lower. Hemodialysis has little effect on 
clearance of benazepril and its active metabolite, benazeprilat. 
Enalapril 
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Enalapril maleate was approved by the FDA on December 24, 1985. Enalapril is 
now available in either branded (“Vasotec”) or generic form. Enalapril is available in 
combination with a diuretic, hydrochlorothiazide, in either branded (“Vaseretic”) or 
generic form. Enalapril has three indications: (1) treatment of hypertension; (2) treatment 
of HF, typically in combination with a diuretic and digitalis; and (3) to reduce the 
incidence of overt heart failure and subsequent hospitalization for HF in patients with an 
ejection fraction ≤ 35%.112  
An important early study of enalapril was the Cooperative North Scandinavian 
Enalapril Survival Study (CONSENSUS). In that study, 253 patients with severe heart 
failure (New York Heart Association functional class IV) were randomized to receive 
placebo or enalapril. Risk of death was 27% lower in patients treated with enalapril.
112
 
The efficacy of enalapril was clearly established in the landmark Study of Left 
Ventricular Dysfunction (SOLVD) Treatment trial.
113
 In that study, 2569 patients were 
randomized to receive placebo or enalapril and followed for up to 55 months. Study 
participants had symptomatic heart failure with ejection fraction ≤ 35%; patients with 
serum creatinine > 2.5 mg/dL were excluded. Compared to placebo, enalapril was 
associated with 11% lower risk of death due to any cause and 30% lower risk of 
hospitalization for heart failure. In the SOLVD Prevention trial, 4228 patients with 
asymptomatic heart failure (ejection fraction ≤ 35%) were assigned to receive placebo or 
enalapril.
114
 Compared to placebo, enalapril was associated with 8% lower risk of death 
due to any cause and 32% lower risk of hospitalization for heart failure; only the latter 
contrast was statistically significant. 
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Enalapril is available in potencies of 2.5, 5, 10, and 20 mg. Enalapril is a prodrug 
that is hydrolyzed to enalaprilat; in fact, all ACE inhibitors except captopril and lisinopril 
are prodrugs. The half-life of enalaprilat is approximately 11 hours. Thus, enalapril is 
often administered two times per day, although once-daily regimens may be sufficient for 
treatment of hypertension. The presence of food does not significantly alter the 
absorption of enalapril. Usual daily doses range from 10 to 40 mg. Enalapril and its 
active metabolite, enalaprilat, are excreted primarily by the kidneys. Because of renal 
excretion, the required dosage of enalapril is usually lower in patients with impaired renal 
function. Enalaprilat is removed by dialysis, albeit less rapidly than captopril is removed. 
Lisinopril 
Lisinopril was approved by the FDA on December 29, 1987. Lisinopril is 
available in either branded (“Prinivil,” “Zestril) or generic form. The drug is also 
available in combination with a diuretic, hydrochlorothiazide, in either branded 
(“Prinzide,” “Zestoretic”) or generic form. Lisinopril has three indications: (1) treatment 
of hypertension; (2) adjunctive treatment of HF in patients who have failed to respond 
adequately to a diuretic and digitalis; and (3) to reduce the incidence of death in patients 
who are hemodynamically stable in the first 24 hours after acute myocardial infarction.
116
 
Lisinopril is the most frequently prescribed ACE inhibitor in the US. Early trials of 
lisinopril were short in duration and assessed occurrence of improvement in symptoms of 
heart failure. Arguably the most important trial of lisinopril in the treatment of heart 
failure was the Assessment of Treatment with Lisinopril and Survival (ATLAS) study.
117
 
In that study, 3164 patients were randomized to receive lisinopril at daily doses of either 
2.5 to 5.0 mg or 32.5 to 35.0 mg. Study participants had symptomatic heart failure with 
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ejection fraction ≤ 30%, but just as in SOLVD, participants with serum creatinine > 2.5 
mg/dL were excluded. More than 90% of study participants in each arm were 
successfully titrated to target dose ranges. The hazard ratios of death due to any cause, 
due to cardiovascular causes, and the composite endpoint of death and hospitalization for 
heart failure were 0.92, 0.90, and 0.85, respectively, for high versus low doses of 
lisinopril; only the final contrast, which was not pre-specified, was significant (P < 0.05). 
Lisinopril is available in potencies of 2.5, 5, 10, 20, 30, and 40 mg. Like captopril, 
the molecule is not further metabolized. Its half-life is approximately 12 hours. Lisinopril 
is almost always administered once per day. The presence of food in the gastrointestinal 
tract does not significantly alter the absorption of lisinopril, but wide inter-subject 
variability in absorption has been observed. The bioavailability of lisinopril is modestly 
lower in patients with heart failure. Typical daily doses for treatment of heart failure 
range from 5 to 20 mg, although less is required in patients with severely impaired renal 
function (including patients treated with hemodialysis), because lisinopril is excreted 
exclusively by the kidneys. Lisinopril is removed by dialysis. 
Ramipril 
Ramipril was approved by the FDA on January 28, 1991. Ramipril is available in 
either branded (“Altace”) or generic form. It is not available in combination with another 
molecular entity. Ramipril has three indications: (1) treatment of hypertension; (2) to 
reduce the incidence of myocardial infarction, stroke, or death from cardiovascular 
causes in patients aged ≥55 years and at high risk of cardiovascular morbidity because of 
a history of coronary artery disease, stroke, peripheral vascular disease, or diabetes and 
the presence of another risk factor (e.g., hypercholesterolemia, hypertension, micro-
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albuminuria, or smoking); and (3) to reduce the incidence of overt heart failure, 
subsequent hospitalization for HF, and death in patients who exhibit clinical symptoms of 
HF in the first days after acute myocardial infarction.
118
 Efficacy of ramipril in treatment 
of heart failure was established in the Acute Infarction Ramipril Efficacy (AIRE) 
study.
119
 In that study, 2006 patients were randomized to receive placebo or ramipril. 
Study participants were randomized between 2 and 9 after acute myocardial infarction, if 
they exhibited clinical signs of heart failure. Compare to placebo, ramipril was associated 
with a 27% reduction in risk of death and a 26% reduction in risk of hospitalization for 
heart failure. There was modest evidence that older patients (i.e., age > 65 years) 
benefited relatively more from treatment with ramipril than younger patients did. 
Ramipril is available in potencies of 1.25, 2.5, 5, and 10 mg. Ramipril is almost 
entirely metabolized in the liver to ramiprilat, which exhibits about 6 times as much 
inhibitory activity of ACE as ramipril itself. Elimination of ramiprilat is triphasic: an 
initial decline with a half-life of 4 hours, during which the drug distributes into peripheral 
compartments; an apparent elimination phase with a half-life of 9 to 18 hours; and a 
terminal elimination phase with a half-life greater than 50 hours. Ramipril is typically 
administered twice per day in patients with hypertension or who exhibit symptoms of HF 
after acute myocardial infarction, but only once per day in older patients at high risk of 
cardiovascular morbidity; multiple doses per day appear to inhibit ACE activity more 
completely in the 24 hours following administration than do single doses. Presence of 
food in the gastrointestinal tract does not significantly alter the absorption of ramipril. 
Usual cumulative daily doses vary by indication. In patients with hypertension, doses 
range from 2.5 to 20 mg per day. In older patients at high risk of cardiovascular 
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morbidity and in those who exhibit symptoms of HF after acute myocardial infarction, 
doses of 10 mg per day are often prescribed. In patients with either hepatic or renal 
impairment, the required dosage may be lower. Whether dialysis removes ramipril or its 
active metabolite, ramiprilat, remains unknown. 
Losartan 
Losartan potassium was approved by the FDA on April 14, 1995. It is the oldest 
ARB that is available for human prescription in the US. Losartan is currently available in 
either branded (“Cozaar”) or generic form. The drug is also available in combination with 
a diuretic, hydrochlorothiazide, in either branded (“Hyzaar”) or generic form. Losartan 
possesses three indications: (1) treatment of hypertension; (2) to reduce the incidence of 
stroke in patients with both hypertension and left ventricular hypertrophy; and (3) 
treatment of diabetic nephropathy (i.e., both hypercreatinemia [serum creatinine ≥ 1.3 
mg/dL in females, ≥ 1.3 mg/dL in males ≤60 kg, and ≥ 1.5 mg/dL in males > 60 kg] and 
macro-albuminuria [urinary albumin-to-creatinine ratio ≥ 300 mg/g]) in patients with 
type II (i.e., non-insulin-dependent) diabetes mellitus and hypertension.
120
 Several trials 
have assessed the efficacy of losartan in the treatment of heart failure. In the Evaluation 
of Losartan in the Elderly (ELITE) II trial, 3126 patients were randomized to receive 
captopril or losartan.
121
 Study participants had clinical heart failure (New York Heart 
Association functional class II, III, or IV) and ejection fraction ≤ 40%. With mean 
follow-up of about 1.5 years, the hazard ratio of death due to any cause was 1.13 (95% 
confidence interval, 0.95-1.35) for losartan versus captopril, thereby admitting neither 
superiority nor inferiority. In the more recent Heart Failure End Point Evaluation of 
Angiotensin II Antagonist Losartan (HEAAL) trial, 3846 patients with similar heart 
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failure severity as in ELITE II were randomized to receive losartan at doses of either 50 
mg daily or 150 mg daily.
122
 Relative to the lower dose, the higher dose was associated 
with 10% lower risk of the composite endpoint of death or hospitalization for heart 
failure; the effect was modestly stronger for the component of hospitalization for heart 
failure. Although hyperkalemia, hypotension, and renal impairment occurred more 
frequently in patients who received the higher dose, treatment discontinuation rates were 
similar in the treatment groups. 
Losartan is available in potencies of 25, 50 and 100 mg. Losartan is not a prodrug 
per se, as losartan itself antagonizes angiotensin II receptors. However, roughly 14% of 
an administered dose is metabolized by cytochrome P450 enzymes to an active 
metabolite (EXP3174) with an affinity to angiotensin II receptors that is roughly 10 times 
greater than losartan itself. The half-life of losartan is 2 hours, while the half-life of 
EXP3174 is between 6 and 9 hours. The drug is usually administered once per day, 
although twice-daily regimens may be prescribed for patients with hypertension and 
inadequate trough responses. Absorption is unaffected by the presence of food. Usual 
daily doses in patients with left ventricular hypertrophy or diabetic nephropathy are 
between 50 and 100 mg. Dose adjustment is unnecessary in patients with renal 
impairment, but is recommended in those with hepatic impairment. Dialysis does not 
clear losartan. 
Valsartan 
Valsartan was approved by the FDA on July 18, 2001. Valsartan is available in 
branded (“Diovan”) or generic form. The agent is also available in combination with a 
calcium channel blocker, amlodipine, in branded (“Exforge”) or generic form; a diuretic, 
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hydrchlorothiazide, in branded (“Diovan HCT”) or generic form; or both amlodipine and 
hydrochlorothiazide, in branded (“Exforge HCT”) or generic form. Valsartan has three 
indications: (1) treatment of hypertension; (2) treatment of HF; and (3) to reduce the 
incidence of death from cardiovascular causes in patients with an ejection fraction ≤ 40% 
by ventriculography or ≤ 35% by electrocardiography after acute myocardial 
infarction.
123
 Efficacy of valsartan for treatment of heart failure was established by the 
Valsartan in Heart Failure (Val-HeFT) trial.
124
 In that study, 5018 patients were 
randomized to received placebo or valsartan, in tandem with currently prescribed 
treatment. Study participants had clinical heart failure with ejection fraction ≤ 40% and 
left ventricular dilatation. Compared to placebo, valsartan had no effect on survival. 
However, valsartan was associated with 13% lower risk of the composite endpoint of 
death due to any cause, cardiac arrest with resuscitation, hospitalization for heart failure, 
or receipt of intravenous inotropic or vasodilator therapy for at least 4 hours; the 
reduction was dominated by 24% lower risk of hospitalization for heart failure. 
Valsartan is available in potencies of 40, 80, 160, and 320 mg. The drug has a half-life of 
roughly 9 hours. Valsartan may be administered either once or twice per day in patients 
with uncomplicated hypertension, but twice-daily regimens are recommended in patients 
with heart failure or depressed ejection fraction after acute myocardial infarction. The 
presence of food in the gastrointestinal tract does lower bioavailability, but this feature 
appears to be unimportant. Valsartan is primarily excreted by the liver, and dosage 
adjustment may be required in patients with severe hepatic impairment. Dialysis does not 
clear valsartan. 
